



Diagnostic Radiology
CORE Examination Study Guide
Updated 8/25/2018

Contents

Preamble.....	3
Exam Purpose Statements	4
Breast Imaging	5
Cardiac Imaging.....	7
Gastrointestinal Imaging.....	12
Interventional Radiology.....	18
Musculoskeletal Imaging	20
Neuroradiology	30
Nuclear Radiology	45
Pediatric Radiology	58
Physics.....	78
Radioisotope Safety Examination (RISE).....	95
Reproductive/Endocrine Imaging and Therapy	98
Noninterpretive Skills.....	100
Thoracic Imaging.....	102
Ultrasound	110
Urinary Imaging.....	132
Vascular Imaging.....	135

Preamble

This study guide is a resource to guide your preparation for the Core Examination in diagnostic radiology.

The Core Examination is designed to evaluate a candidate's core radiology knowledge and clinical judgement, across both the subspecialties and imaging modalities of diagnostic radiology. It tests knowledge and comprehension of anatomy, pathophysiology, diagnostic radiology, and physics concepts important for the practice of diagnostic radiology. The purpose of this exam relative to that of other ABR exams is given on the next page.

The 18 categories are: breast imaging, cardiac imaging, computed tomography (CT), gastrointestinal (GI) imaging, interventional radiology, magnetic resonance (MR), musculoskeletal imaging, neuroradiology, nuclear radiology, pediatric radiology, physics, radiography/fluoroscopy, reproductive/endocrine imaging, noninterpretive skills, thoracic imaging, ultrasound (US), urinary imaging, and vascular imaging.

- Individual category study guides are presented for 15 categories.
- For the three modalities of CT, MR and radiography/fluoroscopy, the relevant portion of the study guides in each of the other categories should be used to guide preparation.

In general, the Core Examination is based on material in this study guide. However, not all material in the study guide is included on every form of the examination. Items that are not included in this study guide may appear on the examination.

If you are reviewing this in printed format, please be sure to check the ABR website, www.theabr.org, for updated study guide materials and questions.

Nonprofit educational programs have permission to use or reproduce all or parts of this document for educational purposes only. Use or reproduction of this document for commercial use or for-profit use is strictly prohibited.

Exam Purpose Statements

Core Exam:

The purpose of the ABR Core (qualifying) Exam is to validate that the candidate has acquired the knowledge, skills, and understanding basic to the entire field of diagnostic radiology, including physics.

Certifying Exam:

The purpose of the ABR Certifying Exam is to validate that the candidate has acquired and is able to apply the requisite knowledge, skills, and understanding that:

1. every practicing physician should possess (20%).
2. every practicing radiologist should possess (20%).
3. this particular practicing radiologist should possess to begin independent practice in his or her chosen clinical practice area(s) (60%).

Subspecialty Certifying Exams:

The purpose of the subspecialty certifying exam is to validate that the candidate has acquired and is able to apply the requisite knowledge, skills, and understanding essential to the practice of the subspecialty.

Maintenance of Certification (MOC) Exam:

The purpose of the MOC exam is to validate that the certified diplomate has maintained and applies the essential knowledge, skills, and understanding in the major clinical areas in which the diplomate currently practices.

Breast Imaging

1) Regulatory/Standards of Care

- a) Components and desired goals of the medical audit for breast cancer detection
- b) Appropriate application of the Breast Imaging Reporting and Data System (BI-RADS) terminology and assessment categories
- c) Mammography Quality Standards Act (MQSA) requirements
- d) Quality determinants of mammography, breast ultrasound, and breast MR, including positioning, image processing, artifacts, optimal technique, and equipment

2) Screening

- a) Indications
- b) Normal anatomy (mammography, ultrasound, MR)
- c) Lesion detection and localization
- d) Computer-aided detection
- e) Breast cancer risk factors, including the identification and management of women at high risk for breast cancer

3) Diagnostic Breast Imaging

- a) Appropriate mammographic views for work-up of a breast lesion
- b) Evaluate and manage women and men with breast symptoms
 - i) Palpable masses
 - ii) Breast thickening
 - iii) Nipple discharge
 - iv) Nipple retraction
 - v) Skin changes
- c) Appearance and management of inflammatory processes in the breast
 - i) Benign
 - ii) Malignant
- d) Role of imaging in surgical staging and surgical planning in women with recently diagnosed breast cancer
- e) Normal and abnormal appearance after surgical procedures
 - i) Breast implants
 - ii) Breast augmentation
 - iii) Breast reduction
 - iv) Breast reconstruction
 - v) Normal and abnormal appearance of breast-conserving therapy

4) Pathology

- a) Appearance and management of benign breast lesions, high-risk lesions, ductal carcinoma in situ, invasive ductal carcinoma, and other special types of breast carcinoma
- b) Appearance and causes of benign and malignant male breast disease

5) Imaging findings

- a) Characteristics of benign and malignant breast calcifications
- b) Characteristics of benign and malignant breast masses
- c) Identify and appropriately manage imaging findings
 - i) Mammography
 - (1) Abnormal calcifications
 - (2) Masses
 - (3) Asymmetries
 - (4) Architectural distortion
 - ii) Ultrasound
 - iii) Breast MR
 - (1) Masses
 - (2) Non-mass findings
- d) Identify and understand the causes of abnormal lymph nodes on mammography, ultrasound, or MRI

6) Breast Intervention

- a) Percutaneous breast biopsy techniques
 - i) Wire localization
 - ii) Core biopsy
 - iii) Vacuum-assisted biopsy
 - iv) Fine-needle aspiration
 - v) Galactography
 - vi) Cyst aspiration
- b) Specimen radiography
- c) Concordant versus discordant percutaneous biopsy results for imaging appearance of a breast abnormality and appropriate management
- d) Patient safety

7) Physics

- a) Mechanism of obtaining and optimizing film-screen or digital mammograms
 - i) Target/filter combinations
 - ii) Use of a grid
 - iii) Reduction of scatter
 - iv) Radiation dose
- b) Adjustment of mammography techniques for special cases, including thin breasts
- c) Mechanism of obtaining and optimizing breast US images
- d) Mechanism of obtaining and optimizing breast MR images
- e) Recognizing, understanding, and correcting artifacts in breast imaging, including mammography, US, and MR imaging
- f) Workstation display of digital mammograms
 - i) Required equipment parameters
 - ii) Image processing

Computer-assisted display software for breast MRI, including the role of dynamic enhancement characteristics

Cardiac Imaging

1) Basics of Imaging: Radiography, CT, and MR

- a) Indications and limitations of the modalities and comparison to echocardiography, angiography and cardiac catheterization, SPECT, and PET.
- b) Physics behind image creation and potential artifacts on radiography, CT, and MR
 - i) X-ray physics
 - ii) CT physics
 - (1) Multidetector CT artifacts relevant to cardiac imaging
 - (2) Tradeoffs between noise, dose and image quality
 - (3) Spatial resolution, contrast resolution, and imaging reconstruction algorithms
 - (4) Temporal resolution, half scan, and multi-segment reconstruction
 - (5) Contrast injection—principles, protocols, bolus geometry, and iodine flux
 - iii) MR physics
 - (1) MR artifacts relevant to cardiac and vascular imaging
 - (2) Trade-off between spatial resolution, temporal resolution, contrast resolution, and acquisition time
 - (3) Principles of black blood, edema, and scar imaging
 - (4) Steady-state free precession cine imaging
 - (5) Velocity-encoded cine (phase contrast) imaging—principles, applications, and limitations
- c) 3D imaging and post-processing
 - i) Multiplanar reconstruction (MPR)
 - ii) Maximum intensity projection (MIP)
 - iii) Volume rendering (VR)
- d) Patient safety
 - i) Radiation exposure and how technical modifications may modify dose
 - ii) Drugs and contrast agents used for cardiac imaging
 - iii) Cardiac devices and the effect of the magnetic field of the MR unit

2) Normal Anatomy, Including Variants, Encountered on Radiography, CT, and MR

- a) Heart, including chambers, valves, pericardium, and coronary arteries
- b) Aorta and pulmonary arteries
- c) Venaee cavae and pulmonary veins

3) Physiological Aspects of Cardiac Imaging as Assessed with Radiography, CT, and MR

- a) Normal cardiac cycle
- b) Physiological anatomy of cardiac muscle
- c) Mechanics of cardiac contraction
- d) Physical basis for blood flow, pressure, and resistance
 - i) Ventricular volume and pressure relationship
 - ii) Functional cardiac measurements

- (1) Ejection fraction
 - (2) Stroke volume
 - (3) Left ventricular mass
 - (4) Flow ($Q = V \times A$)
 - (5) Pressure gradient (modified Bernoulli equation, $\Delta P = 4V^2$)
 - (6) Pulmonary-to-systemic flow (Qp/Qs) ratio
 - (7) Regurgitant volume and regurgitant fraction
 - (8) Diastolic heart function
- iii) Normal cardiac and pulmonary pressures
 - iv) Vascular regions supplied by the coronary arteries

4) Ischemic Heart Disease

- a) Risk factors, primary prevention, and screening
- b) Roles of echocardiography, angiography, SPECT, PET, CT, and MR in the evaluation of a patient with suspected ischemic heart disease, including the advantages and limitations of each modality
- c) Inducible myocardial ischemia
- d) Acute myocardial infarction
- e) Chronic myocardial infarction
- f) Post-myocardial infarction complications
 - i) Cardiac rupture
 - ii) Left ventricular aneurysm and pseudoaneurysm
 - iii) Papillary muscle rupture
 - iv) Congestive heart failure
 - v) Dressler syndrome
- g) Myocardial perfusion and viability
 - i) Stunned myocardium
 - ii) Hibernating myocardium
- h) Role of myocardial delayed-enhancement imaging in guiding management of left ventricular dysfunction
 - i) Coronary artery stenosis and aneurysm
 - j) Role of coronary CT angiography in guiding management of chest pain
- k) Therapeutic and interventional options

5) Cardiomyopathy

- a) Hypertrophic
- b) Dilated
- c) Restrictive
 - i) Distinguish restrictive cardiomyopathy from constrictive pericarditis
- d) Arrhythmogenic right ventricular dysplasia
- e) Therapeutic and interventional options

6) Cardiac Masses

- a) Thrombus

- i) Distinguish thrombus from tumor
- b) Primary benign tumors
 - i) Myxoma
 - ii) Lipoma
 - iii) Rhabdomyoma
 - iv) Fibroma
 - v) Lipomatous hypertrophy of the interatrial septum
- c) Primary malignant tumors
 - i) Angiosarcoma
 - ii) Lymphoma
- d) Metastasis
- e) Therapeutic and interventional options

7) Valvular Disease

- a) Myxomatous degeneration
- b) Rheumatic heart disease
- c) Infective endocarditis
- d) Congenital valve disease
- e) Specific lesions
 - i) Aortic stenosis
 - ii) Aortic regurgitation
 - iii) Mitral stenosis
 - iv) Mitral regurgitation
 - v) Mitral annular calcification
 - vi) Tricuspid regurgitation
 - vii) Pulmonary stenosis
 - viii) Pulmonary regurgitation
- f) Therapeutic and interventional options

8) Pericardial Disease

- a) Acute pericarditis
- b) Constrictive pericarditis
 - i) Distinguish restrictive cardiomyopathy from constrictive pericarditis
- c) Pericardial effusion
 - i) Hemopericardium
 - ii) Tamponade
- d) Pericardial cyst
- e) Pericardial defect
- f) Pneumopericardium
- g) Therapeutic and interventional options

9) Congenital Heart Disease

- a) Left-to-right shunts
 - i) Atrial septal defect

- ii) Ventricular septal defect
- iii) Partial anomalous pulmonary venous connection
 - (1) Scimitar syndrome
- iv) Patent ductus arteriosus
- b) Eisenmenger syndrome
- c) Admixture lesions (bidirectional shunts)
 - i) Transposition of the great arteries
 - ii) Truncus arteriosus
 - iii) Total anomalous pulmonary venous connection
- d) Right-to-left shunts
 - i) Tetralogy of Fallot and pulmonary atresia with ventricular septal defect
 - ii) Ebstein anomaly
- e) Great vessel anomalies
 - i) Coarctation of the aorta
 - (1) Distinguish from pseudocoarctation
 - ii) Double aortic arch
 - iii) Right aortic arch
 - (1) Mirror image
 - (2) Non-mirror image
 - iv) Pulmonary sling
 - v) Persistent left superior vena cava
- f) Coronary artery anomalies
 - i) Retroaortic course
 - ii) Interarterial course
- g) Miscellaneous anomalies
 - i) Cardiac malposition, including situs abnormalities
 - ii) Congenitally corrected transposition of the great arteries
- h) Therapeutic and interventional options

10) Acquired Disease of the Thoracic Aorta and Great Vessels

- a) Aneurysms
 - i) Atherosclerotic
 - ii) Marfan syndrome
 - iii) Ehlers-Danlos syndrome
- b) Pseudoaneurysms
 - i) Mycotic
 - ii) Post-traumatic and post-surgical
- c) Dissection
 - i) Intramural hematoma
- d) Aortitis and arteritis
- e) Atherosclerosis
 - i) Plaque
 - ii) Ulcerated plaque
 - iii) Penetrating ulcer

- f) Thromboembolism
 - i) Acute pulmonary embolism
 - ii) Chronic pulmonary embolism
- g) Pulmonary hypertension
- h) Pulmonary arteriovenous malformation
- i) Compression
 - i) Superior vena cava syndrome
- j) Pulmonary vein complications after radiofrequency ablation
- k) Therapeutic and interventional options

11) Devices and Postoperative Appearance

- a) Monitoring and support devices
 - i) Intra-aortic balloon pump
 - ii) Pacemaker generator and pacemaker leads
 - iii) Implantable cardiac defibrillator
 - iv) Left ventricular assist device
 - v) Pericardial drain
- b) Postoperative chest
 - i) Coronary artery bypass graft surgery
 - ii) Cardiac valve replacement
 - iii) Transluminal septal closure iv)
Aortic graft and aortic stent v)
Heart transplant

Gastrointestinal Imaging

1) Pharynx

- a) Benign diseases
 - i) Zenker diverticulum
 - ii) Foreign bodies
 - iii) Trauma
- b) Motility disorders

2) Esophagus

- a) Benign diseases
 - i) Diverticula
 - ii) Trauma
 - iii) Esophagitis
 - (1) Reflux
 - (2) Infectious
 - (3) Caustic
 - (4) Drug-induced
 - iv) Barrett esophagus
 - v) Rings, webs, and strictures
 - vi) Varices
 - vii) Benign tumors and tumor-like conditions
 - viii) Extrinsic processes affecting the esophagus
 - (1) Pulmonary lesions
 - (2) Mediastinal structures
 - ix) Hiatal hernia (types and significance)
- b) Malignant tumors
 - i) Squamous
 - ii) Adenocarcinomas
 - iii) Other malignant tumors
 - (1) Lymphoma
 - (2) Kaposi
 - (3) Metastases (lymphatic and hematogenous)
- c) Motility disorders
 - i) Primary motility disorders
 - ii) Secondary motility disorders
- d) Postoperative esophagus

3) Stomach

- a) Benign diseases
 - i) Diverticula
 - ii) Gastritis
 - (1) Erosive

- (2) Atrophic
 - (3) Infectious
 - (4) Other
 - (a) Crohn disease
 - iii) Peptic ulcer disease
 - iv) Hypertrophic gastropathy
 - v) Varices
 - vi) Volvulus
 - vii) Entrapment after diaphragmatic injury
- b) Malignant diseases
 - i) Primary
 - (1) Adenocarcinoma
 - (2) Lymphoma
 - (3) GI stromal tumors
 - (4) Carcinoid
 - ii) Metastatic
 - c) Postoperative stomach
 - i) Expected surgical appearance
 - (1) Bariatric, including gastric banding
 - (2) Nissen and other funduplications
 - (3) Whipple
 - (4) Billroth procedures
 - d) Complications

4) Duodenum

- a) Benign diseases
 - i) Congenital abnormalities
 - ii) Diverticula
 - iii) Trauma
 - iv) Inflammation (1)
 - Duodenitis (2)
 - Ulcer disease
 - (3) Crohn disease
 - v) Aortoduodenal fistula
 - vi) Benign tumors
- b) Malignant diseases
 - (1) Adenocarcinoma
 - (2) Lymphoma
 - (3) Metastatic disease

5) Small Intestine

- a) Benign diseases
 - i) Congenital disorders
 - ii) Diverticula

- iii) Trauma
 - iv) Vascular diseases
 - (1) Intestinal ischemia and infarction
 - (2) Radiation enteritis
 - (3) Scleroderma
 - (4) Vasculitides
 - (a) Henoch-Schönlein purpura
 - (b) Polyarteritis nodosa
 - (c) Systemic lupus erythematosus
 - v) Malabsorption
 - (1) Sprue
 - (2) Lymphangiectasia
 - vi) Inflammatory diseases
 - (1) Crohn disease
 - (2) Infectious and parasitic diseases
 - vii) Benign tumors
 - (1) Sporadic
 - (2) Associated with polyposis syndromes
 - viii) Malrotation/Volvulus
 - ix) Obstruction
 - x) Hemorrhage
 - xi) Other
 - (1) Status post bone marrow transplant
 - (2) Drug effects
 - (a) NSAIDs enteritis
 - (b) ACE inhibitors
- b) Malignant tumors
- i) Adenocarcinoma
 - ii) Lymphoma
 - iii) Carcinoid
 - iv) GI stromal tumors
 - v) Metastases

6) Colon and Appendix

- a) Benign disease
 - i) Congenital abnormalities
 - ii) Diverticular disease
 - iii) Inflammatory diseases
 - (1) Crohn disease
 - (2) Ulcerative colitis
 - (3) Infectious colitis
 - (a) Pseudomembranous
 - (b) Viral
 - (c) Bacterial

- (d) Colitis in AIDS
- (4) Appendicitis
- iv) Ischemic colitis
- v) Benign neoplasms
 - (1) Adenoma
 - (2) Mesenchymal tumors
 - (3) Polyposis syndromes
- b) Malignant diseases
 - i) Adenocarcinoma
 - ii) Other malignant tumors
 - (1) Lymphoma
 - (2) Carcinoid
 - (3) Melanoma
 - (4) Squamous (anal)
 - (5) Metastases

7) Pancreas

- a) Congenital abnormalities and variants
- b) Pancreatitis
 - i) Acute
 - ii) Chronic
 - iii) Complications
 - iv) Autoimmune
- c) Pancreatic neoplasms
 - i) Duct cell adenocarcinoma
 - ii) Cystic pancreatic neoplasms
 - (1) Intraductal papillary mucinous neoplasm (IPMN)
 - (2) Mucinous cystadenomas
 - (3) Serous cystadenomas
 - iii) Islet cell tumors
 - iv) Lymphoma
 - v) Metastases

8) Liver

- a) Normal anatomy
- b) Diffuse diseases of the liver
 - i) Cirrhosis
 - ii) Diseases associated with infiltration
 - (1) Fatty infiltration/nonalcoholic steatohepatitis (NASH)/NAFLD
 - (2) Hemochromatosis
 - (3) Storage diseases
 - iii) Vascular diseases
 - (1) Portal hypertension
 - (2) Portal vein occlusion

- (3) Hepatic venous hypertension/Budd Chiari syndrome, and nutmeg liver
- c) Focal diseases of the liver
 - i) Benign
 - (1) Cavernous hemangioma
 - (2) Liver cell adenoma
 - (3) Focal nodular hyperplasia
 - ii) Malignant
 - (1) Hepatocellular carcinoma
 - (2) Metastases
 - (3) Other malignant liver lesions
- d) Liver transplantation
 - (1) Surgical candidates
 - (2) Expected postoperative appearance
 - (3) Complications

9) Spleen

- a) Splenomegaly
- b) Focal lesions
 - i) Cysts
 - ii) Hemangioma
 - iii) Infarction
 - iv) Abscess/microabscesses
 - v) Granulomatous disease
- c) Trauma

10) Bile Ducts and Gallbladder

- i) Congenital abnormalities and variants
 - (1) Choledochal cysts
 - (2) Caroli disease
- ii) Inflammatory diseases
 - (1) Gallbladder
 - (a) Acute cholecystitis
 - (b) Emphysematous cholecystitis
 - (c) Porcelain bladder
 - (2) Biliary ducts
 - (a) Primary sclerosing cholangitis
 - (b) Ascending cholangitis
 - (c) Recurrent pyogenic cholangitis
 - (d) AIDS cholangiopathy
 - (e) Ischemic injury
 - (f) Surgical injury
 - (g) Stone disease
- iii) Tumors
 - (1) Gallbladder cancer

- (2) Cholangiocarcinoma
- (3) Metastases

11) Peritoneal Spaces

- a) Normal anatomy
- b) Fluid collections
- c) Diseases of the peritoneum
 - i) Inflammatory diseases
 - (1) Bacterial peritonitis
 - (2) Tuberculosis
 - (3) Other
 - ii) Primary tumors
 - iii) Metastatic tumors
- d) Mesenteries
 - i) Normal anatomy
 - ii) Pathologic conditions
 - (1) Sclerosing mesenteritis/misty mesentery
 - (2) Mesenteric fibromatosis
- e) Retroperitoneum
 - i) Normal anatomy
 - ii) Retroperitoneal spaces
 - iii) Benign diseases
 - (1) Fibrosis
 - (2) Inflammatory diseases
 - iv) Malignant tumors

12) Multisystem Disorders

- a) Acute abdomen
- b) Trauma to the abdomen
- c) Syndromes involving the GI tract
- d) Hernias, including internal hernias
- e) All obstruction

Interventional Radiology

1) Basic Procedures

Questions will assess whether the candidate possesses the knowledge, skills, and abilities needed for safe and effective care before, during, and after the procedure.

Candidates are expected to have a detailed knowledge of the procedure itself, as well as pre- and postprocedure care.

- a) Biopsies: neck, chest, abdomen, pelvis, and extremities, including thyroid, lung, chest wall, liver, pancreas, renal, retroperitoneal, pelvic, and extremity. Note: breast biopsies will be covered in the mammography section. Bone biopsies will be covered in the musculoskeletal section.
- b) Aspirations: neck, chest, abdomen, pelvis, and extremities including thyroid, pleural, peritoneal, and abdominal/pelvic/extremity cysts. Note that lumbar puncture and myelography will be covered in the neuroradiology section.
- c) Central venous: PICCs and uncomplicated non-tunneled catheters
- d) Abscess drainage: uncomplicated chest, abdomen, pelvic, and superficial abscesses
- e) Extremity venography
- f) Catheter injections: cholangiography, abscessogram, nephrostograms, and feeding tube checks

2) Complex Procedures

Because these procedures are typically performed by radiologists with more specialized training, Core Exam candidates are not expected to possess the knowledge, skills, and abilities required to perform these procedures. However, candidates are responsible for a general knowledge of these procedures. Test items will also cover pre- and postprocedure care in more detail because general radiologists are often the first to encounter patients whose clinical presentation and imaging findings warrant these complex interventions. Candidates are also expected to correctly distinguish between expected and unexpected clinical and imaging findings after these procedures.

- a) Arteriography and arterial interventions, including angioplasty, stent placement, stent graft placement, lysis, embolization, thrombectomy, and therapeutic infusion
- b) Central venography and venous interventions, including inferior vena cava (IVC) filter placement, IVC filter retrieval, angioplasty, stent placement, lysis, thrombectomy, sclerosis, tunneled/implanted catheter placement, dialysis interventions, and TIPS
- c) Biliary interventions, including percutaneous transhepatic cholangiography (PTC), internal/external drainage, stent placement, stone removal, and percutaneous cholecystostomy
- d) Nephrostomy and ureteral stent placement, manipulation, and exchange
- e) Tumor ablation (radiofrequency, cryoablation, bland embolization, chemoembolization, and radioembolization)
- f) Feeding tube placement, manipulation, and exchange
- g) Complicated drainages, including transrectal drainage, tunneled catheter placement for pleural/peritoneal collections, and pediatric procedures

3) Physics Knowledge Needed to Safely Perform These Procedures

- a) Optimal use of radiation
- b) Imaging artifacts

Musculoskeletal Imaging

1) Imaging Techniques—Indications and Limitations

- a) Musculoskeletal modalities
 - i) Radiography
 - ii) CT
 - iii) MRI
 - iv) Nuclear scintigraphy/PET
 - v) Ultrasound
 - vi) Fluoroscopy
 - vii) Considerations for musculoskeletal modalities
 - (1) Appropriateness, limitations, contraindications, and safety issues
 - (2) Protocols, standard positioning, technique
 - (3) Indications for contrast with MRI and CT
 - (4) Scintigraphic agents
 - (5) Artifacts and pitfalls
- b) Interventional musculoskeletal procedures
 - i) Types
 - (1) Arthrography
 - (2) Joint aspiration and injection
 - (3) Percutaneous biopsy
 - (4) Therapeutic procedure
 - ii) Considerations for musculoskeletal procedures
 - (1) Appropriateness, limitations, contraindications, and safety issues
 - (2) Universal protocol
 - (3) Approach and technique
 - (4) Injectate (composition and amount)
 - (5) Laboratory studies
 - (6) Complications
- c) Dual-energy X-ray Absorptiometry (DEXA)
 - i) Indications and follow-up
 - ii) WHO classification
 - iii) DEXA positioning
 - iv) DEXA artifacts and pitfalls

2) Normal/Normal Variants

- a) Musculoskeletal anatomy pertinent to the various imaging modalities
- b) Primary and secondary ossification centers and sequence of ossification
- c) Physiologic radiolucencies and radiodensities
- d) Physiologic bowing
- e) Sesamoids, accessory ossicles, and related syndromes
- f) Accessory muscles
- g) Tug lesions
- h) Cortical desmoid

- i) Dorsal defect of the patella
- j) Glenoid labrum variants

3) Congenital Anomalies and Dysplasias

- a) Lower extremity
 - i) Developmental hip dysplasia
 - ii) Discoid meniscus
 - iii) Talipes equinovarus
 - iv) Metatarsus adductus
 - v) Pes cavus and planus
 - vi) Tarsal coalition
 - vii) Proximal focal femoral deficiency
 - viii) Protrusio acetabuli
 - ix) Acetabular version
 - x) Patella baja and alta
- b) Upper extremity
 - i) Madelung deformity
 - ii) Congenital dislocation of the radial head
 - iii) Carpal coalition
 - iv) Sprengel deformity
 - v) Supracondylar process
 - vi) Radial ray anomaly
 - vii) Ulnar variance
- c) Spine (see neuroradiology section)
- d) Diffuse/multifocal
 - i) Achondroplasia
 - ii) Osteogenesis imperfecta
 - iii) Sclerosing osseous dysplasias
 - (1) Melorheostosis
 - (2) Osteopathia striata
 - (3) Osteopoikilosis
 - iv) Osteopetrosis
 - v) Cleidocranial dysplasia/dysostosis
 - vi) Neurofibromatosis
 - vii) Cerebral palsy
 - viii) Mucopolysaccharidosis
 - ix) Trisomy 21
 - x) Macrodystrophy lipomatosa
 - xi) Nail-patella syndrome
 - xii) Wormian bones
 - xiii) Thanatophoric dwarf
 - xiv) Marfan syndrome
 - xv) Tuberous sclerosis

4) Infections (including routes of spread and predisposing factors)

- a) Osteomyelitis

- i) Demographics
- ii) Acute vs subacute vs chronic osteomyelitis
- iii) Features with different imaging modalities
- iv) Terminology
- v) Bacterial vs nonbacterial
- vi) Congenital syphilis
- b) Septic arthritis, bursitis, and tenosynovitis
- c) Soft tissue
 - i) Abscess
 - ii) Cellulitis
 - iii) Pyomyositis
 - iv) Gas gangrene
 - v) Necrotizing fasciitis
 - vi) Cat-scratch disease
 - vii) Cysticercosis

5) Tumors and Tumor-Like Conditions

- a) Demographics
- b) Imaging features and description
- c) Benign and malignant primary bone lesions
 - i) Cartilaginous tumors
 - (1) Osteochondroma
 - (2) Enchondroma
 - (3) Chondroblastoma
 - (4) Periosteal chondroma
 - (5) Chondromyxoid fibroma
 - (6) Chondrosarcoma
 - ii) Osteogenic tumors
 - (1) Osteoid osteoma
 - (2) Osteoblastoma
 - (3) Osteoma
 - (4) Osteosarcoma
 - (a) Conventional osteosarcoma
 - (b) Telangiectatic osteosarcoma
 - (c) Parosteal (surface) osteosarcoma
 - iii) Fibrohistiocytic tumors
 - (1) Non-ossifying fibroma
 - iv) Ewing sarcoma
 - v) Hematopoietic tumors
 - (1) Plasma cell myeloma (Myeloma)
 - (2) Solitary plasmacytoma of bone
 - (3) Primary non-Hodgkin lymphoma of bone
 - (4) Giant cell tumor of bone
 - vi) Notochordal tumors
 - (1) Chordoma

- vii) Vascular tumors
 - (1) Hemangioma
- viii) Lipogenic and epithelial tumors
 - (1) Lipoma
 - (2) Adamantinoma
- ix) Tumors of undefined neoplastic nature
 - (1) Aneurysmal bone cyst (primary and secondary)
 - (2) Unicameral bone cyst
 - (3) Fibrous dysplasia
 - (4) Osteofibrous dysplasia
 - (5) Langerhans cell histiocytosis
- d) Bone metastases
 - i) Primary bone tumor vs metastases
 - ii) Blastic vs. lytic and other differentiating features
- e) Tumor syndromes
 - i) Enchondromatosis (Ollier and Maffucci)
 - ii) Polyostotic fibrous dysplasia, McCune-Albright, and Mazabraud
 - iii) Hereditary multiple osteochondromas
 - iv) Neurofibromatosis
- f) Malignant transformation
 - i) Paget
 - ii) Radiation induced
 - iii) Tumor syndromes (see above)
- g) Benign and malignant soft tissue tumors
 - i) Adipocytic tumors
 - (1) Lipoma
 - (2) Liposarcoma
 - (3) Lipomatosis of nerve (fibrolipomatous hamartoma of nerve)
 - ii) Fibroblastic/myofibroblastic tumors
 - (1) Nodular fasciitis
 - (2) Fibromatosis
 - (3) Elastofibroma
 - (4) Dermatofibrosarcoma protuberans
 - (5) Fibrosarcoma
 - iii) So-called fibrohistiocytic tumors
 - (1) Tenosynovial giant cell tumor (includes localized and diffuse forms of pigmented villonodular synovitis as well as extra-articular giant cell tumor)
 - iv) Smooth-muscle tumors
 - (1) Leiomyosarcoma
 - v) Pericytic tumors
 - (1) Glomus
 - vi) Skeletal-muscle tumors
 - (1) Rhabdomyosarcoma
 - vii) Vascular tumors
 - (1) Hemangioma
 - (2) Lymphangioma

- viii) Nerve sheath tumors
 - (1) Schwannoma
 - (2) Neurofibroma
 - (3) Malignant peripheral nerve sheath tumor
 - ix) Tumors of uncertain differentiation
 - (1) Myxoma
 - (2) Synovial sarcoma
 - x) Undifferentiated/unclassified sarcoma
 - (1) Undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma)
- h) Non-neoplastic masses
- i) Ganglion
 - ii) Geode
 - iii) Morton neuroma
 - iv) Postamputation neuroma
 - v) Epidermal inclusion cyst
 - vi) Xanthoma of the tendon

6) Trauma and Overuse

- a) General principles of osseous trauma and overuse
 - i) Types
 - (1) Closed vs open
 - (2) Pathologic
 - (3) Fatigue
 - (4) Insufficiency
 - (a) Subchondral insufficiency fracture
 - (5) Pediatric
 - (a) Nonaccidental
 - (b) Salter-Harris
 - (c) Greenstick, bowing, and torus
 - (d) Slipped capital femoral epiphysis
 - ii) Relationship of force and deformation to fracture
 - iii) Mechanisms of injury
 - iv) Fracture patterns, bone contusions, and associated injuries
 - v) Fracture description
 - vi) Fracture healing
 - vii) Complications of fracture healing
 - viii) Fracture eponyms and overuse syndromes
- b) Dislocations
- c) General principles of soft-tissue trauma and overuse
 - i) Tendinosis, tendon tears, and tenosynovitis
 - ii) Muscle injuries and grading
 - iii) Ligamentous injuries and grading
 - iv) Bursitis
 - v) Hematomas
 - vi) Degloving injuries and Morel-Lavallee lesions
 - vii) Myositis ossificans
 - viii) Compartment syndrome

- ix) Myonecrosis
- d) Site-specific entities (should know important fractures and dislocations for all sites)
 - i) Shoulder
 - (1) Labral and ligamentous tears
 - (a) Bankart and Bankart variants
 - (b) Superior labrum anterior posterior (SLAP; not including subtypes)
 - (c) Paralabral cysts
 - (d) Humeral avulsion glenohumeral ligament (HAGL)
 - (2) Rotator cuff
 - (a) Partial vs full-thickness
 - (b) Acute vs chronic
 - (c) Tendinopathy (including hydroxyapatite deposition disease/calcific tendinosis)
 - (3) Acromial-clavicular injuries
 - (4) Biceps tears and dislocations
 - (5) Pectoralis major injuries
 - (6) Adhesive capsulitis
 - (7) Impingement disorders
 - (8) Little leaguer shoulder
 - ii) Elbow
 - (1) Biceps and triceps tears
 - (2) Epicondylitis and tears of the common flexor and extensor tendons
 - (3) Tears of the medial and lateral collateral ligamentous complexes
 - (4) Osteochondral lesions
 - (5) Little leaguer elbow
 - iii) Wrist and hand
 - (1) Ulnar abutment
 - (2) Triangular fibrocartilage, scapholunate, and lunatotriquetral ligament tears
 - (3) De Quervain tenosynovitis
 - (4) Intersection syndrome
 - (5) Tendon tears and dislocations
 - (6) Scapholunate advanced collapse
 - (7) DISI, VISI, and perilunate wrist instability
 - (8) Gamekeeper and Stener lesions
 - iv) Spine (see neuroradiology section)
 - v) Hip
 - (1) Labral tears and paralabral cysts
 - (2) Femoroacetabular impingement
 - (3) Tears of the gluteal and hamstring tendons
 - (4) Apophyseal injuries
 - (5) Psoas tendon abnormalities
 - vi) Knee and leg
 - (1) Meniscus
 - (a) Normal variants and pitfalls
 - (b) Types of tears
 - (c) Parameniscal and Intrameniscal cysts
 - (2) Tears and abnormalities of the cruciate and collateral ligaments
 - (3) Posterolateral corner injury

- (4) Iliotibial band syndrome
 - (5) Osteochondral lesions
 - (6) Patellar tracking disorder
 - (7) Tennis leg
 - (8) Tendon tears
 - (9) Jumper's knee, Sinding-Larsen-Johansson, and Osgood-Schlatter disease
- vii) Ankle and foot
 - (1) Plantar fasciitis
 - (2) Sinus tarsi syndrome
 - (3) Tendon tears and dislocations
 - (4) Impingement disorders
 - (5) Haglund deformity
 - (6) Ligamentous tears
 - (7) Osteochondral defect

7) Nerve Entrapment and Associated Disorders

- a) General principles of nerve entrapment
- b) Specific disorders
 - i) Suprascapular nerve entrapment
 - ii) Acute brachial neuritis (Parsonage-Turner)
 - iii) Quadrilateral space syndrome
 - iv) Carpal, cubital, and tarsal tunnel syndromes
 - v) Sciatic and peroneal nerve entrapment
 - vi) Radial, median, posterior interosseous, and ulnar nerve entrapment
 - vii) Obturator and femoral nerve entrapment

8) Metabolic Disorders

- a) Osteoporosis and osteopenia
- b) Hyperparathyroidism
- c) Thyroid acropachy
- d) Hypothyroidism
- e) Scurvy
- f) Rickets and osteomalacia
- g) Renal osteodystrophy
- h) Tumoral calcinosis
- i) Calciphylaxis
- j) Acromegaly
- k) Bisphosphonate-related fractures
- l) Intoxication/poisoning
 - i) Heavy metal/lead
 - ii) Hypervitaminosis A and D
 - iii) Fluorosis

9) Hematologic and Marrow Disorders

- a) Sickle cell and thalassemia
- b) Hemophilia
- c) Myelofibrosis

- d) Extramedullary hematopoiesis
- e) Marrow reconversion
- f) Leukemia and myelodysplasia
- g) Radiation-induced marrow changes
- h) Mastocytosis
- i) Gaucher disease

10) Osteonecrosis and Related Disorders

- a) Osteonecrosis
 - i) Etiology
 - ii) Imaging characteristics
- b) Osteochondritis dissecans
- c) Bone marrow edema syndromes (transient osteoporosis of the hip)
- d) Osteochondroses
 - i) Legg-Calve-Perthes
 - ii) Kienböck
 - iii) Kohler
 - iv) Panner
 - v) Freiberg
 - vi) Sever
 - vii) Scheuermann
 - viii) Tibia vara (Blount disease)

11) Miscellaneous

- a) Paget disease
- b) Sarcoidosis
- c) Hypertrophic osteoarthropathy (primary and secondary)
- d) Periosteal changes from venous stasis
- e) Infantile cortical hyperostosis/Caffey disease
- f) Complex regional pain syndrome (reflex sympathetic dystrophy)
- g) Muscle infarction

12) Arthropathy

- a) General features
 - i) Distribution and demographics
 - ii) Imaging findings
- b) Osteoarthritis (including erosive osteoarthritis)
- c) Inflammatory
 - i) Rheumatoid arthritis
 - ii) Psoriatic arthritis
 - iii) Reactive arthritis
 - iv) Ankylosing spondylitis
 - v) Enteropathic arthritis
 - vi) Juvenile idiopathic arthritis

- vii) SAPHO syndrome and chronic recurrent multifocal osteomyelitis (CRMO)
- d) Connective tissue diseases
 - i) Systemic lupus erythematosus (SLE)
 - ii) Scleroderma
 - iii) Dermatomyositis
 - iv) Polymyositis
- e) Crystal-associated
 - i) Gout
 - ii) Calcium pyrophosphate deposition disease (CPPD)
 - iii) Hydroxyapatite deposition disease (HADD)
- f) Neuropathic
- g) Miscellaneous
 - i) Hemochromatosis
 - ii) Pigmented villonodular synovitis
 - iii) Synovial chondromatosis
 - iv) Osteitis condensans ilii
 - v) Osteitis pubis and pubic instability
 - vi) Degenerative disk disease
 - vii) Diffuse idiopathic sclerosing hyperostosis (DISH)
 - viii) Ossification of the posterior longitudinal ligament
 - ix) Alkaptonuria/ochronosis
 - x) Lipoma arborescens
 - xi) Post-traumatic osteolysis
 - xii) Scheuermann disease

13) Postoperative Imaging

- a) Internal and external fixation (including spine)
 - i) Important types of hardware
 - ii) Appropriate positioning of hardware
 - iii) Complications
 - (1) Infection
 - (2) Loosening
 - (3) Component fracture
- b) Arthroplasty
 - i) Important types
 - ii) Appropriate positioning
 - iii) Complications
 - (1) Infection
 - (2) Loosening, cement fractures, component shift, and subsidence
 - (3) Osteolysis (particle disease)
 - (4) Component (polyethylene liner or prosthesis) wear, breakage, and dislocation
 - (5) Periprosthetic fracture
 - (6) Heterotopic ossification
 - (7) Metallosis
- c) Other postoperative imaging
 - i) Normal vs abnormal appearance of the following surgeries:

- (1) Anterior cruciate ligament
- (2) Meniscus
- (3) Vertebral augmentation
- (4) Sarcoma resection
- (5) Rotator cuff
- (6) Glenoid labrum
- (7) Osteochondral lesions

14) ACR Appropriateness Criteria specific to Musculoskeletal Imaging

Neuroradiology

1) Technique and Indications: Understand the Basic Principles Behind and Indications for Use of Methods of Examination

- a) Radiography
- b) CT
- c) MR
- d) Ultrasound
- e) Angiography
- f) Advanced imaging techniques
 - i) MR angiography
 - ii) CT angiography
 - iii) CT perfusion
 - iv) MR perfusion
 - v) Diffusion-weighted imaging
 - vi) MR spectroscopy
 - vii) Functional MRI
 - viii) Diffusion tensor imaging
 - ix) Myelography
 - x) Cisternography
 - xi) PET CT and other nuclear medicine imaging techniques

Be able to appropriately choose study types for a variety of clinical situations, and recognize the strengths and weaknesses of each type of imaging exam.

2) Brain

- a) Normal anatomy
 - i) Brain parenchyma
 - ii) Ventricular system
 - iii) Extra-axial spaces
 - iv) Pial and dural coverings
 - v) Cranial nerves
 - vi) Arterial and venous structures
 - vii) Skull and surrounding soft tissues
 - viii) Intracranial arterial and venous structures on imaging studies

- (1) CT angiography
- (2) MR angiography
- (3) Catheter angiography

Understand the function of the anatomic structures and how they are affected by various pathologies.

- b) White matter disease (inherited)
 - i) Adrenoleukodystrophy
 - ii) Metachromatic leukodystrophy
 - iii) Alexander disease
 - iv) Canavan disease
 - v) Krabbe disease
 - vi) Pelizaeus- Merzbacher disease
 - vii) Phenylketonuria and other amino acid disorders
- c) Neurodegenerative disorders
 - i) Aging brain
 - ii) Alzheimer disease
 - iii) Other cortical dementias
 - iv) Parkinson disease
 - v) Cerebellar degeneration
 - vi) Amyotrophic lateral sclerosis
 - vii) Wallerian degeneration
 - viii) Huntington disease
 - ix) Fahr disease
 - x) Wilson disease
 - xi) Hallervorden-Spatz disease
 - xii) Leigh disease
 - xiii) Tay-Sachs disease
 - xiv) Hurler syndrome
 - xv) MELAS syndrome
- d) Infection/inflammation/demyelinating
 - i) Viral
 - ii) Bacterial
 - iii) Mycobacterial
 - iv) Fungal
 - v) Parasitic
 - vi) Prion infections
 - vii) Congenital and neonatal infections
 - (1) Cytomegalovirus (CMV)
 - (2) Toxoplasmosis
 - (3) Herpesvirus (HSV)
 - (4) HIV
 - (5) Varicella

- (6) Rubella
- (7) Enterovirus
- viii) Non-infectious inflammatory processes
 - (1) Chemical meningitis
 - (2) Limbic encephalitis
 - (3) Lymphocytic hypophysitis
 - (4) Granulomatous processes
 - (a) Sarcoidosis
 - (b) Histiocytosis
- ix) White matter inflammatory conditions
 - (1) Multiple sclerosis
 - (2) Viral and post-viral demyelination
- e) Congenital/ developmental
 - i) Chiari malformations
 - ii) Cephaloceles
 - iii) Corpus callosum anomalies
 - iv) Holoprosencephalies
 - v) Septo-optic dysplasia
 - vi) Sulcation and migrational disorders
 - vii) Posterior fossa malformations
 - viii) Cysts
 - ix) Neurocutaneous syndromes
 - (1) Neurofibromatosis (NF) I and II
 - (2) Tuberous sclerosis
 - (3) von Hippel-Lindau disease
 - (4) Sturge-Weber syndrome
 - (5) Basal cell nevus syndrome
 - (6) Klippel-Trenaunay-Weber syndrome
 - (7) Wyburn-Mason syndrome
 - (8) Rendu-Osler-Weber syndrome
 - (9) Ataxia- telangiectasia
 - (10) Neurocutaneous melanosis
 - x) Normal patterns of cortical and white matter development, and deviations from normal
 - (1) Cortical dysplasias
 - (2) Hemimegalencephaly

Recognize and be familiar with the imaging appearance and clinical presentation of mesial temporal sclerosis and other seizure-associated conditions.

- f) Cyst and hydrocephalus
 - i) Communicating and obstructive hydrocephalus
 - ii) Arachnoid cyst
 - iii) Colloid cyst

- iv) Rathke cleft cyst
- v) Neuroepithelial cyst
- vi) Disorders of cerebrospinal fluid hydrodynamics
 - (1) Increased intracranial pressure from hydrocephalus and shunt malfunction
 - (2) Intracranial hypotension
 - (3) Complications of cerebrospinal fluid diversion procedures
- g) Tumors and tumorlike conditions
 - i) Locations
 - (1) Parenchymal
 - (2) Meningeal
 - (3) Pineal region
 - (4) Intraventricular
 - (5) Sellar/suprasellar
 - (6) Cerebellopontine angle
 - (7) Skull base
 - (8) Cavernous sinus
 - (9) Foramen magnum
 - ii) Tumor types
 - (1) Low-grade and malignant astrocytomas
 - (2) Glioblastoma multiforme
 - (3) Gliosarcoma
 - (4) Gliomatosis cerebri
 - (5) Pleomorphic xanthoastrocytoma
 - (6) Pilocytic astrocytoma
 - (7) Subependymal giant cell astrocytoma
 - (8) Oligodendrogioma
 - (9) Ependymoma
 - (10) Subependymoma
 - (11) Choroid plexus tumors
 - (12) Meningioma
 - (13) Hemangiopericytoma
 - (14) Hemangioblastoma
 - (15) Ganglioglioma
 - (16) Gangliocytoma
 - (17) Central neurocytoma
 - (18) Dysembryoplastic neuroepithelial tumor (DNET)
 - (19) Lhermitte-Duclos syndrome
 - (20) Germ cell tumors
 - (21) Primitive neuroectodermal tumor (PNET)
 - (22) Lymphoma
 - (23) Leukemia
 - (24) Myeloma
 - (25) Schwannoma
 - (26) Neurofibroma
 - (27) Malignant peripheral nerve sheath tumor

- (28) Craniopharyngioma
- (29) Pituitary adenoma
- (30) Chordoma
- (31) Chondrosarcoma
- (32) Dermoid
- (33) Epidermoid
- (34) Lipoma

In the case of primary brain tumors, be familiar with differentiating imaging findings for various tumor grades. Recognize imaging appearance in postoperative and post-treatment changes.

h) Trauma

- i) Subarachnoid hemorrhage
 - ii) Epidural and subdural hematoma
 - iii) Contusion
 - iv) Axonal injury
 - v) Diffuse cerebral edema
 - vi) Herniation patterns
 - vii) Complications and sequelae of head trauma
 - (1) Ischemia
 - (2) Infarction
 - (3) Secondary hemorrhage
 - (4) Pneumocephalus
 - (5) Cerebrospinal fluid leak
 - (6) Encephalomalacia
 - viii) Non-accidental trauma
- i) Vascular pathology: Clinical presentation of, complications from, and treatment options for:
- i) Aneurysm
 - (1) Saccular
 - (2) Mycotic
 - (3) Traumatic
 - (4) Oncotic
 - (5) Flow-related
 - (6) Drug-related
 - (7) Vasculopathic
 - (8) Fusiform
 - (9) Dissecting
 - (10) Pseudoaneurysm
 - ii) Vascular malformations
 - (1) Pial
 - (2) Dural
 - (3) Mixed
 - (4) Arteriovenous-fistulae

- (5) Cavernous angiomas
- (6) Capillary telangiectasias
- (7) Developmental venous anomalies
- (8) Vein of Galen malformations
- (9) Venous varix
- iii) Stroke
 - (1) Arterial
 - (2) Venous
 - (3) Vasculitic, including specific patterns
 - (4) Hypoxic-anoxic encephalopathy
 - (5) Vasculitis
 - (6) Posterior reversible encephalopathy syndrome
 - (7) Vascular occlusive disease
- iv) Intracranial hemorrhage
 - (1) Age of blood products on CT and MRI
 - (2) Patterns of hemorrhage with regard to causative factors
 - (a) Trauma
 - (b) Neoplasm
 - (c) Aneurysm
 - (d) Vascular malformation
 - (e) Vasculitis
 - (f) Non-aneurysmal subarachnoid hemorrhage
 - (g) Hypertension
 - (h) Hemorrhagic infarct (arterial and venous)
 - (i) Amyloid angiopathy

3) Spine

- a) Normal anatomy
 - i) Bony vertebral anatomy
 - ii) Intervertebral discs
 - iii) Facet joints
 - iv) Ligaments
 - v) Spinal cord
 - vi) Nerve roots and plexuses
 - vii) Meninges
 - viii) Intradural and extradural spaces
 - ix) Surrounding soft tissues
- b) Congenital/developmental
 - i) Chiari malformations
 - ii) Spinal dysraphism (open and occult)
 - iii) Tethered cord
 - iv) Caudal regression syndrome
 - v) Spinal lipomas
 - vi) Sacral meningocele

- vii) Sacrococcygeal teratoma
 - viii) Split notochord syndromes
 - ix) Enterogenous cyst
 - x) Scoliosis
 - xi) Fusion anomalies
 - xii) Segmentation anomalies
 - xiii) Neurofibromatosis type I
 - xiv) Neurofibromatosis type II
 - xv) von Hippel-Lindau disease
- c) Degenerative disease
- i) Normal aging
 - ii) Disc degeneration
 - iii) Disc bulges and herniations (including appropriate descriptive terminology)
 - iv) Spondylosis
 - v) Arthrosis
 - vi) Synovial cyst
 - vii) Spondylolisthesis
 - viii) Spondylysis
 - ix) Spinal stenosis
 - x) Ossification of the posterior longitudinal ligament (OPLL)
 - xi) Diffuse idiopathic sclerosing hyperostosis (DISH)
 - xii) Scheuermann disease
 - xiii) Arthritides
 - xiv) Postoperative spine
- d) Infection/inflammatory/demyelinating in specific anatomic sites
- i) Arachnoiditis
 - ii) Diskitis
 - iii) Osteomyelitis
 - iv) Epidural infection
 - v) Subdural infection
 - vi) Subarachnoid infection
 - vii) Meningitis
 - viii) Myelitis
 - ix) Spinal cord abscess
- e) Infection/inflammatory/demyelinating-specific pathologies
- i) Bacterial
 - ii) Mycobacterial
 - iii) Fungal
 - iv) Viral
 - v) Parasitic
 - vi) Granulomatous

- vii) Transverse myelitis
 - viii) HIV myelopathy
 - ix) Radiation-induced myelitis
 - x) Acute disseminated encephalomyelitis (ADEM)
 - xi) Multiple sclerosis
- f) Trauma
- i) Cervical, thoracic, and lumbosacral fracture
 - ii) Osteoporotic compression fracture
 - iii) Subluxation
 - iv) Dislocation
 - v) Spinal cord injury and its sequelae
 - vi) Epidural and subdural hematoma
 - vii) Plexus injuries
- g) Vascular
- i) Spinal cord ischemia and infarction (arterial & venous)
 - ii) Arteriovenous malformations
 - (1) Dural arteriovenous fistula (AVF)
 - (2) Glomus malformations
 - (3) Juvenile type malformations
 - (4) Intradural extramedullary AVF
 - (5) Cavernous angiomas
- h) Tumors and tumorlike masses: benign and malignant neoplasms of the vertebral column, spinal cord, and nerves
- i) Schwannoma
 - ii) Neurofibroma
 - iii) Malignant peripheral nerve sheath tumor
 - iv) Meningioma
 - v) Dermoid
 - vi) Epidermoid
 - vii) Paraganglioma
 - viii) Astrocytoma
 - ix) Ependymoma
 - x) Hemangioblastoma
 - xi) Lymphoma
 - xii) Leukemia
 - xiii) Myeloma
 - xiv) Plasmacytoma
 - xv) Chordoma
 - xvi) Chondrosarcoma
 - xvii) Osteosarcoma
 - xviii) Fibrosarcoma

- xix) Ewing sarcoma
 - xx) Hemangiomas
 - xxi) Osteoblastoma
 - xxii) Osteoid osteoma
 - xxiii) Osteochondroma
 - xxiv) Giant cell tumor
 - xxv) Aneurysmal bone cyst
 - xxvi) Angiolipoma
 - xxvii) Eosinophilic granuloma
 - xxviii) Pathologic fractures
 - xxix) Metastatic disease
- i) Miscellaneous
 - i) Arachnoid cyst
 - ii) Parameningeal cyst
 - iii) Spinal cord herniation

4) Extracranial Head and Neck

- a) Normal anatomy—bone and soft tissues
 - i) Orbit
 - ii) Paranasal sinuses
 - iii) Facial bones
 - iv) Skull base
 - v) Temporal bone, including temporomandibular joint (TMJ)
 - vi) Nasal cavity
 - vii) Oral cavity
 - viii) Oropharynx
 - ix) Nasopharynx
 - x) Hypopharynx
 - xi) Larynx
 - xii) Neck spaces (suprathyroid and infrathyroid)
 - xiii) Classification of lymph node level
- b) Normal anatomy—vascular: normal extracranial arterial and venous structures on vascular imaging modalities
 - i) CT angiography
 - ii) MR angiography
 - iii) Ultrasound
 - iv) Catheter angiography
- c) Infectious/inflammatory/granulomatous
 - i) Orbit
 - (1) Preseptal cellulitis
 - (2) Orbital cellulitis

- (3) Subperiosteal phlegmon and abscess
 - (4) Extension of fungal sinus disease
 - (5) Pseudotumor
 - (6) Thyroid orbitopathy
 - (7) Sarcoid
 - (8) Lacrimal adenitis
 - (9) Wegener granulomatosis
 - (10) Tolosa-Hunt syndrome
 - (11) Optic neuritis
- ii) Sinonasal cavity/facial bones
 - (1) Osteomyelitis
 - (2) Acute sinusitis
 - (3) Chronic sinusitis
 - (4) Complications of sinusitis
 - (5) Fungal infection
 - (a) Immunocompromised and immunocompetent patients
 - (b) Allergic fungal sinusitis
 - (6) Polyps
 - (7) Polyposis
 - (8) Mucocele
 - (9) Retention cyst
 - (10) Antrochoanal polyp
 - (11) Sarcoid
 - (12) Wegener granulomatosis
 - iii) Skull base and temporal bone
 - (1) Osteomyelitis
 - (2) Necrotizing otitis externa
 - (3) Petrous apicitis
 - (4) Otitis externa
 - (5) Otitis media
 - (6) Mastoiditis
 - (7) Cholesteatoma
 - (8) Ramsey-Hunt syndrome
 - (9) Labyrinthitis
 - (10) Labyrinthitis ossificans
 - (11) Bell palsy
 - (12) Otosclerosis
 - iv) Oral cavity, pharynx, supra- and infrahyoid neck
 - (1) Odontogenic infections
 - (2) Infections of salivary gland origin
 - (3) Tonsillitis
 - (4) Adenoiditis
 - (5) Cellulitis, phlegmon, and abscess involving neck spaces
 - (6) Sjögren disease

- (7) Non-neoplastic lymphadenopathy
 - (a) Viral
 - (b) Bacterial
 - (c) Mycobacterial
 - (d) Granulomatous
- (8) Thyroiditis (acute and chronic, e.g., Hashimoto)
- d) Tumors and tumor-like conditions
 - i) Orbit
 - (1) Optic nerve sheath meningioma
 - (2) Optic glioma
 - (3) Lacrimal gland tumors
 - (4) Rhabdomyosarcoma
 - (5) Retinoblastoma
 - (6) Ocular hamartoma
 - (7) Uveal melanoma
 - (8) Metastases
 - (9) Cavernous hemangiomas
 - (10) Vasoformative lesions
 - (a) Infantile hemangiomas
 - (b) Lymphatic/venous malformations
 - (11) Lymphoma/leukemia
 - ii) Sinonasal cavity and facial bones
 - (1) Squamous cell carcinoma
 - (2) Undifferentiated carcinoma
 - (3) Lymphoma
 - (4) Melanoma
 - (5) Esthesioneuroblastoma
 - (6) Inverted papilloma
 - (7) Minor salivary gland neoplasms
 - (8) Schwannoma and meningioma
 - (9) Juvenile nasal angiofibroma
 - (10) Vasoformative lesions
 - (a) Infantile hemangiomas
 - (b) Lymphatic/venous malformations
 - (c) Arteriovenous malformations
 - (11) Hemangiopericytoma
 - (12) Rhabdomyosarcoma
 - (13) Osteoma
 - (14) Osteoblastoma
 - (15) Giant cell tumor
 - (16) Rhabdomyosarcoma
 - (17) Malignant fibrous histiocytoma
 - (18) Plasmacytoma

- (19) Paget disease
 - (20) Fibrous dysplasia
 - (21) Ossifying fibroma and other fibroosseous lesions
 - (22) Myxoma
 - (23) Chondroma
 - (24) Chondrosarcoma
 - (25) Osteosarcoma
 - (26) Ewing sarcoma
 - (27) Ameloblastoma
 - (28) Aneurysmal bone cyst
 - (29) Odontogenic cysts and tumors
 - (30) Langerhans cell histiocytosis
 - (31) Metastases
- iii) Skull base and temporal bone
- (1) Hemangiomas
 - (2) Angiofibroma
 - (3) Schwannoma
 - (4) Neurofibroma
 - (5) Teratoma
 - (6) Dermoid
 - (7) Pituitary adenoma
 - (8) Germinoma
 - (9) Lymphoma
 - (10) Nasopharyngeal carcinoma
 - (11) Salivary gland tumors
 - (12) Chloroma
 - (13) Plasmacytoma
 - (14) Metastases
 - (15) Myeloma
 - (16) Chondrosarcoma
 - (17) Chordoma
 - (18) Endolymphatic sac tumor
 - (19) Paraganglioma
 - (20) Adenoma
 - (21) Neuroma
 - (22) Langerhans cell histiocytosis/eosinophilic granuloma
 - (23) Osteoblastoma
 - (24) Giant cell tumor
 - (25) Pigmented villonodular synovitis
 - (26) Rhabdomyosarcoma
 - (27) Paget disease
 - (28) Fibrous dysplasia
 - (29) Osteoma/exostosis
 - (30) Meningioma

- iv) Oral cavity, pharynx, supra, and infrahyoid neck
 - (1) Malignant adenopathy
 - (2) Lymphoma
 - (3) Squamous cell carcinoma
 - (4) Schwannoma
 - (5) Neuroma
 - (6) Neurofibroma
 - (7) Goiter
 - (8) Thyroid neoplasms
 - (9) Parathyroid neoplasms
 - (10) Salivary gland neoplasms
 - (11) Vasoformative lesions
 - (a) Infantile hemangiomas
 - (b) Lymphatic/venous malformations
 - (c) Arteriovenous malformations
 - (12) Paraganglioma
 - (13) Lipoma/liposarcoma
- e) Cystic lesions of the head and neck i)
 - Branchial cleft cysts (types I-IV)
 - ii) Thyroglossal duct cyst
 - iii) Ranula
 - iv) Dermoid/epidermoid
 - v) Thymic cyst
 - vi) Cystic hygroma (lymphangioma)
 - vii) Laryngopyocele
 - viii) Cystic lymph nodes
- f) Trauma
 - i) Orbital fractures
 - ii) Soft tissue injuries of the globe and orbit
 - iii) Maxillofacial fracture
 - iv) Mandibular fractures
 - v) Temporomandibular joint (TMJ) fracture/dislocation
 - vi) Skull base fractures
 - vii) Temporal bone fractures (including classification systems)
 - (1) Longitudinal/transverse
 - (2) Otic capsule spared/involved
 - viii) Laryngeal fractures
- g) Vascular
 - i) Orbit
 - (1) Venous varix
 - (2) Hemangiomas

- (3) Lymphangioma
- (4) Superior ophthalmic vein thrombosis
- (5) Carotid-cavernous fistula ii)
- Sinonasal cavity/facial bones
- iii) Skull base/temporal bone
 - (1) Dissection
 - (2) Aneurysm
 - (3) Pseudoaneurysm
 - (4) Aberrant internal carotid artery
 - (5) Persistent stapedial artery
 - (6) Jugular dehiscence
 - (7) Jugular diverticulum
 - (8) High-riding jugular bulb
- iv) Oral cavity, pharynx, supra- and infrahyoid neck
 - (1) Medial course of internal carotid artery
 - (2) Dissection
 - (3) Thrombosis
 - (4) Occlusion
 - (5) Pseudoaneurysm
 - (6) Fibromuscular dysplasia
 - (7) Aneurysm
- h) Congenital
 - i) Orbit
 - (1) Sphenoid wing dysplasia
 - (2) Septooptic dysplasia
 - (3) Coloboma
 - (4) Congenital glaucoma
 - (5) Persistent hyperplastic primary vitreous (PHPV)
 - (6) Coats disease
 - (7) Toxocariasis
 - (8) Infantile hemangiomas
 - (9) Lymphatic malformation
 - (10) Dermoid
 - ii) Sinonasal cavity/facial bones
 - (1) Hypoplasia
 - (2) Aplasia
 - (3) Down syndrome
 - (4) Kartagener syndrome
 - (5) Cephaloceles/nasal glioma
 - (6) Choanal atresia
 - iii) Skull base/temporal bone
 - (1) Cephaloceles
 - (2) Arachnoid cyst

- (3) External auditory canal atresia
- (4) Aberrant facial nerve course
- (5) Congenital cholesteatoma
- (6) Ossicular deformities
- (7) Large vestibular aqueduct syndrome
- (8) Mondini defect
- (9) Michel aplasia
- iv) Oral cavity, pharynx, and supra- and infrahyoid neck
- i) Branchial cleft cysts (types I-IV)
 - i) Thyroglossal duct cyst
 - ii) Lingual thyroid
 - iii) Dermoid/epidermoid
 - iv) Thymic cyst
 - v) Vasoformative lesions
 - (1) Infantile hemangiomas
 - (2) Lymphatic/venous malformations
 - (3) Arteriovenous malformations

Nuclear Radiology

1) Breast

- a) Benign neoplasm
 - i) Radiopharmaceuticals: ^{18}F FDG
 - ii) Imaging techniques: PET and PET-CT
 - iii) Quantitative Analysis: SUV_{\max}
 - iv) Typical Indication: Incidental lesion
- b) Malignant neoplasm, primary
 - i) Radiopharmaceutical: ^{18}F FDG
 - ii) Imaging techniques: Planar, SPECT and SPECT/CT; PET and PET/CT
 - iii) Quantitative Analysis: SUV_{\max}
 - iv) Typical Indication: Staging breast cancer
- c) Malignant neoplasm, metastatic
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ HDP/MDP; ^{18}F FDG; ^{18}F NaF
 - ii) Imaging techniques: Planar, SPECT and SPECT/CT; PET and PET/CT
 - iii) Quantitative Analysis: SUV_{\max}
 - iv) Typical Indications: Skeletal metastases, staging/restaging breast cancer, treatment strategy/monitoring breast cancer
- d) Infection and inflammation
 - i) Radiopharmaceuticals: ^{67}GA citrate, $^{111}\text{In}/^{99\text{m}}\text{Tc}$ WBCs, ^{18}F FDG
 - ii) Imaging techniques: Planar, SPECT and SPECT/CT; PET and PET/CT
 - iii) Quantitative Analysis: SUV_{\max}
 - iv) Typical Indications: Identification and localization of SLN for intra-operative gamma probe-directed sampling in breast cancer
- e) Lymphatic mapping/sentinel lymph node (SLN)
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ sulfur colloid; $^{99\text{m}}\text{Tc}$ tilmanocept (Lymphoseek)
 - ii) Injection techniques: intradermal, periareolar
 - iii) Imaging and localization techniques: Planar, SPECT and SPECT-CT; intra-operative gamma probe
 - iv) Typical indications: breast abscess and inflammation
- f) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Injection techniques: all of the above
 - iii) Typical indications: all of the above
- g) Artifacts and quality control
 - i) Patient Issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
 - iii) Technical issues: instrumentation, acquisition and processing, transmission imaging, and quantification (e.g., SUV_{\max})

2) Cardiac

- a) Perfusion imaging, coronary artery disease
 - i) Radiopharmaceuticals: ^{99m}Tc sestamibi/tetrofosmin, ^{201}TI chloride; $^{13}\text{N NH}_3$ (ammonia), and ^{82}Rb chloride
 - ii) Stress protocols: exercise, pharmacologic (adenosine, dipyridamole, dobutamine, regadenoson)
 - iii) Imaging techniques: SPECT and SPECT-CT ECG-gated SPECT; PET and PET-CT
 - iv) Quantitative analysis: End-diastolic/end-systolic volumes, systolic function, diastolic function, summed stress score (SSS), transient ischemic dilatation (TID), left ventricular ejection fraction (LVEF)
 - v) Typical indications: Perfusion, function, regional wall motion/wall thickening; ischemia vs. infarction/scar, stunned myocardium, hibernating myocardium, risk stratification, ischemic cardiomyopathy
- b) Perfusion imaging, non-coronary artery disease
 - i) Radiopharmaceuticals: ^{99m}Tc sestamibi/tetrofosmin, ^{201}TI chloride; $^{13}\text{N NH}_3$ (ammonia), ^{82}Rb chloride, ^{99m}Tc , $^{18}\text{F FDG}$
 - ii) Stress protocols: exercise, pharmacologic (adenosine, dipyridamole, dobutamine, regadenoson)
 - iii) Imaging techniques: SPECT and SPECT-CT; ECG-gated SPECT and SPECT/CT; PET and PET/CT
 - iv) Typical indications: perfusion, function, regional wall motion/wall thickening; dilated/hypertrophic/non-ischemic cardiomyopathies, sarcoidosis, amyloidosis
- c) Metabolism and viability
 - i) Radiopharmaceuticals: ^{201}TI chloride; $^{18}\text{F FDG}$
 - ii) Imaging techniques: SPECT and SPECT/CT; ECG-gated SPECT; PET and PET/CT
 - iii) Typical Indications: Pre-operative evaluation for hibernating/viable myocardium vs. infarction/scar
- d) Function: multigated acquisition (MUGA)/Gated Blood Pool Imaging
 - i) Radiopharmaceuticals: ^{99m}Tc RBCs
 - ii) Imaging techniques: ECG-gated planar; ECG-gated SPECT
 - iii) Quantitative analysis: left ventricular ejection fraction (LVEF), phase analysis
 - iv) Typical Indications: baseline function, cardiotoxicity after chemotherapy, cardiomyopathy
- e) Right-to-left shunts
 - i) Radiopharmaceuticals: ^{99m}Tc MAA
 - ii) Imaging techniques: Planar
 - iii) Quantitative analysis: quantification of right-to-left shunt
 - iv) Typical indications: Right-to-left shunt (intra-cardiac or intra-pulmonary)
- f) Infection and inflammation
 - i) Radiopharmaceuticals: ^{67}Ga citrate, $^{111}\text{In}/^{99m}\text{Tc}$ WBCs; $^{18}\text{F FDG}$
 - ii) Imaging techniques: Planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: pericarditis/myocarditis, myocardial/valvular abscess, sarcoidosis
- g) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above

- h) Artifacts and quality control
- i) Patient issues: preparation, motion, positioning, and contamination; arrhythmia
- ii) Radiopharmaceutical issues: preparation, administration technique and timing, and altered biodistribution
- iii) Technical issues: instrumentation, acquisition and processing, attenuation-correction, ECG-gating, and quantification (e.g., SSS, TID, LVEF)

3) Gastrointestinal (GI)

- a) Biliary
 - i) Radiopharmaceuticals: 99m Tc IDA analogs
 - ii) Imaging techniques: Planar, SPECT, and SPECT-CT
 - iii) Pharmacologic protocols: morphine sulfate and sincalide (CCK)
 - iv) Quantitative analysis: gallbladder ejection fraction (GBEF)
 - v) Typical indications: acute cholecystitis, chronic acalculous cholecystitis/biliary dyskinesia, common bile duct obstruction, bile leak/biloma, post-operative complications, sphincter of Oddi dysfunction
- b) Liver and spleen
 - i) Radiopharmaceuticals: 99m Tc sulfur colloid, 99m Tc MAA, 99m Tc RBCs, damaged 99m Tc RBCs
 - ii) Imaging techniques: Planar, SPECT, and SPECT-CT
 - iii) Typical indications: cirrhosis, focal nodular hyperplasia (FNH), hepatic arterial perfusion/systemic shunting prior to radioembolization, cavernous hemangioma, accessory spleen/splenosis
- c) Bowel: Gastrointestinal (GI) bleeding
 - i) Radiopharmaceuticals: 99m Tc RBCs and 99m Tc pertechnetate
 - ii) Imaging techniques: Planar, SPECT, and SPECT-CT
 - iii) Pharmacologic protocols: H2 blockers
 - iv) Typical indications: active GI bleeding; Meckel diverticulum
- d) Bowel: Gastrointestinal (GI) motility
 - i) Radiopharmaceuticals: 99m Tc sulfur colloid as solid meal (eggs, other) or as liquid meal
 - ii) Imaging techniques: Planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: Warthin tumor, liver mass (e.g., focal nodular hyperplasia (FNH))
- e) Benign neoplasm
 - i) Radiopharmaceuticals: 99m Tc pertechnetate, 123 I/ 131 I NaI, 99m Tc sulfur colloid, 99m Tc IDA; 18 F FDG
 - ii) Imaging techniques: planar, SPECT and/or SPECT-CT; PET and PET-CT
 - iii) Typical indications: liver mass (e.g., fibronodular hyperplasia)
- f) Malignant neoplasm, primary
 - i) Radiopharmaceutical: 18 F FDG
 - ii) Imaging techniques: planar, SPECT and/or SPECT-CT; PET and PET-CT
 - iii) Typical indications: esophageal/gastric/hepatocellular (HCC)/biliary/pancreatic/GI stromal (GIST)/colorectal/peritoneal tumor, lymphoma
- g) Malignant neoplasm, metastatic
 - i) Radiopharmaceutical: 18 F FDG
 - ii) Imaging techniques: PET and PET-CT
 - iii) Typical indications: staging/restaging disease, treatment strategy/monitoring

- h) Infection and inflammation
 - i) Radiopharmaceuticals: ^{99m}Tc pertechnetate, $^{123}\text{I}/^{131}\text{I}$ NaI, ^{67}Ga citrate, $^{111}\text{In}/^{99m}\text{Tc}$ WBCs; ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: Sialadenitis, Sjogren syndrome, abscess, FUO, inflammatory bowel disease
- i) Therapy
 - i) Radiopharmaceutical: ^{90}Y
 - ii) Quantitative analysis: shunt fraction incorporation
 - iii) Patient issues: pregnancy, extra-hepatic activity
 - iv) Typical indications: colon cancer, metastases
- j. Normal and other
 - i) Radiopharmaceutical: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: Pleuro-peritoneal fistula, peritoneovenous shunt evaluation and all of the above
- k) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
 - iii) Technical issues Instrumentation, acquisition and processing, pharmaceutical injection (morphine sulfate), infusion (sincalide) protocols, and fatty-meal challenge; quantification (e.g., GBEF, SUV_{max})

4) Musculoskeletal

- a) Benign neoplasm
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, ^{18}F FDG
 - ii) Imaging techniques: Planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: Radiographically-visible (e.g., osteoid osteoma, osteoma, bone island, fibrous cortical defect, exostosis, cyst, chondromatous lesions), occult lesions
- b) Malignant neoplasm, primary
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, ^{18}F FDG
 - ii) Quantitative analysis: SUV_{max}
 - iii) Imaging techniques: Planar, SPECT and SPECT-CT; PET and PET-CT
 - iv) Typical indications: osteosarcoma, Ewing sarcoma, multiple myeloma, lymphoma
- c) Malignant neoplasm, metastatic
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, ^{18}F FDG
 - ii) Imaging techniques: Planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: staging/restaging disease, flare phenomenon, treatment strategy/monitoring
- d) Tumor-like conditions
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; F-18 NaF, F-18 FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT

- iii) Quantitative analysis: SUV_{max}
- iv) Typical indications: fibrous dysplasia, Paget disease, hypertrophic osteoarthropathy, heterotopic bone formation
- e) Metabolic and vascular abnormalities
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP, ^{99m}Tc sulfur colloid; ¹⁸F NaF, ¹⁸F FDG
 - ii) Imaging techniques: three-phase, planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: hyperparathyroidism, "Superscan" (renal osteodystrophy, myelofibrosis), avascular necrosis, complex regional pain syndrome, and hypertrophic arthropathy
- f) Trauma
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP, ¹⁸F NaF, ¹⁸F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: traumatic/stress/insufficiency/occult fracture, nonaccidental trauma, neuropathic joint, heterotopic bone formation, rhabdomyolysis
- g) Infection and inflammation
 - i) Radiopharmaceuticals: ⁶⁷Ga citrate, ¹¹¹In/^{99m}Tc WBCs, ^{99m}Tc HDP/MDP, ^{99m}Tc sulfur colloid; ¹⁸F NaF, ¹⁸F FDG
 - ii) Imaging techniques: three-phase, dual-radiopharmaceutical; planar, SPECT and SPECT/CT; PET and PET/CT
 - iii) Typical indications: osteomyelitis, cellulitis, synovitis/arthritis, septic joint, discitis, myositis, hardware infection vs. loosening
- h) Extraskeletal processes
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Typical findings: benign (e.g., metastatic pulmonary calcification as in hypercalcemia, myocardial infarction/myocarditis/pericarditis, cardiac amyloidosis, vascular calcifications, renal anomalies, rhabdomyolysis, calciphylaxis) vs. malignant (e.g., primary breast carcinoma, lung cancer, pleural effusion, liver metastases as in breast or colon cancer, peritoneal ovarian carcinomatosis, renal cancer)
- i) Bone mineral density (BMD) (dual-energy x-ray absorptiometry, DEXA/DXA)
 - i) Imaging techniques: DEXA/DXA
 - ii) Quantitative analysis and pitfalls: T-score, Z-score, region-of-interest (ROI) selection, artifacts (e.g., arthritis, hardware)
 - iii) Typical indications: osteoporosis vs osteopenia, fracture risk assessment, treatment strategy/monitoring effects of medication, hyperparathyroidism
- j) Therapy
 - i) Radiopharmaceuticals: ²²³Ra dichloride (Xofigo), dosing regimen
 - ii) Patient issues: lab values, exclusion criteria
 - iii) Typical indications: symptomatic bone mets from prostate cancer
- k) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above
- l) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, altered

biodistribution

- iii) Technical issues: instrumentation, acquisition and processing, quantification (SUV_{max} ; T-score, Z-score)

5) Neurology

- a) Brain death/viability
 - i) Radiopharmaceuticals: ^{99m}Tc ECD (Neurolite)/HMPAO (Ceretec), and ^{99m}Tc DTPA
 - ii) Imaging techniques: planar, SPECT, and SPECT-CT
 - iii) Typical indications: evaluation of cerebral perfusion, confirmation of clinical brain death vs. brain viability
- b) Stroke, cerebrovascular disease, and vascular reserve
 - i) Radiopharmaceuticals: ^{99m}Tc ECD (Neurolite)/HMPAO (Ceretec); ^{18}F FDG
 - ii) Imaging techniques: SPECT and SPECT-CT; PET and PET-CT
 - iii) Stress protocols: Acetazolamide (Diamox) challenge
 - iv) Typical indications: ischemia vs infarction (stroke), vascular reserve, cross-cerebellar diaschisis
- c) Dementias, behavioral disorders, and movement disorders
 - i) Radiopharmaceuticals: ^{99m}Tc ECD (Neurolite)/HMPAO (Ceretec), ^{123}I FP CIT (ioflupane; DaTscan); ^{18}F FDG, ^{18}F amyloid agents
 - ii) Imaging techniques: SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: Dementia (e.g., Alzheimer, Lewy body-associated, frontotemporal, multi-infarct, senile); depression; Parkinson disease/essential tremor, Huntington disease
- d) Seizure
 - i) Radiopharmaceuticals: ^{99m}Tc ECD (Neurolite)/HMPAO (Ceretec); ^{18}F FDG
 - ii) Imaging techniques: SPECT and SPECT-CT; PET and PET-CT
 - iii) Stress protocols: ictal injection/timing
 - iv) Typical indications: localization of seizure focus, and interictal vs ictal protocols
- e) Benign neoplasm
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP, ^{111}In pentetreotide (OctreoScan), and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: meningioma
- f) Malignant neoplasm, primary
 - i) Radiopharmaceuticals: ^{18}F FDG, ^{99m}Tc sestamibi, ^{201}TI CI
 - ii) Imaging techniques: PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: glioblastoma, astrocytoma, lymphoma, tumor viability, radionecrosis
- g) Malignant neoplasm, metastatic
 - i) Radiopharmaceutical: ^{18}F FDG
 - ii) Imaging techniques: PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Indications: staging/restaging disease, treatment strategy/monitoring, tumor viability, radionecrosis
- h) Infection and inflammation

- i) Radiopharmaceuticals: ^{67}Ga citrate, $^{111}\text{In}/^{99m}\text{Tc}$ WBCs; ^{18}F FDG
- ii) Imaging techniques: SPECT and SPECT-CT; PET and PET-CT
- iii) Typical indications: abscess, encephalitis, toxoplasmosis (e.g., immunocompromised)
- i) Cerebrospinal fluid (CSF)
 - i) Radiopharmaceuticals $^{111}\text{In}/^{99m}\text{Tc}$ DTPA
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Typical indications: normal pressure, hydrocephalus, leak, V-P shunt patency
- j) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above
- k) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
 - iii) Technical issues: instrumentation, acquisition and processing, quantification (e.g., SUV_{max})

6) Pediatrics

- a) Brain and cerebrospinal fluid (CSF)
 - i) Radiopharmaceuticals: ^{99m}Tc ECD (Neurolite)/HMPAO (Ceretec); ^{18}F FDG; $^{111}\text{In}/^{99m}\text{Tc}$ DTPA
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: evaluation of cerebral perfusion, confirmation of clinical brain death vs. brain viability; seizure, neoplasm; V-P shunt patency, hydrocephalus, leak
- b) Cardiac
 - i) Radiopharmaceuticals: ^{99m}Tc RBCs, ^{99m}Tc sestamibi/tetrofosmin
 - ii) Imaging techniques: ECG-gated planar, SPECT, SPECT and SPECT-CT; ECG-gated SPECT and SPECT-CT
 - iii) Quantitative analysis: left ventricular ejection fraction (LVEF)
 - iv) Typical indications: congenital heart disease, Kawasaki disease, left ventricular (LV) dysfunction
- c) Thoracic
 - i) Radiopharmaceuticals: ^{99m}Tc MAA, ^{99m}Tc DTPA aerosol, ^{133}Xe gas,
 - ii) Imaging techniques: planar, SPECT, and SPECT-CT
 - iii) Typical indications: pulmonary artery atresia, right-to-left shunt, cystic fibrosis, Swyer-James-MacLeod syndrome
- d) Hepatobiliary system
 - i) Radiopharmaceuticals: ^{99m}Tc sulfur colloid, ^{99m}Tc RBCs, ^{99m}Tc IDA analogs
 - ii) Imaging techniques: planar, SPECT, and SPECT-CT
 - iii) Pharmacologic protocols: phenobarbital, sincalide (CCK)
 - iv) Quantitative analysis: gallbladder ejection fraction (GBEF)
 - v) Typical indications: Hepatic masses, cavernous hemangioma, biliary atresia vs. neonatal hepatitis, acute cholecystitis, chronic acalculous cholecystitis/biliary dyskinesia, common bile duct obstruction, bile leak/biloma, post-operative complications
- e) Gastrointestinal Tract

- i) Radiopharmaceuticals: ^{99m}Tc sulfur colloid, ^{99m}Tc pertechnetate, ^{99m}Tc RBCs, heat-damaged ^{99m}Tc RBCs
- ii) Imaging techniques: planar, SPECT and SPECT/CT
- iii) Pharmacologic protocols: H₂ blockers, etc.
- iv) Quantitative Analysis: Gastric emptying T½
- v) Typical indications: aspiration, gastroesophageal reflux, gastric emptying/gastroparesis; Meckel diverticulum, active GI bleeding; accessory spleen/splenosis, splenomegaly
- f) Musculoskeletal
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT, and SPECT-CT; PET and PET-CT
 - iii) Typical indications: osteoid osteoma, fracture, avascular necrosis, osteomyelitis, congenital/developmental syndromes, nonaccidental trauma, metastases, fibrous dysplasia, spondylolysis
- g) Endocrine
 - i) Radiopharmaceuticals: ^{123}I Nal, ^{99m}Tc pertechnetate; ^{131}I Nal
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Typical indications: hypothyroidism (lingual thyroid, agenesis, organification defect), hyperthyroidism, thyroid cancer, and radioiodine therapy
- h) Infection and inflammation
 - i) Radiopharmaceuticals: ^{67}Ga citrate, $^{111}\text{In}/^{99m}\text{Tc}$ WBCs; ^{99m}Tc HDP/MDP; ^{18}F FDG
 - ii) Imaging techniques: three-phase, dual-radiopharmaceutical; planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: osteomyelitis cellulitis, synovitis/arthritis, septic joint, diskitis, abscess, FUO, inflammatory bowel disease, lung inflammation
- i) Neoplasm
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP, ^{123}I MIBG, ^{111}In pentetreotide (OctreoScan); ^{18}F FDG, ^{18}F NaF
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical Indications: staging/restaging osteosarcoma/Ewing sarcoma, histiocytosis/eosinophilic granuloma, neuroblastoma, lymphoma, hepatic tumors, renal tumors; treatment strategy/monitoring; thymus
- j) Urinary Tract
 - i) Radiopharmaceuticals: ^{99m}Tc DMSA, ^{99m}Tc DTPA, ^{99m}Tc MAG3, and ^{99m}Tc sulfur colloid
 - ii) Imaging techniques: planar (e.g., radionuclide cystography (RNC)), SPECT and SPECT-CT
 - iii) Pharmacologic protocols: diuretics (e.g., furosemide)
 - iv) Quantitative analysis: relative renal function, glomerular filtration rate (GFR) calculation; renogram curves, response to diuretic challenge (T½)
- k) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging Techniques: all of the above
 - iii) Typical Indications: all of the above
- l) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination; radioiodine dosimetry

- ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
- iii) Technical issues: instrumentation, acquisition and processing, and quantification (e.g., 24-hour uptake, T_½, GBEF; SUV_{max})

7) Reproductive/Endocrine

- a) Thyroid gland
 - i) Radiopharmaceuticals: ¹²³I Nal, ^{99m}Tc pertechnetate, ¹⁸F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT, PET and PET/CT
 - iii) Quantitative techniques: uptake probe (24-hour radioiodine uptake), SUV_{max}
 - iv) Typical indications: goiter (*in situ*, substernal), pyramidal lobe, benign and malignant (e.g., “cold”) thyroid nodules, multinodular gland, hyperthyroidism (e.g., Graves’ disease, thyroiditis, toxic “hot” nodules)
- b) Thyroid cancer
 - i) Radiopharmaceuticals: ¹²³I/¹³¹I Nal, ¹¹¹In pentetreotide (OctreoScan), and; ¹⁸F FDG
 - ii) Pharmacologic protocols: rhTSH (Thyrogen)
 - iii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iv) Quantitative analysis: Uptake probe (e.g., 24-hour radioiodine uptake); SUV_{max}
 - v) Typical indications: Thyroid nodules, post-operative thyroid bed remnant, staging/restaging locoregional disease/distant metastases for differentiated and dedifferentiated papillary/follicular thyroid cancers and medullary thyroid cancers; treatment strategy/monitoring
- c) Therapy
 - i) Radiopharmaceuticals: ¹³¹I Nal
 - ii) Quantitative Analysis: calculation of administered activity for benign vs. malignant conditions
 - ii) Patient issues: selection, preparation, informed consent, understanding and calculation of administered activity, counseling of patients and families on radiation safety issues, release criteria, follow-up; pregnancy and lactation
 - iii) Typical indications: benign (hyperthyroidism, goiter), malignant (thyroid cancer remnant vs. metastases)
- d) Adrenal
 - i) Radiopharmaceuticals: ¹²³I MIBG, ¹¹¹In pentetreotide (OctreoScan), ¹⁸F FDG,
 - ii) Imaging techniques: planar, SPECT and SPECT-CT, PET and PET/CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: pheochromocytoma, cortical adenoma, metastasis
- e) Neuroendocrine
 - i) Radiopharmaceuticals: ¹²³I MIBG, ¹¹¹In pentetreotide (OctreoScan); ¹⁸F FDG, ⁶⁸Ga dotatate
 - ii) Imaging techniques: planar, SPECT and SPECT-CT, PET and PET/CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: carcinoid, pancreatic islet cell tumors, medullary thyroid cancer, pheochromocytoma/paraganglioma/neuroblastoma, metastasis
- f) Parathyroid gland
 - i) Radiopharmaceuticals: ^{99m}Tc sestamibi, ^{99m}Tc pertechnetate, and ¹²³I Nal
 - ii) Imaging techniques: dual-phase, dual-radiopharmaceutical, planar, SPECT and SPECT-CT
 - iii) Typical Indications: hyperparathyroidism (adenoma, hyperplasia, and ectopia)

- g) Female reproductive system neoplasms
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, ^{18}F FDG, ^{18}F NaF
 - ii) Quantitative analysis: SUV_{max}
 - iii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iv) Typical indications: differentiating benign from malignant uterine/ovarian lesions, staging/restaging disease, treatment strategy/monitoring
- h) Male reproductive system neoplasms
 - i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F FDG, ^{18}F NaF, ^{18}F fluciclovine
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iii) Typical indications: Prostate cancer, testicular cancer, skeletal metastases, staging/restaging disease, treatment strategy/monitoring
- i) Pregnancy safety concerns
 - i) Hyperthyroidism (^{131}I NaI)
 - ii) Thyroid cancer (^{131}I NaI)
 - iii) Radiation dosimetry and dose reduction in pregnant patients
- j) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above
- k) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
 - iii) Technical issues: instrumentation, acquisition and processing, quantification (e.g., 24-hour uptake, SUV_{max})

8) Thoracic

- a) Ventilation/perfusion, thromboembolic disease
 - i) Radiopharmaceuticals: ^{99m}Tc MAA, ^{99m}Tc DTPA aerosol, ^{133}Xe gas
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Typical indications: acute or chronic pulmonary emboli, secondary pulmonary hypertension (due to pulmonary emboli)
- b) Ventilation/perfusion, nonthromboembolic disease
 - i) Radiopharmaceuticals: ^{99m}Tc MAA, ^{99m}Tc DTPA aerosol, ^{133}Xe gas
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Quantitative techniques: regional/split/differential lung function/perfusion
 - iv) Typical indications: Fat emboli, hilar mass/neoplasm, vasculitis, pneumonia, pleural effusion, pre-pulmonectomy, pre-/post-pulmonary transplant evaluation
- c) Ventilation/perfusion, chronic obstructive airways disease (COPD) and airway disease
 - i) Radiopharmaceuticals: ^{99m}Tc MAA, ^{99m}Tc DTPA aerosol, ^{133}Xe gas
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Quantitative techniques: regional/split (differential) lung function/perfusion
 - iv) Typical indications: COPD, asthma, cystic fibrosis, mucus plug
- d) Benign neoplasm/mass/solitary pulmonary nodule (SPN)
 - i) Radiopharmaceuticals: ^{18}F FDG

- ii) Imaging techniques: PET and PET-CT
- iii) Typical indications: hamartoma, granuloma, "exclude malignancy", cancer
- e) Malignant neoplasm, primary
 - i) Radiopharmaceuticals: ^{111}In pentetreotide (OctreoScan) and ^{18}F FDG
 - ii) Imaging techniques: SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: carcinoid, esophageal cancer, mediastinal tumor, lung cancer, pleural neoplasm, lymphoma, thymic tumor
- f) Malignant neoplasm, metastatic
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ HDP/MDP; ^{18}F NaF, and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: Skeletal metastases, staging/restaging disease, treatment strategy/monitoring
- g) Infection and inflammation
 - i) Radiopharmaceuticals: ^{67}Ga citrate, $^{111}\text{In}/^{99\text{m}}\text{Tc}$ WBCs, and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: sarcoidosis, occupational lung disease, pneumonia, abscess, tuberculosis/ MAI, opportunistic infections (pneumocystis jirovecii), FUO, histoplasmosis, talc pleurodesis
- h) Trauma
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ HDP/MDP, $^{99\text{m}}\text{Tc}$ MAA, ^{133}Xe , and $^{99\text{m}}\text{Tc}$ DTPA aerosol, ^{133}Xe gas
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET CT
 - iii) Typical indications: rib fractures, pneumothorax, hemothorax
- i) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above
- j) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, altered biodistribution
 - iii) Technical issues: instrumentation, acquisition and processing, and quantification (e.g., regional/split/differential function; SUV_{max})

9) Urinary

- k) Perfusion and function
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ MAG-3, $^{99\text{m}}\text{Tc}$ DTPA
 - ii) Imaging techniques: planar
 - iii) Pharmacologic protocols: diuretics (e.g., furosemide)
 - iv) Quantitative analysis: split/differential renal function, response to diuretic challenge, renogram curves
 - v) Typical indications: obstructive vs. non-obstructive hydronephrosis, ureteral stent function
- l) Diuretic challenge
 - i) Radiopharmaceuticals: $^{99\text{m}}\text{Tc}$ MAG-3, $^{99\text{m}}\text{Tc}$ DTPA
 - ii) Imaging techniques: planar

- iii) Pharmacologic protocols: diuretics (e.g., furosemide)
 - iv) Quantitative analysis: Split/differential renal function, response to diuretic challenge, renogram curves
 - v) Typical indications: obstructive vs nonobstructive hydronephrosis, ureteral stent function
- m) Cortical
- i) Radiopharmaceutical: ^{99m}Tc DMSA
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Quantitative analysis: split/differential renal function
 - iv) Typical indications: split/differential function, pyelonephritis/scarring, ectopia/horseshoe kidney, pre-nephrectomy assessment
- n) Transplant
- i) Radiopharmaceuticals: ^{99m}Tc MAG-3 and ^{99m}Tc DTPA
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Quantitative analysis: renogram curves
 - iv) Typical indications: acute tubular necrosis, types of rejection, drug toxicity (e.g., cyclosporine), early and late complications (e.g., obstruction, infection, infarction, lymphocele, urinoma)
- o) Leak
- i) Radiopharmaceuticals: ^{99m}Tc MAG-3 and ^{99m}Tc DTPA
 - ii) Imaging techniques: planar, SPECT and SPECT-CT
 - iii) Typical indications: urinoma, leak after transplant/other surgery/instrumentation, trauma
- p) Benign neoplasm
- i) Radiopharmaceutical: ^{18}F FDG
 - ii) Imaging techniques: PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: angiomyolipoma, complex cystic mass
- q) Malignant neoplasm, primary
- i) Radiopharmaceutical: $^{18}\text{FFDG}$
 - ii) Imaging techniques: PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: lymphoma, renal cell cancer
- r) Malignant neoplasm, metastatic
- i) Radiopharmaceuticals: ^{99m}Tc HDP/MDP; ^{18}F NaF, and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: skeletal metastases, staging/restaging disease, treatment strategy/monitoring
- s) Infection and inflammation
- i) Radiopharmaceuticals: ^{99m}Tc DMSA, ^{67}Ga citrate, $^{111}\text{In}/^{99m}\text{Tc}$ WBCs, and ^{18}F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Typical indications: pyelonephritis, abscess
- t) Normal and other
- i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above

- iii) Typical indications: all of the above
- u) Artifacts and quality control
 - i) Patient issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, and altered biodistribution
 - iii) Technical Issues: instrumentation, acquisition and processing, quantification (e.g., SUV_{max})

10) Vascular

- a) Patency
 - i) Radiopharmaceuticals: ^{99m}Tc pertechnetate, ^{99m}Tc RBCs
 - ii) Imaging techniques: planar
 - iii) Typical indications: pre- and postoperative evaluation of native vessels, grafts
- b) Malignant neoplasm, primary
 - i) Radiopharmaceuticals: ¹⁸F FDG
 - ii) Imaging techniques: PET and PET-CT
 - iii) Typical indications: angiosarcoma, lymphoma
- c) Malignant neoplasm, metastatic/sentinel lymph node (SLN)
 - i) Radiopharmaceuticals: ^{99m}Tc sulfur colloid, ¹⁸F FDG, ^{99m}Tc tilmanocept (Lymphoseek)
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: lymphatic mapping/sentinel lymph node (SLN) (e.g., melanoma; staging/restaging disease, treatment strategy/monitoring (cardiovascular metastasis)
- d) Infection and inflammation
 - i) Radiopharmaceuticals: ⁶⁷Ga citrate, ¹¹¹In/^{99m}Tc WBCs, and ¹⁸F FDG
 - ii) Imaging techniques: planar, SPECT and SPECT-CT; PET and PET-CT
 - iii) Quantitative analysis: SUV_{max}
 - iv) Typical indications: vasculitis, vascular graft infection, catheter/line infection, atherosclerosis
- e) Normal and other
 - i) Radiopharmaceuticals: all of the above
 - ii) Imaging techniques: all of the above
 - iii) Typical indications: all of the above
- f) Artifacts and quality control
 - i) Patient Issues: preparation, motion, positioning, and contamination
 - ii) Radiopharmaceutical issues: preparation, administration technique, altered biodistribution
 - iii) Technical Issues: instrumentation, acquisition and processing, and quantification (e.g., SUV_{max})

Pediatric Radiology

- 1) **General Pediatric Imaging: Basic Knowledge/Competency with:**
 - a) National patient safety goals as they apply to pediatric imaging
 - b) Contrast reactions in children (features, prevention, and treatment)
 - c) General knowledge of practice-based imaging guidelines and appropriateness criteria (ACR Appropriateness Criteria and Practice Guidelines and Technical Standards)
 - d) ALARA principles (e.g., Image Gently Campaign) for modalities using ionizing radiation
 - e) Age-related development and normal anatomy
 - f) Appropriate appearance of surgical devices and support apparatus
 - g) Communication of urgent/emergent findings
 - i) List of urgent/emergent findings in children
 - h) Unique considerations for modalities:
 - i) Indications
 - (1) General for each
 - (2) Ultrasound
 - (a) Hips (effusion, congenital hip dysplasia)
 - (b) Spine
 - (c) Brain
 - (d) Chest/mediastinum
 - (e) Neck
 - (f) Imperforate anus (level of pouch)
 - (g) Intussusceptions
 - (h) Appendicitis
 - (i) Pyloric stenosis
 - (j) Diaphragm motion (infant)
 - (k) Interventional guidance
 - (3) CT urography
 - (4) MR urography, MR cholangiopancreatography (MRCP)
 - ii) Limitations
 - iii) General techniques
 - (1) Radiography
 - (a) Collimation
 - (b) Settings
 - (c) Numbers of views
 - (2) Fluoroscopy/angiography
 - (a) Pulsed fluoroscopy
 - (b) Other fluoroscopy settings
 - (c) Shielding
 - (d) Dose reduction techniques
 - (e) Special contrast use/considerations
 - (3) CT: dose reduction techniques and contrast doses
 - (4) MRI: coil optimization; contrast types and dose

- (5) RNI: see nuclear medicine study guide
iv) Risks

2) Brain, Head and Neck, and Spine

- a) Skull
 - i) Congenital
 - (1) Synostoses
 - (2) Congenital dermal sinus
 - (3) Dermoid/epidermoid
 - ii) Inflammatory
 - (1) Osteomyelitis
 - iii) Trauma
 - (1) Caput succedaneum
 - (2) Subgaleal hemorrhage
 - (3) Cephalohematoma
 - (4) Fractures (especially non-accidental injury/abuse)
 - iv) Basic temporal bone anatomy
 - (1) Congenital
 - (a) Mondini malformation
 - (b) Michele malformation
 - v) Inflammatory disorders
 - (1) Cholesteatoma
 - (2) Mastoiditis
 - vi) Variants
 - (1) Lückenschädel
 - (2) Wormian bones
 - (3) Parietal foramina
- b) Vertebral column
 - i) Congenital
 - (1) Absence or hypoplasia of odontoid
 - (2) Os odontoideum
 - (3) Segmentation anomalies
 - (4) Klippel-Feil anatomy
 - (5) Sprengel deformity
 - (6) Butterfly vertebra
 - (7) Spinal dysraphism
 - (8) Diastematomyelia
 - (9) Sacral agenesis (including caudal regression syndrome)
 - (10) Partial absence (including Currarino triad/ASP)
 - ii) Inflammatory
 - (1) Discitis
 - (2) Infectious spondylitis (tuberculosis)
 - iii) Neoplasms
 - (1) Ewing sarcoma

- (2) Aneurysmal bone cyst
 - (3) Osteoblastoma
 - (4) Osteoid osteoma
 - (5) Langerhans cell histiocytosis
 - (6) Metastases (including leukemia and lymphoma)
 - iv) Trauma
 - (1) Fractures/dislocations
 - (2) Atlanto-dens and atlanto-occipital injuries
 - (3) Spondylolysis/spondylolisthesis
 - (4) Insufficiency fracture (and etiologies)
 - v) Miscellaneous
 - vi) Dysplasia/syndromes
 - (1) Mucopolysaccharidoses
 - (2) Spondylometaphyseal dysplasia
 - vii) Scheuermann disease
 - viii) Scoliosis (repair and hardware complications)
- c) Brain
- i) Congenital
 - (1) Migrational disorders
 - (2) Lissencephaly
 - (3) Pachygryria
 - (4) Schizencephaly
 - (5) Heterotopic gray matter
 - (6) Polymicrogyria
 - (7) Holoprosencephaly
 - (8) Anomalies of corpus callosum
 - (9) Hydranencephaly
 - (10) Dandy-Walker malformations
 - (11) Chiari malformation types I and II
 - (12) Cephalocele
 - (13) Neurocutaneous syndromes
 - (14) Vein of Galen malformation (15)
 - Causes of hydrocephalus
 - (a) Aqueductal stenosis
 - (b) Syndromic
 - (c) Masses
 - ii) Inflammatory
 - (1) Bacterial infections
 - (a) Meningitis
 - (b) Cerebritis
 - (c) Abscess
 - (2) Tuberculosis infections
 - (3) Viral infections (encephalitis)
 - (a) TORCH infections

- iii) Neoplasms
 - iv) Posterior fossa
 - (1) Medulloblastoma
 - (2) Ependymoma
 - (3) Brainstem glioma
 - (4) Astrocytoma
 - v) Supratentorial
 - (1) Pineal region tumors
 - (2) Craniopharyngioma
 - (3) Astrocytoma
 - (4) Oligodendrogioma
 - (5) Primitive neuroectodermal tumor (PNET)
 - (6) Choroid plexus tumors
 - vi) Cerebral infarction/ischemia
 - (1) Childhood infarcts
 - (2) Arteritis
 - (3) Sickle cell (including moyamoya)
 - (4) Carotid occlusion
 - (5) Venous sinus thrombosis
 - (6) Intracranial hemorrhage
 - (7) Neonatal hypoxic ischemic injury
 - (a) Vascular borderzone infarctions
 - (b) Multicystic encephalomalacia
 - vii) Trauma (including nonaccidental injuries)
 - (1) Cerebral injury (including shearing injuries and concussion)
 - (2) Subdural hematoma
 - (3) Epidural hematoma
 - (4) Subarachnoid hemorrhage
 - viii) Syndromic/systemic
 - (1) Neurocutaneous syndromes
 - (2) Chiari malformation types I and II
 - ix) Vascular
 - (1) Arteriovenous malformations, congenital “aneurysms” (vein of Galen)
 - x) Metabolic brain disorders
 - (1) Leukodystrophies
- d) Spinal cord
- i) Congenital
 - (1) Myelomeningocele/meningocele
 - (2) Lipomyelomeningocele
 - (3) Diastematomyelia
 - (4) Tethered cord
 - (5) Dermal sinus
 - (6) Intradural lipoma
 - (7) Hydrosyringomyelia

- (8) Neurenteric cysts
- ii) Tumors
 - (1) Neurofibroma
 - (2) Astrocytoma
 - (3) Ependymoma
 - (4) Metastases
 - (5) Neuroblastoma, ganglioneuroblastoma, ganglioglioma
- iii) Sacrococcygeal masses
 - (1) Germ cell tumors (i.e., teratoma)
 - (2) Neuroblastoma
 - (3) Lymphoma
 - (4) Rhabdomyosarcoma
- iv) Other
 - (1) Infections
 - (2) Demyelinating disorders
 - (3) Trauma
 - (4) Vascular malformations
- e) Neck
 - i) Congenital
 - (1) Fibromatosis colli
 - (2) Lymphatic malformations
 - (3) Branchial cleft cysts
 - (4) Thyroglossal duct cysts
 - ii) Neoplasms
 - (1) Lymphoma
 - (2) Neuroblastoma
 - (3) Rhabdomyosarcoma
 - (4) Nasopharyngeal carcinoma
 - (5) Hemangiomas
 - iii) Infectious/inflammatory
 - (1) Adenitis
 - (2) Retropharyngeal abscess
 - iv) Thyroid disorders
 - (1) Absence/hypoplasia/ectopic
 - (2) Thyroiditis
 - (3) Thyroid masses
 - (4) Goiter
- f) Head/face
 - i) Congenital
 - (1) Vascular malformations
 - (2) Persistent hyperplastic primary vitreous (PHPV)
 - (3) Coloboma
 - ii) Inflammatory
 - (1) Orbital masses

- (2) Ocular masses
- (3) Orbital cellulitis
- (4) Sinusitis
- iii) Neoplastic/mass like
 - (1) Retinoblastoma
 - (2) Nasopharyngeal masses
 - (3) Carcinoma
 - (4) Juvenile angiofibroma
 - (5) Sinus masses
- iv) Trauma
 - (1) Facial fracture (Le Fort classification)

3) Chest and Airway

- a) Upper airway
 - i) Congenital
 - (1) Tracheomalacia/bronchomalacia/laryngomalacia
 - (2) Laryngeal stenosis, web, cleft
 - (3) Choanal atresia
 - (4) Masses: hemangioma
 - ii) Inflammatory
 - (1) Tonsillar enlargement/adenoidal hypertrophy
 - (2) Croup
 - (3) Epiglottitis
 - (4) Tracheitis
 - (5) Retropharyngeal abscess
 - iii) Neoplasm
 - (1) Juvenile angiofibroma
 - (2) Subglottic hemangioma
 - (3) Laryngeal papilloma
 - iv) Trauma
 - (1) Foreign body
 - (2) Acquired subglottic stenosis
- b) Chest
 - i) Congenital
 - (1) Agenesis/hypoplasia
 - (2) Venolobar syndrome
 - (3) Bronchial atresia
 - (4) Bronchopulmonary foregut malformations
 - (a) Sequestration
 - (b) Bronchogenic cyst
 - (c) Congenital pulmonary airway malformation (CPAM)/cystic adenomatoid malformation (CCAM)
 - (d) Congenital lobar emphysema
 - (e) Hybrid lesions

- (5) Tracheal bronchus
- (6) Tracheoesophageal fistula
- (7) Lymphangiectasia
- ii) Inflammatory
 - (1) Infections
 - (a) Bacterial pneumonia
 - (i) Streptococcus
 - (ii) Staphylococcus
 - (iii) Pertussis
 - (iv) Chlamydia
 - (v) Mycoplasma
 - (vi) H. influenza
 - (vii) Round pneumonia
 - (viii) Abscess
 - (ix) Complications
 - 1. Necrosis
 - 2. Abscess
 - 3. Fistulae
 - 4. Empyema
 - 5. Pneumatocele
 - (b) Viral pneumonia
 - (i) Respiratory syncytial virus (RSV)
 - (ii) Varicella
 - (iii) Measles
 - (c) Tuberculosis
 - (d) Fungal infections
 - (e) Other opportunistic infections
 - (f) Plasma cell granuloma/inflammatory pseudotumor and myofibroblastic inflammatory tumor
 - (2) Small airways disease
 - (a) Reactive airways disease
 - (b) Viral pneumonia
 - (3) Bronchiectasis: causes
 - (a) Cystic fibrosis
 - (b) Immotile cilia syndrome
 - (c) Chronic infection (primary immune disorders)
 - (d) Foreign body
 - (e) Aspiration

iii) Neoplasms/mass-like lesions

 - (1) Mediastinal masses
 - (a) Anterior
 - (i) Lymphoma/leukemia
 - (ii) Germ cell tumors
 - (iii) Thymoma/carcinoma

- (iv) Other masses: thymic cysts and bronchogenic cysts
- (v) Normal prominent thymus and thymic rebound
- (b) Middle
 - (i) Adenopathy (lymphoma/mets)
 - (ii) Congenital masses: bronchogenic cysts, esophageal duplication cyst and neurenteric cyst
 - (iii) Neurogenic tumors
- (c) Posterior
 - (i) Neurogenic tumors
 - (ii) Other masses: bronchogenic cyst, infection, hematoma and adenopathy
- (2) Primary lung tumors
 - (a) Adenoma/carcinoid tumor
 - (b) Hamartoma
 - (c) Hemangioma
 - (d) Mesenchymal sarcoma (and its association with developmental cystic lesions of the lung)
 - (e) Metastatic lung lesions
- (3) Chest wall neoplasms/masses
 - (a) Ewing sarcoma family (including Askin tumor)
 - (b) Benign rib and spine neoplasms
 - (c) Vascular malformations
 - (d) Infections
- iv) Trauma
 - (1) Contusion
 - (2) Air leak
 - (a) Pneumothorax
 - (b) Pneumomediastinum
 - (c) Bronchopleural fistula
 - (3) Fracture of tracheobronchial tree
 - (4) Airway foreign body
 - (5) Post-traumatic bronchial stenosis
 - (6) Post-traumatic diaphragmatic hernia
- v) Vascular
 - (1) Pulmonary thromboembolic disease
 - (2) Other venous thrombosis or occlusion, anomalous vessels
 - (3) Arteriovenous malformations
- vi) Unique chest problems in neonate
 - (1) Hyaline membrane disease
 - (2) Transient tachypnea of newborn
 - (3) Neonatal pneumonia
 - (4) Congenital diaphragmatic hernia
 - (5) Chronic lung disease of infancy (bronchopulmonary dysplasia)
 - (6) Meconium aspiration syndrome
 - (7) Persistent fetal circulation

- (8) Extracorporeal membrane oxygenation (ECMO) therapy and its complications
- (9) Air leak in the neonate
 - (a) Including pulmonary interstitial emphysema
- vii) Miscellaneous: includes chest manifestations of systemic disorders
 - (1) Idiopathic pulmonary hemosiderosis
 - (2) Alveolar proteinosis
 - (3) Collagen vascular diseases
 - (4) Spontaneous pneumothorax and pneumomediastinum
 - (5) Cardiogenic and noncardiogenic pulmonary edema
 - (6) Histiocytosis
 - (7) Vasculitis (Wegener disease)

4) Cardiovascular: Cardiac

- a) Congenital heart disease
 - i) Segmental approach to imaging of congenital heart disease
 - (1) Normal segmental anatomy
 - (2) Anomalies of visceroatrial situs
 - (a) Asplenia
 - (b) Polysplenia
 - (c) Situs inversus
 - ii) Left-to-right shunts
 - (1) Ventricular septal defect
 - (2) Patent ductus arteriosus
 - (3) Atrial septal defect
 - (4) Endocardial cushion defect
 - (5) Aortopulmonary window
 - (6) Partial anomalous pulmonary venous return
 - iii) Intermixing (admixture) states with increased pulmonary blood flow
 - (1) Total anomalous pulmonary venous connection (TAPVC) without obstruction
 - (2) D-transposition of the great arteries
 - (3) Truncus arteriosus
 - (4) Single ventricle
 - iv) Intermixing (admixture) states with decreased pulmonary blood flow
 - (1) Tetralogy of Fallot
 - (2) Pulmonary atresia with ventricular septal defect (VSDV)
 - (3) Single ventricle with right ventricular outflow tract (RVOT) obstruction
 - v) Left-sided obstruction
 - (1) Coarctation
 - (2) Hypoplastic left heart syndrome
 - (3) Cor triatriatum
 - (4) Obstructed TAPVC
 - vi) Other congenital heart disease
 - (1) Pulmonary valve stenosis
 - (2) L-transposition of great arteries

- (3) Pulmonary atresia with intact ventricular septum
- (4) Ebstein anomaly
- (5) Congenital absence of the pericardium
- vii) Vascular rings and slings
 - (1) Right aortic arch with aberrant left subclavian artery
 - (2) Double aortic arch and variants
 - (3) Circumflex aortic arch
 - (4) Pulmonary sling
- viii) Anomalous coronary artery origins
 - (1) Anomalous right coronary artery from the left sinus of Valsalva
 - (2) Anomalous left coronary artery from the right sinus of Valsalva
 - (3) Anomalous left coronary artery from the pulmonary artery
- ix) Systemic venous variants
 - (1) Left superior vena cava (SVC)
 - (2) Interrupted inferior vena cava (IVC) with azygos continuation
- x) Late or adult presentations of coronary heart disease (CHD)
 - (1) Bicuspid aortic valve, aortic valve stenosis and aortic root dilatation
- b) Cardiac masses
 - i) Rhabdomyoma, fibroma
 - ii) Thrombus
- c) Trauma
 - i) Hemopericardium
 - ii) Hemopericardium
- d) Syndromes with congenital heart disease or vascular disease
 - i) Marfan syndrome
 - ii) Loeys-Dietz syndrome
 - iii) Ehlers-Danlos syndrome
 - iv) Williams syndrome
 - v) Alagille syndrome
 - vi) Neurofibromatosis type 1
 - vii) Down syndrome
 - viii) Holt Oram syndrome
 - ix) Turner syndrome
 - x) PHACE syndrome
- e) Acquired cardiac disease
 - i) Infectious/inflammatory
 - (1) Pericarditis
 - (2) Myocarditis
 - (3) Kawasaki disease
 - ii) Cardiomyopathies
 - (1) Hypertrophic
 - (2) Dilated
 - (3) Restrictive
 - (4) Arrhythmogenic right ventricular dysplasia (ARVD)

- f) Cardiac operations
 - i) Postoperative cross-sectional imaging assessment of the following procedures:
 - (1) Atrial switch for transposition of great arteries (Senning and Mustard procedures)
 - (2) Arterial switch for transposition of great arteries (Jatene arterial switch and Lecompte maneuver)
 - (3) Single ventricle repair: Norwood 1 and Dames-Kaye Stansel anastomosis
 - (4) Superior cavopulmonary connection, including the bidirectional Glenn procedure
 - (5) Total cavopulmonary connection: Fontan procedure
 - (6) Pulmonary blood flow augmentation as initial palliation for coronary heart disease (CHD), including Blalock-Taussig, Waterston, and Pott shunts

5) Cardiovascular: Vascular

- a) Congenital
 - i) Vascular malformations
- b) Variants: Caval anomalies (e.g., left superior vena cava, absent hepatic inferior vena cava)
- c) Trauma
 - i) Acute traumatic aortic injury
 - ii) Arterial contrast extravasation
 - iii) Pseudoaneurysm
 - iv) Arteriovenous fistulae
 - v) Hypoperfusion complex
- d) Inflammatory/infectious
 - i) Aortitis
 - ii) Vasculitides
 - (1) Takayasu disease and Kawasaki disease
- e) Syndromic/systemic vascular diseases
 - i) Syndromes
 - (1) Ehlers-Danlos
 - (2) Marfan
 - (3) Neurofibromatosis and other causes of mid-aortic syndrome
 - (4) Williams
- f) Idiopathic
 - i) Fibromuscular dysplasia
 - ii) Mid-aortic syndrome
- g) Thrombotic
 - i) Deep venous thrombosis
 - ii) Catheter-related thrombosis and evaluation

6) Gastrointestinal (GI) tract

- a) Biliary system
 - i) Congenital

- ii) Biliary atresia
 - iii) Neonatal hepatitis
 - iv) Choledochal cyst (classification)
 - v) Acquired miscellaneous
 - (1) Cholelithiasis
 - (2) Hydrops of gallbladder
 - (3) Cholangitis
 - vi) Cholecystitis
- b) Liver
- i) Infection
 - (1) Abscess
 - (2) Hepatitis
 - ii) Tumors and tumor-like conditions
 - (1) Benign
 - (a) Mesenchymal hamartoma
 - (b) Hemangioendothelioma
 - (2) Malignant
 - (a) Hepatoblastoma
 - (b) Hepatoma
 - (c) Metastases
 - iii) Trauma
 - (1) Lacerations
 - (2) Subcapsular hematoma
 - (3) Contusion
 - iv) Vascular
 - (1) Portal vein thrombosis
 - (a) Cavernous transformation
 - (2) Portal hypertension
 - (3) Budd-Chiari syndrome
 - v) Transplant complications
 - vi) Other: systemic conditions involving liver
 - (1) Glycogen storage disease
 - (2) Beckwith-Wiedemann syndrome
- c) Spleen
- i) Congenital
 - (1) Abnormal visceroatrial situs
 - (2) Wandering spleen
 - ii) Neoplasms
 - (1) Infection
 - (a) Fungal abscesses
 - (2) Benign
 - (a) Lymphangioma
 - (3) Malignant
 - (a) Lymphoma/leukemia

- (4) Trauma
 - (a) Laceration
 - (b) Contusion
 - (c) Subcapsular hematoma
- (5) Splenic infarction
 - (a) Sickle cell disease
- (6) Etiologies for splenomegaly
- d) Pancreas
 - i) Congenital
 - (1) Pancreas divisum
 - (2) Cystic fibrosis
 - ii) Pancreatitis (and pseudocyst)
 - (1) Trauma
 - (a) Non-accidental trauma
 - (2) Choledochal cyst
 - (3) Familial pancreatitis
 - (4) Iatrogenic
 - iii) Fatty replacement
 - (1) Cystic fibrosis
- e) Aerodigestive track
 - i) Pharynx and esophagus
 - (1) Congenital and developmental anomalies
 - (a) Esophageal atresia and tracheoesophageal fistula (classification)
 - (2) Inflammatory lesions
 - (a) Retropharyngeal abscess/cellulitis
 - (b) Infectious esophagitis
 - (3) Trauma
 - (a) Foreign bodies
 - (b) Iatrogenic perforation
 - (4) Esophageal stricture (etiologies)
 - (5) Gastroesophageal reflux
 - ii) Stomach
 - (1) Congenital
 - (a) Duplications
 - (b) Antral webs
 - (c) Volvulus
 - (2) Gastric outlet obstruction
 - (a) Acquired
 - (i) Hypertrophic pyloric stenosis
 - (ii) Inflammatory
 - (iii) Corrosive ingestion
 - (iv) Chronic granulomatous disease
 - (3) Inflammatory
 - (a) Eosinophilic enteritis

- (b) Peptic diseases
- (c) Chronic granulomatous disease
- (4) Miscellaneous
 - (a) Bezoars
 - (b) Foreign bodies
 - (c) Spontaneous rupture of stomach
- iii) Small Bowel
 - (1) Congenital
 - (a) Duodenal webs, stenosis, and other obstructions
 - (b) Malrotation with/without midgut volvulus
 - (c) Duodenal, jejunal, and ileal stenosis and/or atresia
 - (d) Post-inflammatory/infectious or iatrogenic strictures
 - (e) Meconium ileus
 - (f) Meconium peritonitis
 - (g) Mesenteric and omental cysts
 - (h) Duplication cysts
 - (i) Meckel diverticula (including other omphalomesenteric anomalies)
 - (j) Abdominal wall defects
 - (i) Omphalocele and gastroschisis
 - (ii) Hernias
 - (2) Neoplasms
 - (a) Benign
 - (i) Polyps and leiomyomas
 - (b) Malignant
 - (i) Lymphoma
 - (3) Malabsorption
 - (a) Cystic fibrosis
 - (4) Trauma
 - (a) Blunt abdominal trauma
 - (b) Transplant
 - (5) Miscellaneous
 - (a) Necrotizing enterocolitis
 - (b) Ischemic bowel
 - (c) Intussusception
 - (d) Henoch-Schölein purpura
 - (e) Graft vs host disease
 - (6) Cause of small bowel obstruction
- iv) Colon
 - (1) Congenital
 - (a) Imperforate anus /anorectal malformation
 - (b) Duplications
 - (c) Colonic atresia
 - (d) Hirschsprung disease
 - (e) Meconium plug/neonatal small left colon syndrome

- (2) Infectious/inflammatory
 - (a) Appendicitis
 - (b) Infectious colitis/typhlitis
 - (3) Neoplasms
 - (a) Benign: polyps, leiomyoma
 - (b) Malignant
 - (i) Lymphoma
 - (4) Trauma
- v) Other
- (1) Mesenteric adenitis

7) Genitourinary system

- a) Growth and development/normal variants: kidney (echogenic pyramids, lobulation)
- b) Kidneys
 - i) Congenital anomalies
 - (1) Ureteropelvic junction (UPJ)
 - (2) Duplication
 - (3) Multicystic dysplasia
 - (4) Agenesis
 - (5) Hypoplastic kidney
 - (6) Horseshoe kidney
 - (7) Ectopia
 - (a) Ptosis
 - (b) Pelvic
 - (c) Crossed ectopia
 - (8) Relationship of congenital renal anomalies with other congenital anomalies (VATER association, spinal dysraphism, etc.)
 - ii) Cystic renal disease
 - (1) Autosomal recessive
 - (2) Autosomal dominant
 - (3) Cysts associated with syndromes
 - (4) Associated liver disease (fibrosis)
 - iii) Inflammatory
 - (1) Acute pyelonephritis
 - (2) Abscess
 - (3) Reflux nephropathy
 - iv) Neoplasms
 - (1) Wilms tumor and variants
 - (2) Nephrogenic rests
 - (3) Mesoblastic nephroma
 - (4) Multilocular cystic nephroma
 - (5) Leukemia/lymphoma
 - v) Trauma
 - (1) Subcapsular hematoma

- (2) Laceration (including those communicating with collecting system)
 - (3) Contusion
 - (4) Avulsion of vascular pedicle
 - (5) UPJ avulsion or laceration
 - vi) Vascular
 - (1) Arterial stenosis
 - (2) Renal vein thrombosis
 - (3) Tumor thrombus
 - vii) Involvement by systemic disorders
 - (1) Tuberous sclerosis
 - (2) Von Hippel-Lindau disease
 - viii) Miscellaneous
 - (1) Urolithiasis/nephrocalcinosis
 - (2) Renal transplantation
- c) Adrenal gland
- i) Neoplasms
 - (1) Neuroblastoma
 - (2) Adrenocortical carcinoma
 - ii) Congenital adrenal hyperplasia
 - iii) Trauma
 - (1) hemorrhage (neonatal) and adrenal calcification
- d) Bladder, ureters, and urethra
- i) Congenital
 - (1) Posterior urethral valves
 - (2) Ureteroovesical junction obstruction
 - (3) Primary megaureter
 - (4) Bladder diverticula
 - (5) Ureteral duplication
 - (6) Ureterocele
 - (7) Urachal abnormalities
 - (8) Hypospadias
 - (9) Epispadias/exstrophy
 - (10) Prune belly syndrome
 - (11) Urologic sequela of anorectal anomalies
 - ii) Infectious/inflammatory
 - (1) Urinary tract infection
 - (2) Viral cystitis
 - (3) Hemorrhagic cystitis
 - iii) Trauma
 - (1) Extravasation
 - iv) Neoplasms
 - (1) Rhabdomyosarcoma
 - v) Miscellaneous
 - (1) Vesicoureteral reflux

- (2) Neurogenic bladder
- (3) Dysfunctional voiding
- e) Male genital tract: scrotal
 - i) Testicular torsion
 - ii) Infectious/inflammatory
 - (1) Epididymitis/orchitis
 - iii) Differential for scrotal fluid collections
 - iv) Hernia
 - v) Undescended testis
 - vi) Microlithiasis
 - vii) Neoplasms
 - (1) Germ cell tumors
 - (2) Stroma cell tumors
 - (3) Metastases
 - (4) Leukemia
- f) Female genital tract
 - i) Congenital
 - (1) Cloacal anomalies
 - ii) Ovaries
 - (1) Torsion
 - (2) Ovarian cysts (including neonatal physiologic)
 - (3) Germ cell tumors
 - (4) Cystic neoplasms
 - (5) Polycystic ovarian disease
 - iii) Uterus and vagina
 - (1) Congenital anomalies: vaginal occlusion (hydrometrocolpos, etc.)
 - (2) Fusion anomalies of the müllerian duct (uterus didelphys, etc.)
 - (3) Masses
 - (a) Rhabdomyosarcoma
 - (b) Clear cell adenocarcinoma
 - iv) Intersex states
 - (1) Differential diagnosis
 - (2) Work-up
 - v) Other
 - (1) Prune belly syndrome

8) Musculoskeletal imaging

- a) Normal growth and development/variants
- b) Congenital
 - i) Osteochondrodysplasias affecting growth of tubular bones and spine (identifiable at birth)
 - (1) Thanatophoric dysplasia
 - (2) Chondrodyplasia punctata
 - (3) Achondroplasia

- (4) Asphyxiating thoracic dystrophy
- ii) Osteochondrodysplasias affecting growth of tubular bones and spine (identifiable in later life)
 - (1) Metaphyseal chondrodysplasia
 - (2) Multiple epiphyseal dysplasia
- iii) Osteochondrodysplasias with disorganized development of cartilage and fibrous components of the skeleton
 - (1) Multiple cartilaginous exostoses
 - (2) Enchondromatosis
 - (3) Polyostotic fibrous dysplasia
 - (4) Neurofibromatosis
- iv) Abnormalities of density of cortical diaphyseal structure and metaphyseal modeling
 - (1) Osteogenesis imperfecta
 - (2) Osteopetrosis
 - (3) Pycnodysostosis
 - (4) Diaphyseal dysplasia
 - (5) Metaphyseal dysplasia
- v) Limb reduction anomalies (including proximal focal femoral deficiency and radial ray anomalies)
- vi) Amniotic band syndrome
- vii) Congenital bowing deformities and pseudoarthroses
- viii) Congenital foot deformities
 - (1) Tarsal coalition
 - (2) Pes planus
 - (3) Talipes equinovarus
 - (4) Pes cavus
 - (5) Metatarsus adductus
- ix) Skeletal abnormalities associated with syndromes
 - (1) Trisomy 21 syndrome, Marfan syndrome and neurofibromatosis
- x) Skeletal abnormalities associated with metabolic disorders
 - (1) Mucopolysaccharidoses and mucolipidoses
- xi) Developmental dysplasia of hip
- xii) Skeletal abnormalities associated with neuromuscular diseases
 - (1) Meningomyelocele
 - (2) Cerebral palsy
 - (3) Muscular dystrophy
- c) Infectious inflammatory
 - i) Pyogenic osteomyelitis
 - ii) Septic arthritis
 - iii) Toxic synovitis of the hip
 - iv) Tuberculosis
 - v) Caffey disease
 - vi) Multifocal osteomyelitis
 - vii) Dermatomyositis/polymyositis and other inflammatory myopathies

- viii) Arthropathies
 - (1) Juvenile rheumatoid arthritis (juvenile idiopathic arthritis)
- d) Hemophilic arthropathy
- e) Neoplasm
 - i) Benign
 - (1) Osteochondroma
 - (2) Unicameral bone cyst
 - (3) Aneurysmal bone cyst
 - (4) Nonossifying fibroma/fibrous cortical defect
 - (5) Fibrous dysplasia
 - (6) Langerhans cell histiocytosis
 - (7) Osteoid osteoma
 - (8) Osteoblastoma
 - (9) Chondroblastoma
 - (10) Chondromyxoid fibroma
 - ii) Malignant
 - (1) Ewing sarcoma
 - (2) Osteogenic sarcoma
 - (3) Metastases (including leukemia/lymphoma)
 - iii) Vascular
 - (1) Vascular malformations
 - iv) Trauma
 - (1) Fractures
 - (a) Accidental trauma (including Salter-Harris, greenstick-bowing, and buckle fractures)
 - (b) Nonaccidental trauma (battered child syndrome)
 - v) Growth arrest/bone bar and non union
 - vi) Toddler's fracture
 - vii) Slipped capital femoral epiphysis
 - f) Endocrine/Metabolic
 - i) Rickets
 - ii) Renal osteodystrophy
 - iii) Hyperparathyroidism
 - iv) Hypoparathyroidism
 - v) Hypophosphatasia
 - vi) Scurvy
 - vii) Bone age determination
 - g) Osteochondroses
 - i) Legg-Perthes disease
 - ii) Kohler disease
 - iii) Freiberg disease
 - iv) Osteochondritis dissecans
 - v) Blount disease and physiologic bowing

9) Select general/multiorgan system syndromes with salient imaging findings

- a) Neurocutaneous syndrome
- b) Sturge-Weber syndrome
- c) Trisomy 21 syndrome
- d) CHARGE syndrome
- e) Marfan syndrome
- f) Beckwith-Wiedemann syndrome
- g) Turner syndrome
- h) Ehlers-Danlos syndrome
- i) DiGeorge syndrome
- j) Klippel-Trenaunay-Weber syndrome

10) Multisystemic disorders/processes

- a) Systemic lupus erythematosus and other systemic vasculitides
- b) Juvenile idiopathic arthritis
- c) Wegener disease
- d) Primary immune deficiencies (severe combined immunodeficiency (SCIDS), chronic granulomatous disease, and DiGeorge syndrome)
- e) Sickle cell anemia
- f) Child abuse
- g) Immunocompromised host (transplant immune suppression, antibiotics, steroids, and chemotherapy)
 - i) Includes post-transplant lymphoproliferative syndrome
- h) VATER/VACTERL
- i) Retained surgical material
- j) Ventriculoperitoneal (VP) shunt complications

11) Interventional

- a) Abscess drainage/aspiration
- b) Solid organ soft tissue mass biopsy
 - i) Thyroid, liver, kidney, bone, lymph node and nodule
- c) Thoracentesis/thoracostomy tube placement
- d) Paracentesis
- e) Hip aspirations
- f) Arthrography (diagnostic and therapeutic)

Physics

1) Atomic Structure: Composition of the Atom

- a) Electrons
 - i) Electron orbits
 - ii) Naming of orbits
 - iii) Binding energy
 - iv) Transitions of electrons
 - v) Characteristic radiation
 - vi) Auger electrons
- b) Nucleus
 - i) Composition
 - ii) Nuclear force
 - iii) Mass defect
 - iv) Binding energy
 - v) Instability of the nucleus

2) Electromagnetic Radiation

- a) Wave-particle duality
 - i) Characteristics of waves
 - ii) Characteristics of particles
- b) Electromagnetic spectrum
 - i) Non-ionizing
 - ii) Ionizing

3) Particulate Radiation

- a) Light particles
- b) Heavy charged particles
- c) Uncharged particles
 - i) Neutrons
 - ii) Neutrinos

4) Ionizing Radiation Interactions with Matter

- a) Charged particles
 - i) Ionization and excitation
 - ii) Bremsstrahlung
 - iii) Secondary ionization
 - (1) Specific ionization
 - (2) Linear energy transfer (LET)
 - iv) Positron annihilation
- b) Photons
 - i) Coherent scattering
 - ii) Compton scattering

- iii) Photoelectric effect
- iv) Tissue interactions
- v) Contrast media
- c) Attenuation of photons
 - i) Linear attenuation coefficient
 - ii) Attenuation equation
 - iii) Mono- and polyenergetic x-ray beams
 - iv) Half-value layer (HVL)
 - (1) Effective energy
 - (2) Beam hardening

5) Radiation Units

- a) Unit systems
 - i) SI
 - ii) Classical
- b) Exposure
 - i) Coulomb/kilogram
 - ii) Roentgen (R)
- c) Kerma- kinetic energy released in matter
 - i) Gray (Gy)
 - ii) Rad
- d) Absorbed dose
 - i) Gray (Gy)
 - ii) Rad
- e) Equivalent dose
 - i) Radiation weighting factors
 - ii) Sievert (Sv)
 - iii) Rem
- f) Effective dose
 - i) Tissue weighting factors
 - ii) Sievert (Sv)
 - iii) Rem
 - iv) Reference levels
 - v) Use in radiation protection
- g) Peak skin dose

6) X-ray Production

- a) Properties of x-rays
 - i) Bremsstrahlung
 - (1) Importance in imaging
 - (2) Influence of electron energy
 - (3) Influence of target material
 - (4) Influence of filtration
 - ii) Characteristic radiation

- (1) Importance in imaging
 - (2) Influence of electron energy
 - (3) Influence of target material
 - (4) Influence of filtration
- b) X-ray tube
 - i) Cathode
 - (1) Filament
 - (2) Focusing cup
 - (3) Filament current and tube current
 - ii) Anode
 - (1) Composition
 - (2) Focal spot
 - (3) Line-focus principle
 - (4) Heel effect
 - iii) Application-specific tubes
 - (1) Mammography
 - (2) CT
 - (3) Interventional
 - c) Generators
 - i) Frequency
 - ii) Technique factors
 - (1) kVp
 - (2) mA
 - (3) Time
 - (4) Automatic exposure control (AEC)
 - d) X-ray beam
 - e) Beam filtration
 - (1) Inherent
 - (2) Added (Al, Cu, Mo, Rh, other)
 - (3) Minimum HVL
 - (4) Shaped filters
 - ii) Spectrum
 - iii) Collimators
 - (1) Field size limitation
 - (2) Light/x-ray alignment
 - (3) Effect on image quality

7) Imaging Science

- a) Statistics
 - i) Precision and accuracy
 - ii) Systematic and random errors
 - iii) Metrics
 - iv) Confidence intervals
 - v) Error propagation

- b) Properties of images
 - i) Imaging information domains
 - (1) Spatial
 - (2) Frequency
 - (3) Temporal
 - ii) Image characteristics
 - (1) Contrast
 - (2) Spatial resolution and modulation transfer function (MTF)
 - (3) Quantum noise and other noise sources
 - (4) Dynamic range
 - (5) Contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), and detective quantum efficiency (DQE)
 - (6) Temporal resolution
 - iii) Analog and digital image representation
 - (1) Conversion process (analog-to-digital converter [ADC] and digital-to-analog converter [DAC])
 - (2) Sampling, quantization, and the Nyquist limit
 - iv) Image processing
 - (1) Preprocessing for uniformity and defect corrections
 - (2) Segmentation and region of interest selection
 - (3) Grayscale manipulation and lookup tables
 - (4) Filtering
 - (5) Reconstruction approaches
 - (6) 3D presentation methods
 - (7) Image fusion and image registration
 - (8) Computer-aided detection and diagnosis (CAD)
- c) Display of images
 - i) Display systems: hard copy and soft copy
 - ii) Display characteristics and quality control
 - iii) Viewing conditions for image review
- d) Human perception of medical images
 - i) Human vision characteristics
 - ii) Measures of observer performance and receiver operating characteristic (ROC) analysis
- e) Informatics and management of imaging departments
 - i) Computer technology basics
 - ii) Picture archiving and communications systems (PACS)
 - iii) Radiology information systems (RIS)
 - iv) Hospital information systems (HIS)
 - v) DICOM and other protocols for radiology data management
 - vi) Security and privacy issues and approaches

8) Biological Effects of Ionizing Radiation: Radiation Biology

- a) Principles

- i) Linear energy transfer (LET)
- ii) Relative biologic effectiveness (RBE)
- iii) Radiation and tissue weighting factors
- b) Molecular effects of radiation
 - i) Radiolysis of water and radical formation
 - ii) Direct and indirect effects
 - iii) Radiation damage of DNA
- c) Cellular response of radiation
 - i) Time scale of radiation effects
 - ii) Cell kinetics, mitotic death and apoptosis
 - iii) Chromosomal aberrations
 - iv) Cell cycle stage and radiation sensitivity
 - v) Sublethal damage
 - vi) Cell survival curves (function, key basic concept)
 - vii) Dose rate effect
 - viii) The oxygen effect
 - (1) Oxygen Enhancement Ratio (OER)
- d) Tissue Reactions (deterministic, non-stochastic) effects
 - i) Radiation-induced skin damage; erythema, epilation, desquamation and necrosis
 - ii) Radiation cataractogenesis
- e) Radiation-induced injury to the gonads
 - i) Spermatogenesis
 - ii) Oogenesis
 - iii) Radiation doses to produce sterility
- f) Probabilistic (stochastic) radiation effects
 - i) Radiation Carcinogenesis
 - (1) Irradiated populations from which quantitative data have been obtained for cancer incidence
 - (2) The latent period
 - (3) Sensitivity to radiation-induced cancer as a function of age
 - (4) Risk estimates for radiation-induced cancer
 - (5) Large population-based studies of cancer risk following CT
 - (6) Conditions that increase the risk of radiation carcinogenesis
 - ii) Hereditary effects of radiation
- g) Radiation effects on the developing embryo and fetus
 - i) Preimplantation
 - ii) Organogenesis
 - iii) Fetal period
 - iv) Population-based studies: Survivors of the A-bomb attacks on Hiroshima and Nagasaki irradiated in utero
 - v) Childhood cancer following in utero irradiation
 - vi) Occupational exposure of a declared pregnant woman
- h) Whole-body radiation effects

- i) Acute radiation syndrome
 - (1) Prodromal
 - (2) Latent
 - (3) Cerebrovascular
 - (4) Gastrointestinal
 - (5) Hematopoietic
- ii) Kinetics of depression and recovery of blood cell components
- iii) LD50/60
- iv) Treatment of radiation accident victims
- i) Radiation risk
 - i) Risk/benefit in radiology
 - ii) Risk models
 - (1) Relative
 - (2) Absolute
 - iii) Information sources
 - (1) Biological Effects of Ionizing Radiation (BEIR VII) reports
 - (2) International Council on Radiation Protection (ICRP) reports
 - (3) National Council on Radiation Protection and Measurements (NCRP 116) reports
 - (4) United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) reports

9) Radiation Protection and Associated Regulations

- a) Sources of radiation to the human population (NCRP 160)
 - i) Medical sources
 - ii) Cosmic rays
 - iii) Man-made sources
 - iv) Average annual doses from background and diagnostic procedures
- b) Medical sources: occupational and patient doses
 - i) Projection radiography
 - ii) Mammography
 - iii) Fluoroscopy
 - iv) Interventional radiology and diagnostic angiography
 - v) CT
- c) Factors affecting patient dose from medical sources
 - i) Regulatory dose limits and "trigger" levels
 - ii) The Joint Commission (TJC) reviewable and nonreviewable events
- d) Persons at risk
 - i) Occupational
 - ii) Nonoccupational staff
 - iii) Members of the public
 - iv) Fetus
 - v) Patient
- e) Dose limits
 - i) Occupational dose limits
 - ii) Members of the public

- f) Radiation detectors
 - i) Personal dosimeters
 - (1) Available technologies
 - (2) Appropriate use and limitations
 - ii) Area monitors
 - (1) Dosimeters
- g) Principles of radiation protection
 - i) Time
 - ii) Distance
 - iii) Shielding for facilities, workers, and others
 - iv) Shielding materials
 - v) Procedure appropriateness
- h) Advisory bodies
 - i) International Commission on Radiological Protection (ICRP)
 - ii) National Council on Radiation Protection and Measurements (NCRP)
 - iii) The Joint Commission (TJC)
 - iv) American College of Radiology (ACR)
- i) Estimating effective fetal dose (procedure-specific doses)
- j) Radiological emergencies
 - i) Incidents
 - ii) Purposeful exposures
 - iii) Treatment of radiological casualties
- k) Biologic hazards of magnetic resonance imaging
 - i) Static magnetic fields
 - (1) Projectiles
 - (2) Implanted metal objects
 - (3) Embedded metal objects
 - (4) Pacemakers
 - (5) Vertigo
 - (6) Equipment compatibility (Safe, Conditional, Unsafe)
 - ii) Radiofrequency fields
 - (1) Radiofrequency waves and Specific Absorption Rate (SAR)
 - (2) Response of implanted metal objects
 - (3) Potential risk for burns (Closed loops)
 - iii) Gradient fields
 - (1) Nerve stimulation
 - (2) Loud noise
 - (3) Magnetophosphenes
 - (4) Claustrophobia
 - (5) Quenching (asphyxiation)
 - (6) Contrast Agent Reactions
 - (7) Regulatory Limits
 - i) 5 gauss line
 - ii) Noise limits
 - iii) SAR
- l) Biologic hazards of ultrasonography
 - i) Tissue heating, ultrasound frequency and SPTA intensity
 - (1) Thermal Index (TI)

- ii) Ultrasound induced cavitation
 - (1) Mechanical Index (MI)
 - (2) Pulsed Doppler
 - (3) Regulatory Limits
- i) International Commission on Radiological Protection (ICRP)
- ii) National Council on Radiation Protection and Measurements (NCRP)
- iii) Conference of Radiation Control Program Directors (CRCPD)
- iv) International Atomic Energy Agency (IAEA)
- v) Joint Commission on Accreditation of Healthcare Organizations (JCAHO)
- vi) American College of Radiology (ACR)
- vii) National Electrical Manufacturers Association (NEMA) (Medical Imaging and Technology Alliance or MITA)
- m) Regulatory agencies
 - i) State regulations for machine-produced sources
 - iii) U.S. Food and Drug Administration (FDA)
 - (1) Center for Devices and Radiological Health (CDRH)
 - (2) Center for Drug Evaluation and Research (CDER)
 - iv) U.S. Office of Human Research Protections
 - vi) U.S. Department of Labor Occupational Safety and Health Administration (OSHA)
 - vii) International Electrotechnical Commission (IEC)
- n) Estimating effective fetal dose (procedure-specific doses)
- o) Radiological emergencies
 - i) Incidents
 - ii) Purposeful exposures
 - iii) Treatment of radiological casualties

10) X-ray Projection Imaging: Concepts and Detectors

- a) Radiography concepts
 - i) Geometry
 - (1) Magnification
 - (2) Inverse-square law
 - ii) Radiographic contrast
 - (1) Subject
 - (2) Detector
 - iii) Scatter and scatter reduction
 - (1) Scatter-to-primary ratio
 - (2) Grids
 - (3) Air gap
 - iv) Artifacts and image degradation
 - (1) Distortion
 - (2) Geometric unsharpness
 - (3) Grid
 - (4) Detector
- b) Radiographic detectors
 - i) Screen-film systems
 - (1) Intensifying screens
 - (2) Film and film processing
 - ii) Computed radiography (CR)

- (1) Storage phosphors
- (2) CR readers
- iii) Flat panel detectors
 - (1) Direct detectors
 - (2) Indirect detectors

11) General Radiography

- a) X-ray system components
 - i) Tube and filtration
 - ii) Collimation
 - iii) Automatic exposure control (AEC)
 - iv) Grids and Bucky factor
- b) Geometrical effects and requirements
 - i) Focal spot size
 - ii) Collimation
 - iii) Heel effect
- c) Acquisition systems
 - i) Screen/film
 - ii) Digital
 - (1) CR systems
 - (2) Flat-panel systems
 - iii) Dual-energy
 - iv) Linear tomography
 - v) Tomosynthesis
- d) Image characteristics
 - i) Spatial resolution
 - ii) Contrast sensitivity
 - iii) Noise
 - iv) Temporal resolution
 - v) Artifacts
- e) Application requirements
 - i) Chest
 - ii) Abdomen
 - iii) Spine
 - iv) Extremities
 - v) Pediatrics and neonatal
 - vi) Portable/mobile
- f) Dosimetry
 - i) Entrance skin exposure
 - ii) Effective dose
 - iii) Appropriate organ doses
 - iv) Doses for different procedures
 - v) Technique optimization
- g) Factors affecting patient dose
 - i) Technique (e.g., kVp, mA, time)
 - ii) Imaging geometry
 - iii) Beam filtration and grid

- iv) Field size
- v) Exposure class
- h) Quality control (QC) tests and frequencies

12) Mammography

- a) Clinical importance
- b) Mammography equipment
 - i) Dedicated x-ray tube
 - (1) Anode materials
 - (2) kVp
 - (3) Focal spot size and characteristics
 - (4) Target-filter combinations
 - (5) X-ray spectra
 - (6) Low peak kilovoltage (kVp)
 - (7) Half-value layer (HVL)
 - ii) Breast compression paddle
 - iii) Collimation
 - iv) Grids
 - v) Automatic exposure control (AEC)
- c) Geometry
 - i) Source-to-image receptor distance (SID)
 - ii) Source-to-object distance (SOD)
 - iii) Object-to-image receptor distance (OID)
 - iv) Chest-wall coverage
 - v) Heel effect
 - vi) Magnification
 - vii) Advantages of magnification
- d) Acquisition systems
 - i) Screen/film and film processing
 - ii) Full-field digital mammography
 - iii) Tomosynthesis systems
 - iv) Stereotactic biopsy systems
- e) Artifacts
- f) Radiation dose
 - i) Entrance skin exposure
 - ii) Average glandular dose
 - iii) Dose limits
 - iv) Factors affecting patient radiation dose
 - v) Radiation risk versus benefits of screening
- g) Viewing images
 - i) Lighting requirements: luminance and illuminance
 - ii) Dedicated view boxes and displays
 - iii) Dedicated PACS
- h) Quality control
 - i) Mammography Quality Standards Act (MQSA)
 - (1) Personnel requirements
 - (2) Dose limits

- (3) Image quality and accreditation phantom
- ii) American College of Radiology (ACR) accreditation

13) Fluoroscopy and Interventional Imaging

- a) System components
 - i) Tube
 - ii) Filtration
 - iii) Collimation
 - iv) Grids
 - v) Automatic brightness control (ABC)
 - vi) Automatic brightness stabilization (ABS)
 - vii) Compensation filters
- b) Configurations and geometry
 - i) Focal spot size
 - ii) Magnification
 - iii) Under-table versus over-table x-ray tube
 - iv) C-arms
- c) Image intensifier (II) acquisition systems
 - i) II structure
 - ii) Gain
 - iii) Field of view (FOV), magnification, and resolution
 - iv) Cameras and video systems
 - v) Image distortions
 - (1) Lag
 - (2) Veiling glare
 - (3) Vignetting
 - (4) Other: pincushion, barrel, "S"-distortion
- d) Flat-panel acquisition systems
 - i) Detectors
 - ii) Magnification
 - iii) Binning
 - iv) Comparison to II
 - v) Image distortions
 - (1) Correlated noise
 - (2) Lag
 - (3) Ghosting
- e) Real-time imaging
 - i) Continuous fluoroscopy
 - ii) High-dose rate fluoroscopy
 - iii) Variable frame-rate pulsed fluoroscopy
 - iv) Spot images
 - v) Operating mode variables
 - (1) Effective mA
 - (2) Pulse width
 - (3) Variable beam filtration
 - (4) Software processing
- f) Image quality
 - i) Low-contrast sensitivity

- ii) High-contrast (spatial) resolution
- iii) Temporal resolution
- iv) Noise
- g) Image processing
 - i) Frame averaging
 - ii) Last-image hold and last-series hold
 - iii) Digital subtraction angiography (DSA)
 - iv) Road mapping
 - v) Cone beam CT
- h) Applications
 - i) Dose and dosimetry
 - (1) Dose rates and limits
 - (2) Audible alarms
 - (3) Recording of “beam-on” time
 - (4) Minimum source-to-patient distance
 - (5) Sentinel event
 - ii) Dose-area-product (DAP) and Kerma-area-product (KAP) meters
 - iii) Entrance skin exposure
 - iv) Peak skin dose
 - v) Cumulative dose
 - vi) Patient dose for various acquisition modes
 - vii) Operator and staff dose considerations and protection
- j) Technique optimization and factors affecting patient dose

14) CT

- a) System components
- b) System geometry
- c) Parameters for image acquisition
 - i) kVp
 - ii) mA
 - iii) Rotation time
 - iv) Table speed
 - v) Pitch
 - vi) Image thickness versus beam width
- d) Image formation
 - i) Attenuation coefficient
 - ii) Hounsfield unit (HU) definition
 - iii) Axial filtered back-projection
 - iv) Helical reconstruction
 - v) Iterative reconstruction
- e) Modes of operation
- f) Image contrast, detail and noise
- g) Artifacts
- h) Image processing and display
- i) Clinical application and protocols

- j) Dose and dosimetry
 - i) Dose profile
 - ii) CT dose index and CTDI_{vol}
 - iii) Multiple scan average dose (MSAD)
 - iv) Dose-length product (DLP)
 - v) Organ dose and effective dose
 - vi) Size-specific estimated dose
 - vii) Adult and pediatric technique optimization
 - viii) Beam width and pitch
 - ix) Over-beaming and over-ranging
- k) Technique optimization and factors affecting patient dose
 - i) kVp, mA, and rotation time
 - ii) Patient size
 - iii) Table increment, table speed, and pitch
 - iv) Scan length
 - v) Number of phases (e.g., pre- and post-contrast)
 - vi) Technique selection
 - vii) Dose modulation schemes
 - viii) Dual source
 - ix) Patient shielding (pros and cons)

15) Ultrasound (Please see Ultrasound Section of the Core Exam Study Guide for a more detailed physics outline.)

- a) Properties of ultrasound waves
- b) Interaction of sound waves and tissue
 - i) Acoustic properties of tissues
- c) Transducer components and design
 - i) Transducer selection for clinical applications
- d) Ultrasound beam characteristics and beam formation
- e) Grayscale ultrasound image formation and scanning modes
 - i) Grayscale image optimization
- f) Doppler phenomenon and scanning modes
 - i) Optimization of Doppler parameters
- g) Gray-scale and Doppler artifacts
- h) Advanced imaging methods
 - i) 3D/4D volumetric imaging
 - ii) Harmonic imaging
 - iii) Spatial compounding
 - iv) Ultrasound contrast agents
 - v) Elastography
- i) Thermal and non-thermal effects on tissue, and ultrasound safety
- j) Equipment quality assurance

16) MRI

- a) Magnetism and magnetic fields
 - i) Magnetic susceptibility

- ii) Types of magnetic materials
 - iii) Magnetic fields (B)
 - iv) Magnetic moment interaction with an external field (B_0): the Larmor equation and precessional frequency
 - v) Net magnetization due to B_0 and field strength
- b) Nuclear MR and excitation
 - c) MR signal properties
 - i) Spin density (proton)
 - ii) T2 (transverse) relaxation
 - iii) T2* relaxation
 - iv) T1 (longitudinal) relaxation
 - v) T1-weighting, T2-weighting, proton density-weighting
- d) Pulse sequences and contrast mechanisms
 - i) Echo time (TE), repetition time (TR), and inversion time (TI)
 - ii) Spin-echo (SE) pulse sequences
 - iii) Inversion-recovery spin-echo pulse sequences
 - iv) Gradient-echo (GE or GRE) pulse sequences
 - v) Echo-planar (EPI) pulse sequences
 - vi) Fast- or turbo-spin-echo (FSE) pulse sequences
 - vii) Manipulation of pulse sequence characteristics
- e) MR instrumentation
 - i) Static magnetic field (B_0) systems
 - ii) Gradient fields and the gradient subsystem
 - iii) Shimming and shim coils
 - iv) Radiofrequency transmitter (B_1) subsystem
 - v) Radiofrequency receiver subsystem
 - vi) Radiofrequency coils
- f) Spatial localization
 - i) Slice-selection
 - ii) Phase-encoding
 - iii) Frequency-encoding
- g) Two-dimensional Fourier transform (2DFT) image reconstruction
 - i) k -space description
 - ii) Methods of filling k -space
- h) Image characteristics
 - i) Factors affecting spatial resolution
 - ii) Factors affecting signal-to-noise ratio (SNR)
 - iii) Tradeoffs among spatial resolution, SNR, and acquisition time
 - iv) Factors affecting image contrast
- i) Contrast agents
 - j) Spatial saturation and fat suppression
 - k) Special acquisition techniques
 - i) Angiography
 - ii) Diffusion, perfusion and neuro imaging
 - iii) Functional MRI (fMRI)
 - iv) Magnetization transfer contrast (MTC)
- l) Artifacts

- m) Safety, bioeffects, and FDA limits
 - i) Static magnetic field (ferromagnetic materials)
 - ii) Radiofrequency field (heating)
 - iii) Gradient field (nerve stimulation)
 - iv) Contrast agent safety issues
- n) Accreditation, quality control (QC) and quality improvement
 - i) Components of an ACR MRI accreditation program
 - ii) Quality control phantoms and measurements
 - iii) Quality improvement program considerations

17) Nuclear Radiology Physics and Instrumentation

- a) Physics of the nucleus
 - i) Nuclear nomenclature (isotope, isobar, isotope, isomer)
 - ii) Nuclear stability
 - iii) Radioactivity
- b) Radioactive decay modes
 - i) Gamma emission
 - ii) Alpha decay
 - iii) Beta decay
 - (a) Beta minus
 - (b) Beta plus (positron)
 - (c) Electron capture
 - iv) Isomeric transition: ^{99m}Tc
- c) Radioactivity
 - i) Definition of terms
 - (a) Radioactivity
 - (b) Decay constant, half life
 - ii) Tracer principle
 - iii) Exponential decay equation
 - iv) Radionuclide equilibrium
 - (a) Secular and transient equilibrium
 - (b) Radionuclide generators: $^{99}\text{Mo}/^{99m}\text{Tc}$, $^{82}\text{Sr}/^{82}\text{Rb}$
- d) Radionuclide production
 - i) Neutron activation
 - ii) Fission byproducts
 - iii) Charged particle accelerators
- e) Radiation detectors
 - i) Detection parameters
 - (a) Efficiency
 - (b) Energy resolution
 - (c) Count rate capability
 - (d) Spatial resolution
 - ii) Counting statistics
- f) Ionization detectors
 - i) Ionization versus voltage curve: recombination, saturation, proportional, and Geiger–Müller regions
 - ii) Instruments
 - (a) Dose calibrator

- (b) Survey meters: cutie-pie, G-M detector
- g) Solid state (semi-conductor) detectors
 - i) General principles
 - ii) Cadmium telluride and cadmium zinc telluride
- h) Scintillation detectors
 - i) Scintillators
 - (a) Conventional nuclear radiology: sodium iodide, cesium iodide
 - (b) PET: lutetium oxyorthosilicate (LSO), lutetium yttrium orthosilicate (LYSO)
 - ii) Thyroid probe and well counters
 - iii) Coincidence detection
- i) Gamma cameras
 - i) Scintillation camera
 - ii) Collimation
 - iii) Quality control
 - (a) Uniformity
 - (b) Spatial resolution
 - iv) Performance parameters
 - (a) Uniformity
 - (b) Spatial resolution
 - (c) Energy resolution
 - (d) Count sensitivity
 - v) Image quality
 - (a) Count density requirements
 - (b) Contrast improvement: choice of radiopharmaceutical, delayed imaging, collimation and view choice
- j) Emission tomography
 - i) Fundamentals
 - (a) Projections, uniformity, stationary object, center of rotation
 - (b) Filtered backprojection and iterative reconstruction
 - ii) Degrading factors leading to artifacts
 - (a) Attenuation
 - (b) Scattered radiation
 - (c) Spatial resolution
 - (d) Noise
 - (e) Uniformity
 - (f) Motion
- k) SPECT
 - i) Instrumentation
 - (a) Scintillation camera systems
 - (b) Cardiac systems
 - (c) SPECT/CT
 - ii) Quality control
 - (a) Planar tests
 - (b) Center of rotation
 - (c) SPECT phantom
 - iii) Corrections
 - (a) Motion

- (b) Attenuation
 - (c) Scatter
 - (d) Spatial resolution
- iv) Accreditation
 - (a) ACR
 - (b) IAC
 - (c) TJC
- I) PET
 - i) Instrumentation
 - (a) Coincidence detection
 - (b) Time of flight
 - (c) PET/CT
 - (d) PET/MRI
 - ii) Quality control
 - (a) Normalization
 - (b) Blank scan
 - (c) Uniformity: artifacts
 - (d) PET phantom
 - (e) Standardized uptake value (SUV) calibration
 - iii) Corrections
 - (a) Random coincidences
 - (b) Scatter
 - (c) Attenuation
 - (d) Spatial resolution
 - iv) Accreditation
 - (a) ACR
 - (b) IAC
 - (c) The Joint Commission
- m) Internal dosimetry
 - i) Radiation dose parameters
 - (a) Total decays: cumulated activity and residence time
 - (b) Emitted energy: dose equilibrium constant
 - (c) Absorbed fraction
 - (d) Distribution mass: effective of body size
 - (e) S factor
 - ii) Effective half life
 - (a) Physical decay
 - (b) Biological clearance
 - iii) Critical organ
 - (a) Renal clearance
 - (b) GI clearance

Radioisotope Safety Examination (RISE)

In effect for exams beginning in 2019

General:

(A) 700 hours of training and experience, including a minimum of 80 hours of classroom and laboratory training, in basic radionuclide handling techniques applicable to the medical use of unsealed byproduct material for imaging and localization studies;

and

(B) Work experience, under the supervision of an authorized user who meets the requirements in §§ 35.57, 35.290, or 35.390 and 35.290(c)(1)(ii)(G), or equivalent Agreement State requirements.

Specifics:

1) Radiation Physics

- a) Radioactive decay modes
- b) Mathematics of radioactive decay
- c) Radioactive equilibrium
- d) Units of radioactivity and conversions
- e) Gamma ray and charged particle interactions
- f) Radiation dose
 - i. Absorbed dose
 - ii. Dose equivalent
 - iii. Effective dose

2) Radiation measurement instruments

- a) Survey meters (principles, operation, and use; quality assurance/quality control)
 - i. Geiger Mueller survey meter
 - ii. Ionization survey meter
- b) Dose calibrator (principles, operation, and use; quality assurance/quality control)
- c) Well counter (principles, operation, and use; quality assurance/quality control)

3) Radiopharmaceutical administration

- a) Confirming dosage
- b) Verifying patient identity
- c) Record-keeping
- d) Administering prescribed dosage
- e) Pregnancy considerations
- f) Fetal radiation dose issues
- g) Recommendations for breastfeeding patients

4) Management of radioactive sources

- a) Managing packages (ordering, receiving, opening)
- b) Sealed sources
- c) Exempt quantities
- d) Use records (unit dosage, multi-dosage vials)
- e) Waste management disposal
 - i) Cold trash surveys
 - ii) Waste decay-in-storage surveys and logs

5) Administrative/practice controls and responsibilities

- a) NRC authority/agreement states
- b) Personnel
 - i) Radiation Safety Officer (RSO)
 - ii) Authorized Users (AU)
- c) License types
- d) Written directive (WD)
 - i) Procedures requiring WD
 - ii) Information required on WD
 - iii) Executing administrations requiring Wd
 - iv) Replacing WD with oral directive
- e) Safety during ^{131}I sodium iodide therapy
 - i) Activity threshold: $\leq 1.22 \text{ GBq (33 mCi)}$ vs. $\geq 1.22 \text{ GBq (33 mCi)}$
 - ii) Inpatient concerns
 - iii) Outpatient concerns
 - iv) Patient issues: Selection, preparation, informed consent, understanding and calculation of administered activity, counseling of patients and families on radiation safety issues, release criteria, follow-up; pregnancy, recommendations to breastfeeding patients

6) Radiation safety and protection

- a) Regulatory exposure limits
 - i) Personnel limits (occupational, pregnant workers, fetal dose, general public, minors)
 - ii) Radiation areas (limits, signage)
- b) Personnel dosimeters (individual monitoring of external and internal occupational dose)
- c) ALARA
 - i) Operating and emergency procedures
 - ii) Audits
- d) Respiratory protection
- e) Thyroid bioassays
- f) Area surveys for contamination

- 7) **Radiation accidents/incidents**
 - a) Medical events/reportable events
 - i) Events requiring reporting
 - ii) Information required in report
 - iii) Notifying the NRC and referring physician/patient
 - b) Radiation spills (major vs. minor)
- 8) **Radiation biology**
 - a) Deterministic effects
 - b) Stochastic effects
 - c) Dose effect models
 - d) Risks of radiation-induced cancer
 - e) Organ dose/critical organ

Reproductive/Endocrine Imaging and Therapy

1) Adrenal

- a) Congenital abnormalities
- b) Benign masses
- c) Malignant primary and secondary neoplasms
- d) Endocrine disorders
- e) Acquired diseases and conditions
 - i) Infection
 - ii) Inflammatory conditions
 - iii) Hemorrhage

2) Thyroid

- a) Benign masses
 - i) Goiter
- b) Malignant masses
- c) Endocrine disorders
 - i) Hypothyroidism
 - ii) Hyperthyroidism

3) Parathyroid

- a) Benign masses
- b) Malignant primary and secondary neoplasms
- c) Endocrine disorders
 - i) Hypoparathyroidism
 - ii) Hyperparathyroidism

4) Female genitourinary tract

- a) Congenital abnormalities
- b) Infertility
- c) Menopause
- d) Uterus and cervix
 - i) Benign and malignant masses
 - ii) Acquired conditions (infection, hemorrhage)
- e) Ovaries and fallopian tubes
 - i) Benign and malignant masses
 - (1) Cysts and cystic lesions
 - ii) Acquired conditions (infection, hemorrhage)
 - (1) Infections
 - (a) Pelvic inflammatory disease
 - (2) Torsion
 - (3) Ovarian failure
- f) Vulva and vagina

- i) Benign and malignant masses
 - (1) Cysts and cystic lesions

5) Obstetrical and Fetal Imaging

- a) Early pregnancy and placentation
- b) Ectopic pregnancy
- c) Fetal biometry and fetal growth
- d) Congenital fetal anomalies
- e) Maternal disorders in pregnancy
- f) Multiple gestations

6) Male Genitourinary Tract

- a) Scrotum, testes, penis, seminal vesicles, vas deferens, ejaculatory ducts
- i) Congenital abnormalities
 - ii) Benign and malignant masses
 - iii) Trauma
 - iv) Torsion
- b) Infertility

7) Modalities and Techniques

- a) Fluoroscopy
- b) Radiography
- c) Hysterosalpingography
- d) Ultrasound
 - i) Transabdominal
 - ii) Endovaginal
 - iii) 3D ultrasonography
 - iv) Color, power, and spectral Doppler
 - v) Scrotal and endorectal ultrasound of the male lower genitourinary tract
 - vi) Saline infusion sonohysterography
 - vii) Thyroid and parathyroid ultrasound
- e) CT
- f) MRI
- g) Image-guided biopsy and drainage
 - i) Thyroid uptake and/or scan - Radioiodine (^{131}I and ^{123}I)
- h) Thyroid scan - technetium pertechnetate
- i) Parathyroid scan – $^{99\text{m}}\text{Tc}$ sestamibi
- j) Radionuclide studies: diagnosis and treatment of endocrine disorders (includes octreotide and MIBG imaging)
- k) FDG-PET/CT

Noninterpretive Skills

The Noninterpretive Skills portion of the ABR examinations is intended to focus on established knowledge in the areas of radiology quality and safety, professionalism and ethics, compliance, and regulatory and legal issues, as well as basic research and screening concepts. Since the range of content relevant to these topics is broad, a separate Study Guide has been produced to serve as a syllabus of the “core” knowledge that residents eligible to take the Core Exam and Certifying Exam are expected to know. The Study Guide should be considered a major resource to identify topics and content for the examination, but it is not the “last word” on these topics, nor does it take the place of textbooks, other definitive source material, education you should have received during your residency or fellowship training, or continuing education. We also draw your attention to the Bibliography and Suggested Reading List at the end of the Study Guide and to web links to key public documents, which are available on the websites of the major voluntary organizations in radiology, such as ACR, ARRS, and RSNA. We highly recommend these “deeper” resources to provide perspective and depth of understanding of the concepts that are only superficially outlined here. [CLICK HERE](#) to access the NIS Study Guide.

Noninterpretive Skills Study Guide Outline:

1. Core Elements of Professionalism

- a) ABIM Physician Charter for Medical Professionalism in the New Millennium
- b) Ethical Considerations Specific to Radiology

2. Core Concepts of Quality and Safety

- a) Core Concepts of Quality
- b) Introduction to Quality
- c) Quality as a Discipline
- d) 2001 Institute of Medicine Report, *Crossing the Quality Chasm*
- e) Core Competencies of the ABMS and ACGME
- f) Core Concepts of Safety
- g) 2000 Institute of Medicine Report, *To Err is Human*
- h) 2015 Institute of Medicine Report, *Improving Diagnosis in Health Care*
- i) Human Factors
- j) Human Error
- k) Culture of Safety

3. Practical Quality and Safety Applications in Healthcare

- a) Practical Quality Applications in Healthcare
- b) Daily Management Systems
- c) Project-based Improvement Methods
- d) Practical Safety Applications in Healthcare
- e) Periprocedural Care
- f) Hand Hygiene
- g) Root Cause Analysis

4. Practical Safety Applications in Radiology

- a) MR Safety
- b) Zoning and Screening
- c) Intracranial Aneurysm Clips and Pacemakers
- d) MR and Pregnancy
- e) MR-induced Burns
- f) Quenching
- g) Management of Intravascular Contrast Media
- h) Iodinated Contrast Media
- i) Gadolinium-based Contrast Media
- j) Treatment of Acute Contrast Reactions

5. Reimbursement, Regulatory Compliance, and Legal Considerations in Radiology

- a) Reimbursement and Regulatory Compliance
- b) Coding, Billing, and Reimbursement
- c) Patient Privacy and HIPAA
- d) Human Subjects Research
- e) Malpractice and Risk Management
- f) General Principles of Malpractice
- g) Malpractice Related to Diagnostic Errors
- h) Malpractice Related to Procedural Complications
- i) Malpractice Related to Communications Deficiencies
- j) Discoverability of Communications

Thoracic Imaging

- 1. Basics of Imaging, including Chest Radiography (CXR), CT and MRI, Ultrasound (US), and Percutaneous Intervention**
 - a) Indications and limitations of the modalities
 - b) Physics behind image creation, including artifacts on CXR, CT, MRI, and US
 - i. X-ray physics
 - ii) CT physics
 - (1) CT artifacts relevant to thoracic imaging
 - (2) Tradeoffs between noise, dose, and image quality
 - (3) Spatial resolution, contrast resolution, and imaging reconstruction algorithms
 - (4) Contrast injection—principles, protocols, bolus geometry, iodine flux
 - iii) MRI physics
 - (1) MR artifacts relevant to thoracic imaging
 - (2) Trade-off between spatial resolution, temporal resolution, contrast resolution, and acquisition time
 - (3) Principles of black blood, edema, and scar imaging
 - (4) Steady-state free precession cine imaging
 - (5) Velocity-encoded cine (phase contrast) imaging—principles, applications, and limitations
 - c) 3D imaging and post-processing
 - i) Multiplanar reconstruction (MPR)
 - ii) Maximum intensity projection (MIP) and minimum intensity projection (minIP)
 - iii) Volume rendering (VR)
 - d) Patient safety
 - i) Radiation exposure and how technical modifications may modify dose
 - ii) Contrast agents used for thoracic imaging
 - 2) Normal Anatomy, including Variants, Encountered on CXR, CT, MRI and US**
 - a) Lungs, including tracheobronchial and pulmonary lobar anatomy, and fissures
 - b) Mediastinal and thoracic inlet anatomy
 - c) Chest wall anatomy

 - 3) Physiology Relevant to Thoracic Imaging, including Pulmonary Function Tests, Restrictive and Obstructive Patterns**

 - 4) Definition, Identification, and Significance of Signs and Finding Nomenclature in Thoracic Radiology. Knowledge should include diseases for which these signs are classic, potential alternative diagnoses, or pitfalls [Hansell et al. Fleischner Society: Glossary of Terms for Thoracic Imaging. *Radiology* 2008;246:697-722]**
 - a) Air bronchogram
 - b) Air crescent sign
 - c) Deep sulcus sign on a supine radiograph

- d) Continuous diaphragm sign
- e) Ring around the artery sign
- f) Fallen lung sign
- g) Flat waist sign
- h) Gloved finger sign
- i) Golden S sign
- j) Luftsichel sign
- k) Hampton hump
- l) Silhouette sign
- m) Cervicothoracic sign, tapered margins sign
- n) Figure 3 sign
- o) Fat pad sign or sandwich sign
- p) Scimitar
- q) Hilum overlay sign and hilum convergence sign
- r) Beaded septum sign
- s) Tree-in-bud
- t) Centrilobular nodules
- u) Perilymphatic nodules
- v) Random or miliary nodules
- w) Crazy paving
- x) Ground glass halo
- y) Mosaic attenuation
- z) Consolidation
- aa) Ground glass opacity
- bb) Honeycombing
- cc) Interlobular and intralobular septal thickening and reticulation
- dd) Juxtaphrenic peak
- ee) Secondary pulmonary lobule
- ff) Mass and nodule
- gg) Parenchymal and subpleural bands
- hh) Pleural plaques or pseudoplaques
- ii) Reverse halo sign
- jj) Signet ring sign (also known as pearl ring sign)
- kk) Split pleura sign
- ll) Headcheese sign
- mm) Thoracoabdominal sign
- nn) Westermark sign
- oo) CT angiogram sign
- pp) Bulging fissure sign
- qq) Fleischner sign
- rr) Comet tail sign
- ss) Thymic sail sign
- tt) Split pleura sign
- uu) Positive bronchus sign

- vv) Double density sign
- ww) Unilateral hyperlucent lung/hemithorax
- xx) Opaque hemithorax with contralateral versus ipsilateral mediastinal shift

5) Infectious Pneumonia - CXR and CT Findings

- a) Mycobacterial and fungal
- b) Viral
- c) Community- and hospital-acquired bacterial pneumonia
- d) Pneumonia in the immunocompromised, including patients:
 - i) with HIV/AIDS
 - ii) with post-transplantation status
 - iii) on chemotherapy, receiving corticosteroids, or with immune conditions
 - e) Septic emboli

6) Lung Cancer and other Parenchymal Neoplasms

- a) Solitary pulmonary nodule (SPN)
 - i) Approach to diagnosis (contrast-enhancement, imaging features)
 - ii) Management (PET, biopsy, follow-up/comparison)
 - iii) Perception and errors in perception
- b) Screening for lung cancer – current status
- c) Chronic alveolar disease as a manifestation of neoplasm
- d) Lung cancer staging
- e) Manifestations of small cell and non-small cell carcinoma, and bronchoalveolar cell carcinoma, including common locations for metastases
- f) Other tumors
 - i) Metastases
 - ii) Carcinoid
 - iii) Hamartoma
 - iv) Lymphoma
 - v) Chondrosarcoma

7) The Intensive Care Unit CXR - The Expected Location of the Support Devices and the Ability to Recognize Misplaced Lines and Complications (Pneumothorax, Hemothorax, Hematoma, Pneumoperitoneum)

- a) Central lines (including wrong vein and intra-arterial)
- b) Esophageal tubes/probes (including esophageal, nasogastric, and feeding tubes, endobronchial or intrapleural misplacement)
- c) Endotracheal and tracheostomy tubes
- d) Pulmonary artery (Swan-Ganz) catheters (including peripheral placement and pseudoaneurysm formation)
- e) Chest tubes (including intraparenchymal and intrafissural placement)
- f) Assist devices

8) Trauma, including Blunt and Penetrating Trauma

- a) Acute traumatic aortic injury
- b) Esophageal injury
- c) Tracheobronchial injury
- d) Lung injuries (contusion, shear injury, aspiration, laceration)
- e) Diaphragm injury, both acute and delayed presentations
- f) Tension hemopneumothorax, pneumothorax, pneumomediastinum
- g) Flail chest, skeletal fractures, and dislocations
- h) Fat emboli

9) Congenital Lung and Mediastinal Disease Manifesting in the Adult

- a) Foregut duplication cysts, including bronchogenic cysts and esophageal duplication cysts
- b) Bronchial atresia
- c) Arteriovenous malformations
- d) Partial anomalous pulmonary venous return
- e) Left superior vena cava (SVC) and duplicated SVC
- f) Swyer-James syndrome (unilateral bronchiolitis obliterans)
- g) Poland syndrome
- h) Sequestration (intralobar and extralobar)
- i) Congenital cystic adenomatoid malformation
- j) Aortic arch anomalies

10) Diffuse Lung Disease

- a) Cystic disease
 - i) Langerhans cell histiocytosis
 - ii) Lymphangioleiomyomatosis
 - iii) Tracheobronchial papillomatosis
 - iv) Lymphocytic interstitial pneumonia
 - v) Cystic metastases
 - vi) Chronic pneumocystis
- b) Pneumoconioses
 - i) Silicosis/coal workers pneumoconiosis
 - ii) Asbestosis
 - iii) Berylliosis
- c) Idiopathic /fibrotic
 - i) Usual interstitial pneumonia (UIP)
 - ii) Nonspecific interstitial pneumonia (NSIP)
 - iii) Desquamative interstitial pneumonia (DIP)
 - iv) Acute interstitial pneumonia (AIP)
- d) Pulmonary edema
 - i) Cardiogenic
 - ii) Noncardiogenic
- e) Drug toxicity, including chemotherapy agents such as bleomycin and medications such as Amiodarone

- f) Sarcoidosis, including CXR staging
- g) Lymphangitic carcinomatosis
- h) Differential diagnoses for chronic upper lobe predominant disease and chronic lower lobe predominant disease

11) Diffuse Alveolar Disease and Inflammatory Conditions

- a) Pulmonary alveolar proteinosis
- b) Lipoid pneumonia
- c) Organizing pneumonia, including cryptogenic
- d) Eosinophilic pneumonia
- e) Hypersensitivity pneumonia/extrinsic allergic alveolitis
- f) Differential diagnosis of peripheral alveolar opacities

12) Central Airways Diseases, Bronchiectasis, and Obstructive Lung Disease

- a) Tracheal/bronchial tumors or masses
 - i) Squamous cell cancer and papillomas
 - ii) Adenocarcinoma
 - iii) Mucoepidermoid
 - iv) Adenoid cystic carcinoma
 - v) Carcinoid
 - vi) Metastases
- b) Cystic fibrosis
- c) Tracheal stenosis
 - i) Inhalation and iatrogenic (such as tracheostomy or endotracheal tube)
 - ii) Granulomatous disease (Sarcoid, Wegener, tuberculosis)
 - iii) Amyloidosis
 - iv) Conditions that spare the posterior membrane (relapsing polychondritis; tracheopathia osteochondroplastica)
- d) Tracheobronchomalacia
- e) Bronchiectasis, including upper versus lower lobe predominant bronchiectasis
 - i) Immotile cilia syndrome (Kartagener)
 - ii) Recurrent aspiration
 - iii) Tracheobronchomegaly (Mounier-Kuhn)
 - iv) Tuberculosis
- f) Small airway disease
 - i) Asthma
 - ii) Bronchiolitis obliterans
 - iii) Graft-versus-host disease
- g) Small airway infection, including *Mycobacterium avium-intracellulare* (MAI)
- h) Broncholithiasis
 - i) Allergic bronchopulmonary aspergillosis (ABPA)
 - j) Aspiration and foreign bodies
- k) Emphysema, including centrilobular, paraseptal, panacinar, and paracapacitrial
- l) Giant bulla

13) Thoracic Manifestations of Systemic Disease

- a) Rheumatoid arthritis
- b) Scleroderma and mixed connective tissue disease
- c) Systemic lupus erythematosus
- d) Hepatopulmonary syndrome
- e) Vasculitis (Wegener, Goodpasture)
- f) Tuberous sclerosis
- g) Neurofibromatosis
- h) Sickle cell disease
- i) Polymyositis/dermatomyositis
- j) Sjögren syndrome
- k) Metastatic pulmonary calcification

14) Diseases of the Pleura, Chest Wall, and Diaphragm

- a) Mesothelioma
- b) Pleural metastases
- c) Fibrous tumor of the pleura
- d) Lipoma
- e) Empyema
- f) Chylothorax
- g) Pleural plaques, including asbestos exposure, hemothorax, prior infection
- h) Unilateral pleural calcification
- i) Pleural effusions, including differential diagnosis for unilateral and bilateral effusions
- j) Diaphragmatic hernias, including post-traumatic, Bochdalek, Morgagni, sliding hiatal
- k) Disorders of diaphragm motion, including role of sniff test
- l) Neurofibromatosis
- m) Chest wall tumors, including metastases, sarcomas, and desmoid tumors

15) Mediastinal Masses (Including Cardiac and Vascular-related Masses)

- a) Anterior mediastinum
 - i) Thymic origin, including thymoma, carcinoma, carcinoid, and cyst
 - ii) Germ cell tumors, including seminoma and teratoma
 - iii) Lymphoma
 - iv) Goiter
- b) Middle mediastinum
 - i) Duplication cysts
 - ii) Lymph node enlargement
 - iii) Esophageal origin, including cancer, diverticulum, achalasia, varices
 - iv) Airway masses
 - v) Vascular masses
- c) Posterior mediastinum
 - i) Nerve sheath tumors (neurofibromas, schwannomas)
 - ii) Paragangliomas (ganglioneuroma and ganglioneuroblastoma)
 - iii) Spine and paraspinal processes, including extramedullary hematopoiesis, metastases, diskitis
- d) Superior mediastinal / thoracic inlet masses

- i. Goiter
- ii. Lymphangioma
- e) Differential diagnoses of mediastinal masses based on location and CT attenuation (fat, fluid, calcified, enhancing)/MR signal characteristics
- f) Vascular masses (aneurysms and pseudoaneurysms)
- g) Diffuse mediastinal disease
 - i) Mediastinitis
 - ii) Fibrosing mediastinitis
- h) Differential diagnosis for egg-shell calcifications
- i) Mediastinal lymph node enlargement

16) Atelectasis and Collapse, including CXR/CT Findings and Differential Diagnosis

- a) Lobar collapse (right upper, middle, right lower, left upper, lingual, left lower, and combined right middle/lower)
- b) Unilateral lung collapse
- c) Collapse from an obstructing mass
- d) Round atelectasis

17) Pulmonary Arteries

- a. Acute pulmonary embolism
- b. Chronic pulmonary embolism
- c. Pulmonary infarct
- d. Pulmonary embolism mimics, including pulmonary artery sarcoma
- e. Pseudoaneurysm
- f. Vasculitis (Takayasu)

18) Postoperative and Post-treatment Thorax

- a) Lung resection, including post-lobectomy, post-wedge resection, pneumonectomy, and post-pneumonectomy syndrome
- b) Lobar torsion
- c) Radiation fibrosis and pneumonitis
- d) Post lung transplantation, including acute, subacute, and chronic complications, single and bilateral transplantation
- e) Post-esophagectomy
- f) Post-lung volume reduction surgery
- g) Airway and esophageal stents
- h) Eloesser flap

19) Percutaneous Thoracic Interventions

- a. Aspiration, biopsy and drainage
- b. Clinical indications and contraindications

- c. Techniques
- d. Accuracy
- e. Complications
- f. Post-procedure care

Ultrasound

1) Medical and Comprehensive knowledge

- a) "Hands-on" scanning: recognize the normal appearance as well as the most common pathology of the following:
 - i) Pleural space (effusion)
 - ii) Peritoneal space
 - (1) Ascites
 - (2) Hemorrhage
 - iii) Gallbladder
 - (1) Gallstones
 - (2) Acute cholecystitis
 - iv) Biliary
 - (1) Common bile duct
 - (2) Biliary ductal dilatation
 - v) Liver
 - (1) Masses
 - (2) Steatosis
 - (3) Cirrhosis
 - vi) Kidney
 - (1) Hydronephrosis
 - (2) Stones
 - (3) Mass/cyst
 - vii) Pancreas
 - (1) Pancreatitis
 - (2) Mass/cyst
 - viii) Retroperitoneal
 - (1) Abdominal mass
 - (2) Cyst
 - (3) Adenopathy
 - ix) Alimentary tract
 - (1) Normal gut signature
 - (2) Appendicitis
 - (3) Intussusception
 - (4) Inflammatory bowel disease
 - x) Thyroid
 - (1) Nodules
 - (2) Diffuse disease
 - xi) Parathyroid
 - (1) Adenoma
 - (2) Hyperplasia
 - (3) Testis/Epididymis/Scrotum
 - (4) Mass/cyst

- (5) Torsion
 - (6) Trauma
 - (7) Infection
- xii) Transabdominal/transvaginal pelvis
- (1) Uterus – measurement
 - (2) Fibroids
 - (3) Adenomyosis
 - (4) Endometrial stripe
 - (5) Adnexal mass/cyst
 - (6) Free fluid
- xiii) First Trimester Pregnancy
- (1) Normal
 - (2) Failed early intrauterine pregnancy
 - (3) Ectopic pregnancy
- xiv) Obstetrics
- (1) Basic fetal biometry
 - (2) Basic second/third trimester fetal anatomy
 - (3) Placental localization
 - (4) Amniotic fluid volume
 - (5) Comprehensive second/third trimester
- xv) Pediatrics
- (1) Abdomen
 - (2) Spine
 - (3) Hips
 - (4) Neonatal brain
 - (5) GI tract
- xvi) Breast
- (1) Solid mass/cyst
 - (2) Lymph nodes
 - (3) Breast cancer staging
- xvii) Vascular
- (1) Lower and upper extremity venous (deep vein thrombosis)
 - (2) Lower and upper extremity arterial
 - (3) Carotid and vertebral arteries
 - (4) Abdominal aorta (aneurysm, including how to measure)
 - (5) Abdominal Doppler
 - (6) Inferior vena cava (IVC)
 - (7) Hepatic and renal transplants
- xviii) Musculoskeletal (MSK)
- (1) Tendons
 - (2) Mass/cyst
 - (3) Muscle
- xix) US guided procedures
- (1) Aspiration

- (2) Fine-needle aspiration (FNA)
 - (3) Biopsy
 - (4) Line placement
- b) Physics/instrumentation: The resident should understand the basic principles of physics that form the foundation of clinical ultrasound.
- i) Range of US frequencies used in generating diagnostic images
 - ii) Transducer type: curvilinear, linear, sector, vector, endoluminal
 - iii) Transducer selection for various clinical applications
 - iv) Transducer components and beam characteristics
 - v) Beam formation/focusing
 - vi) Frequency, sound speed, wavelength, intensity, decibels, beam width
 - vii) Trade-off of frequency in terms of depth versus resolution
 - viii) Mode: grayscale, M-mode, A-mode, B-mode, pulsed wave Doppler, color and power Doppler, B-flow
 - ix) Image orientation
 - x) Frame rate
 - xi) Grayscale image optimization
 - (1) Focal zone
 - (2) Power output
 - (3) Gain
 - (4) Time gain compensation
 - (5) Line density
 - (6) Transmit frequency
 - (7) Dynamic range
 - xii) Acoustic properties of matter
 - (1) Fluid
 - (2) Cyst
 - (3) Calcification
 - (4) Complex fluid and solid structures, gas, metal, fat
 - xiii) Interaction of sound waves with tissues
 - (1) Reflection
 - (2) Attenuation
 - (3) Scattering
 - (4) Refraction
 - (5) Absorption
 - (6) Acoustic impedance
 - (7) Pulse-echo principles
 - xiv) Thermal and nonthermal effects on tissue
 - (1) Biological health risks
 - (2) Mechanical index
 - (3) Cavitation
 - (4) Relative risks for different scan modes
 - (5) Thermal and mechanical indices
 - xv) Doppler phenomenon, Doppler equation

- xvi) Grayscale vs Doppler (trade-off of penetration and resolution)
- xvii) Optimization of Doppler parameters
 - (1) Color box – size, shape, and angle
 - (2) Transmit frequency
 - (3) Doppler angle
 - (4) Wall filter
 - (5) Pulse repetition frequency
 - (6) Scale, gain
 - (7) Color write priority
 - (8) Sample volume size
- xviii) Artifacts
 - (1) Beam width
 - (2) Side lobe
 - (3) Slice thickness
- xix) Multiple reflection artifacts - mirror image/reverberation xx) Refractive artifacts, misregistration
 - (1) Ring down
 - (2) Acoustic shadowing and enhancement
 - (3) Speed propagation artifact
 - (4) Anisotropy
- xxi) Doppler artifacts
 - (1) Pulse wave
 - (2) Color imaging, including aliasing
 - (3) Color blooming
 - (4) Soft tissue vibration
 - (5) Flash
 - (6) Motion
- xxii) 3D/4D volumetric imaging
- xxiii) Harmonic imaging
- xxiv) Spatial compounding
- xxv) Panoramic imaging
- xxvi) Fusion imaging (transducer tracking)
- xxvii) Ultrasound contrast agents
- xxviii) Elastography
- xxix) Equipment quality assurance
 - (1) Phantoms
 - (2) Spatial/contrast resolution
 - (3) Care of probes
 - (4) Cleaning/disinfection
 - (5) Infection control

2) Clinical applications

a) General

- i) Understand the importance of clinical ultrasound protocols. Published guidelines from the American College of Radiology (ACR) with or without local modification are

- acceptable frames of reference. Residents should also be familiar with ACR appropriateness criteria as a guide for appropriate clinical use of ultrasound and other imaging modalities.
- ii) Understand the clinical uses and limitations of ultrasound, as well as the appropriate integration of other complementary cross-sectional imaging studies, particularly CT and MRI.
 - iii) Understand the importance of documentation, reporting, communication and reporting of critical findings.
 - iv) Understand the importance of clinical quality assurance, including radiologic-pathologic correlation, as well as sonographer-physician discrepancies.
- b) Abdomen
- i) Liver
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Normal variants
 - (3) Diffuse disease
 - (a) Steatosis, including focal steatosis and focal sparing
 - (b) Acute and chronic hepatitis
 - (c) Cirrhosis
 - (d) Edema
 - (4) Masses
 - (a) Cyst
 - (b) Cavernous hemangioma
 - (c) Focal nodular hyperplasia
 - (d) Adenoma
 - (e) Metastasis
 - (f) Hepatocellular carcinoma
 - (g) Lymphoma
 - (h) Cholangiocarcinoma
 - (i) Granuloma
 - (j) Hematoma
 - (k) Biloma
 - (l) Abscess
 - (i) Pyogenic/Echinococcal/Amebic
 - (m) Post-liver transplantation collections
 - (i) Hematoma/ Biloma/Abscess
 - (5) Trauma
 - ii) Gallbladder
 - (1) Normal size/shape/wall
 - (2) Gallstones
 - (3) Sludge
 - (4) Acute cholecystitis
 - (a) Calculous/acalculous/gangrenous/perforated/emphysematous
 - (5) Other etiologies of wall thickening

- (a) Polyp
 - (b) Hyperplastic cholecystosis
 - (c) Carcinoma
 - (d) Porcelain gallbladder
- iii) Bile ducts
 - (1) Normal intra- and extrahepatic bile duct appearance/size
 - (2) Normal variants
 - (3) Ductal dilatation
 - (4) Bile duct stones
 - (5) Cholangitis
 - (a) Primary sclerosing/Pyogenic/Recurrent pyogenic/AIDS
 - (6) Caroli disease
 - (7) Choledochal cysts
 - (8) Pneumobilia
 - (9) Cholangiocarcinoma
- iv) Pancreas
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Normal variants
 - (3) Pancreatic duct
 - (4) Masses
 - (a) Cyst
 - (b) Pseudocysts
 - (c) Cystic neoplasms
 - (d) Cancer
 - (e) Metastases
 - (f) Lymphoma
 - (g) Islet cell tumor
 - (h) Intraductal papillary mucinous neoplasm (IPMN)
 - (5) Pancreatitis
 - (a) Abscess
 - (b) Pseudocyst
 - (c) Pseudoaneurysm
 - (d) Chronic pancreatitis
- v) Spleen
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Normal variants
 - (3) Masses
 - (a) Cyst
 - (b) Lymphoma
 - (c) Metastases
 - (d) Abscess
 - (e) Infarct
 - (f) Granuloma
 - (4) Trauma

- vi) Peritoneal cavity
 - (1) Normal anatomy
 - (2) Ascites
 - (3) Hemorrhage
 - (4) Abscess
 - (5) Omental/peritoneal metastasis
 - (6) Omental infarct
 - (7) Mesothelioma
 - (8) Free air
- vii) Gastrointestinal tract
 - (1) Normal gut ultrasound signature
 - (2) Acute appendicitis
 - (3) Diverticulitis
 - (4) Inflammatory bowel disease (Crohn disease, ulcerative colitis)
 - (5) Colitis
 - (6) Bowel obstruction (including intussusception, malignancy)
 - (7) Cancer
 - (8) Lymphoma
 - (9) GI stromal tumor (GIST)
 - (10) Fistulae, abscess
- viii) Abdominal wall
 - (1) Normal echogenicity/echotexture
 - (2) Hematoma
 - (3) Abscess
 - (4) Hernia
 - (5) Masses
 - (a) Primary tumor
 - (b) Metastasis
 - (c) Lymphoma
 - (d) Desmoids tumor
 - (e) Lipoma
 - (f) Endometriosis
- ix) Organ transplants: see vascular section
- c) Urinary Tract and Adrenal Glands
 - i) Kidney
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Normal variants/congenital anomalies
 - (3) Calculi
 - (4) Hydronephrosis
 - (5) Glomerular & interstitial renal disease
 - (6) Cysts
 - (a) Simple
 - (b) Complex
 - (c) Peripelvic

- (d) Adult polycystic disease
 - (e) Acquired renal cystic disease
 - (7) Perinephric fluid/collections
 - (8) Masses
 - (a) Angiomyolipoma
 - (b) Oncocytoma
 - (c) Multilocular cystic nephroma
 - (d) Renal cell carcinoma
 - (e) Transitional cell carcinoma
 - (f) Lymphoma
 - (g) Metastasis
 - (9) Infection
 - (a) Pyelonephritis
 - (b) Xanthogranulomatous pyelonephritis
 - (c) Emphysematous pyelonephritis
 - (d) Abscess
 - (e) Perinephric abscess
 - (10) Medullary nephrocalcinosis
 - (11) Infiltrative disease
 - (12) Renal transplant (see vascular section)
- ii) Ureters
 - (1) Dilatation of the collecting system
 - (2) Megaureter
 - (3) Ureterocele (including ectopic ureterocele)
 - (4) Ureteral stone
 - (5) Pyonephrosis
 - (6) Clot in collecting system
 - (7) Transitional cell cancer
 - (8) Stents
 - iii) Urinary bladder
 - (1) Normal size/shape/wall
 - (2) Calculi
 - (3) Wall thickening
 - (4) Ureteral jets
 - (5) Bladder volume, including post-void residual
 - (6) Masses
 - (a) Transitional cell carcinoma
 - (b) Pheochromocytoma
 - (c) Endometriosis
 - (7) Cystitis, including emphysematous cystitis
 - (8) Hemorrhage
 - (9) Wall thickening
 - (10) Bladder outlet obstruction
 - (11) Diverticula

- (12) Ureterocele, including ectopic ureterocele
- (13) Ureterovesical junction (UVJ) stone
- (14) Fungus balls
- iv) Adrenal glands
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Masses
 - (a) Adenoma
 - (b) Pheochromocytoma
 - (c) Myelolipoma
 - (d) Metastasis
 - (e) Lymphoma
 - (f) Cancer
 - (g) Hemorrhage
- v) Transabdominal and transrectal prostate
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Benign prostatic hypertrophy
 - (3) Cancer
 - (4) Prostatitis
 - (5) Abscess
- vi) Retroperitoneum
 - (1) Adenopathy
 - (2) Primary sarcoma
 - (3) Hemorrhage
 - (4) Abscess
- d) Gynecology
 - i) Uterus
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Endometrium
 - (a) Normal appearance during phases of menstrual cycle
 - (b) Thickness measurement
 - (i) Premenopausal
 - (ii) Postmenopausal
 - (iii) Effects of hormone replacement
 - (c) Normal variants/congenital anomalies
 - (d) Intrauterine device
 - (i) Normal location
 - (ii) Displaced/extruded
 - (e) Endometrial fluid
 - (f) Endometrial polyp
 - (g) Endometrial hyperplasia
 - (h) Endometrial carcinoma
 - (i) Endometritis
 - (3) Myometrium
 - (a) Fibroids

- (b) Leiomyosarcoma
- (c) Adenomyosis
- ii) Ovary
 - (1) Normal echotexture/echogenicity/size/shape, including physiologic variation during phases of menstrual cycle
 - (a) Follicles
 - (b) Corpus luteum
 - (c) Hemorrhagic ovarian cyst
 - (2) Polycystic ovarian disease
 - (3) Ovarian hyperstimulation syndrome
 - (4) Masses/Cysts
 - (a) Simple/hemorrhagic/ruptured ovarian cyst
 - (b) Endometrioma
 - (c) Cystadenoma/carcinoma
 - (d) Dermoid
 - (e) Fibroma and other stromal tumors
 - (f) Germ cell tumor
 - (g) Metastasis
 - (5) Ovarian torsion
 - (6) Pelvic inflammatory disease
 - (a) Tubo-ovarian abscess
 - (7) Ovarian cancer, including staging
- iii) Cervix
 - (1) Normal echotexture/echogenicity
 - (2) Stenosis
 - (3) Polyp
 - (4) Cancer
 - (5) Fibroid
- iv) Fallopian tube
 - (1) Hydrosalpinx
 - (2) Pyosalpinx
 - (3) Postoperative changes
 - (4) Essure devices
- v) Post-hysterectomy appearance of pelvis
- vi) Free pelvic fluid
- vii) Peritoneal inclusion cyst
- viii) Saline hysterosonography
- e) Obstetrics
 - i) First trimester
 - (1) Normal findings of intrauterine gestational sac
 - (a) Size
 - (b) Gestational sac growth
 - (c) Yolk sac
 - (d) Embryo

- (e) Cardiac activity, including normal embryonic heart rate
 - (f) Amnion
 - (g) Chorion
 - (h) Chorionic villus sampling (CVS)/Amniocentesis
 - (i) Normal early fetal anatomy/growth
 - (j) Crown-rump length measurement
 - (k) Correlation with β -hCG levels and menstrual dates
 - (2) Multiple gestations (chorionicity and amnionicity)
 - (3) Failed early pregnancy
 - (a) Spontaneous complete/incomplete abortion
 - (b) Anembryonic gestation
 - (c) Embryonic demise
 - (d) Subchorionic hematoma
 - (4) Ectopic pregnancy, including unusual ectopic pregnancy
 - (a) Interstitial
 - (b) Cervical
 - (c) Ovarian
 - (d) Scar (Caesarian delivery)
 - (e) Abdominal
 - (f) Rudimentary horn
 - (5) Gestational trophoblastic disease
 - (6) Nuchal translucency
 - (7) Embryonic structural abnormalities, anencephaly
- ii) Second and third trimester
- (1) Normal findings
 - (a) Normal fetal anatomy/situs/development
 - (b) Placenta
 - (c) Biometry
 - (d) Amniotic fluid volume
 - (2) Multiple gestations
 - (3) Common congenital anomalies
 - (4) Recognition of fetal abnormalities that require high-risk obstetrics referral
 - (a) Intrauterine growth retardation
 - (b) Hydrops
 - (c) Holoprosencephaly
 - (d) Hydrocephalus
 - (e) Neural tube defects
 - (f) Multicystic dysplastic kidney
 - (g) Hydronephrosis
 - (h) Anencephaly
 - (i) Chromosomal abnormalities and syndromes
 - (i) Down syndrome
 - (ii) Turner syndrome
 - (j) Hydrops

- (k) Congenital infections
 - (l) Chest masses
 - (m) Cardiac malformations and arrhythmias
 - (n) Diaphragmatic hernia
 - (o) Abdominal wall defects
 - (p) Abdominal masses
 - (q) Gastrointestinal tract obstruction/abnormalities
 - (r) Ascites
 - (s) Skeletal dysplasias
 - (t) Cleft lip/palate
 - (u) Complications of twin pregnancy
 - (v) Hydranencephaly
- (5) Borderline findings
- (a) Nuchal thickening
 - (b) Choroid plexus cyst
 - (c) Echogenic cardiac focus
 - (d) Echogenic bowel
 - (e) Borderline hydrocephalus
- (6) Oligohydramnios
- (a) Spontaneous premature rupture of membranes
 - (b) Renal disease
 - (c) Fetal death
 - (d) Intrauterine growth retardation
 - (e) Infection
- (7) Polyhydramnios
- (8) Placenta
- (a) Placenta previa
 - (b) Vasa previa
 - (c) Abruptio
 - (d) Percreta-, increta- and accreta
 - (e) Placental masses
 - (f) Succenturiate placenta
- (9) Cervical appearance and length, cervical incompetence
- (10) Umbilical cord
- (a) Two-vessel umbilical cord
 - (b) Cord masses
 - (c) Placental cord insertion site
 - (d) Velamentous cord insertion
 - (e) Cord prolapse
 - (f) Umbilical cord Doppler
 - (g) Fetal cranial Doppler
 - (h) Biophysical profile
 - (i) Guidance for amniocentesis
 - (j) Retained products of conception

- f) Thyroid/neck
 - i) Thyroid
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Hashimoto thyroiditis
 - (3) Graves disease
 - (4) Subacute thyroiditis
 - (5) Characterization of thyroid nodules
 - (a) Benign nodules
 - (i) Colloid cysts
 - (ii) Cysts
 - (b) Malignant nodules
 - (i) Papillary carcinoma
 - (ii) Follicular neoplasm
 - (iii) Medullary carcinoma
 - (iv) Anaplastic carcinoma
 - (v) Lymphoma
 - (vi) Metastasis
 - (c) Non-specific nodules
 - (d) Multinodular goiter
 - (6) National consensus guidelines for performing fine-needle aspiration (FNA)
 - (7) Post-thyroidectomy neck surveillance for recurrence of papillary thyroid cancer – role of ultrasound
 - (a) Central versus lateral neck, levels
 - ii) Parathyroid
 - (1) Normal
 - (2) Adenoma
 - (3) Carcinoma
 - (4) Hyperplasia
 - iii) Congenital cysts
 - (1) Branchial cleft cyst
 - (2) Thyroglossal duct cyst
 - iv) Lymph nodes
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Benign reactive
 - (3) Metastasis (including surveillance for papillary thyroid cancer)
 - (4) Lymphoma
 - v) Salivary glands
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Benign and malignant neoplasms
 - (a) Pleomorphic adenoma
 - (b) Warthin tumor
 - (c) Adenoid cystic carcinoma
 - (d) Mucoepidermoid carcinoma
 - (3) Infection

- (4) Inflammation
- (5) Stones
- g) Chest
 - i) Normal anatomy
 - ii) Pleural effusion
 - iii) Atelectasis
 - iv) Pneumonia
 - v) Lung cancer
 - vi) Lung metastasis
 - vii) Pleural metastasis
 - viii) Adenopathy
 - (1) Mediastinal and axillary
 - (2) Metastasis
 - (3) Lymphoma
 - (4) Reactive
 - ix) Mediastinal tumors
 - x) Chest wall
 - (1) Hematoma
 - (2) Abscess
 - (3) Primary tumor
 - (4) Metastasis
 - (5) Lymphoma
 - (6) Lipoma
- h) Vascular/Doppler
 - i) Aorta and mesenteric branches
 - (1) Normal size/measurements/appearance/Doppler waveform
 - (2) Normal variants
 - (3) Aneurysm
 - (4) Dissection
 - (5) Thrombosis
 - (6) Status post stent graft placement including endoleak
 - (7) Status post surgery
 - (8) Coarctation
 - (9) Stenosis
 - (10) Mesenteric ischemia
 - (11) Mesenteric aneurysms
 - (12) Pseudoaneurysms
 - (13) Mesenteric venous thrombosis
 - ii) Spleen
 - (1) Normal artery and vein size/appearance/Doppler waveform
 - (2) Normal variants
 - (3) Artery
 - (a) Thrombosis
 - (b) Aneurysm

- (4) Vein
 - (a) Thrombosis
- (5) Infarction
- iii) Lower and upper extremity arterial
 - (1) Normal appearance and Doppler waveforms
 - (2) Stenosis
 - (3) Occlusion/thrombosis
 - (4) Post catheterization complications
 - (a) Pseudoaneurysm/Arteriovenous fistula/dissection/hematoma
 - (5) Arterial bypass graft
 - (a) Normal and abnormal
 - (6) Peripheral vascular aneurysm
- iv) Renal artery
 - (1) Normal appearance and Doppler waveform
 - (2) Stenosis
 - (3) Occlusion
 - (4) Bypass grafts
 - (5) Stent/Angioplasty
 - (6) Aneurysm
 - (7) Arteriovenous fistula/malformation
 - (8) Fibromuscular dysplasia
 - (9) Infarction
- v) Renal vein
 - (1) Normal appearance and Doppler waveform
 - (2) Thrombosis (bland and tumor)
 - (3) Arteriovenous fistula/malformation
- vi) Carotid artery
 - (1) Normal appearance and Doppler waveforms
 - (2) Atherosclerotic plaque/Fibrointimal thickening
 - (3) Stenosis
 - (4) Occlusion
 - (5) Waveform analysis
 - (6) Dissection
 - (7) Arteriovenous fistula
 - (8) Aneurysm
 - (9) Pseudoaneurysm
 - (10) Status post carotid endarterectomy and stent
 - (a) Normal
 - (b) Restenosis
 - (c) Complications
- vii) Vertebral artery
 - (1) Normal appearance and Doppler waveforms
 - (2) Normal variants
 - (3) Stenosis/Occlusion (proximal or distal)

- (4) Subclavian steal syndrome
- (5) Partial subclavian steal
- viii) Hemodialysis graft/fistula
 - (1) Normal appearance and Doppler waveforms
 - (2) Stenosis
 - (3) Occlusion (including outflow)
 - (4) Lack of maturation
 - (5) Fluid collections
 - (6) Pseudoaneurysms
 - (7) Steal
- ix) Inferior vena cava
 - (1) Normal appearance and Doppler waveform
 - (2) Thrombosis (bland and tumor)
 - (3) Filter
 - (4) Masses
- x) Lower and upper extremity venous
 - (1) Normal appearance and Doppler waveform
 - (2) Deep vein thrombosis
 - (3) Arteriovenous fistula
 - (4) Tricuspid regurgitation, right heart failure
 - (5) Chronic venous insufficiency
 - (6) Pre-arterial bypass graft/dialysis access vein mapping
 - (7) Nonvascular causes of leg pain and swelling
- xi) Hepatic vasculature (native)
 - (1) Normal hepatic artery, portal vein and hepatic vein size/appearance/Doppler waveform
 - (2) Normal variants
 - (3) Portal vein
 - (a) Bland thrombosis
 - (b) Tumor thrombus
 - (c) Cavernous transformation
 - (d) Para umbilical vein
 - (e) Varices
 - (4) Hepatic artery
 - (a) Thrombosis
 - (b) Stenosis
 - (c) Aneurysm/Pseudoaneurysm
 - (5) Hepatic vein
 - (a) Bland thrombosis
 - (b) Tumor thrombus
 - (c) Budd-Chiari syndrome
 - (d) Stenosis
 - (6) Infarction
- xii) Hemodynamics of cirrhosis, portal hypertension, and varices

- xiii) TIPS evaluation
 - (1) Normal appearance and Doppler waveforms
 - (2) Stenosis
 - (3) Occlusion
 - (4) Complications
- xiv) Renal transplant
 - (1) Normal appearance and Doppler arterial and venous waveforms
 - (2) Causes of elevation of arterial resistive index
 - (a) Rejection
 - (b) Acute tubular necrosis
 - (c) Page kidney
 - (d) Hydronephrosis
 - (e) Pyelonephritis
 - (f) Renal vein thrombosis
 - (3) Renal infarction
 - (4) Post-biopsy complications
 - (a) Hematoma
 - (b) Pseudoaneurysm
 - (c) Arteriovenous fistula
 - (5) Renal arterial stenosis/thrombosis
 - (6) Renal vein stenosis/thrombosis
 - (7) Peritransplant fluid collections
 - (8) Post-transplant lymphoproliferative disorder/masses
 - (9) Pyelonephritis
 - (10) Clot/pus in the collecting system
- xv) Liver transplants
 - (1) Normal appearance and Doppler arterial and venous waveforms
 - (2) Hepatic artery stenosis/thrombosis
 - (3) Resistive index
 - (4) Portal vein thrombosis/stenosis
 - (5) Hepatic vein thrombosis/stenosis
 - (6) Post-biopsy complications
 - (a) Hematoma
 - (b) Pseudoaneurysm
 - (c) Arteriovenous fistula
 - (7) Inferior vena cava stenosis/thrombosis
 - (8) Intrahepatic and peri-hepatic fluid collections
 - (9) Post-transplant lymphoproliferative disorder
 - (10) Abnormalities of the biliary tree
- xvi) Pancreas transplant
 - (1) Normal appearance
 - (2) Arterial and venous thrombosis/stenosis
 - (3) Pancreatitis
 - (4) Peritransplant fluid collections

- (5) Pseudoaneurysm
- i) Scrotum
 - i) Testes
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Orchitis
 - (3) Abscess
 - (4) Cysts
 - (a) Intratesticular
 - (b) Tunica cyst
 - (5) Cystic ectasia of rete testis
 - (6) Torsion/Detorsion
 - (7) Microlithiasis
 - (8) Masses
 - (a) Germ cell tumor
 - (b) Lymphoma
 - (c) Metastasis
 - (d) Stromal tumor
 - (e) Epidermoid cyst
 - (f) Infarct/hematoma
 - (9) Focal atrophy/fibrosis
 - (10) Sarcoidosis
 - (11) Tuberculosis
 - (12) Trauma
 - (13) Nondescended testis
 - ii) Epididymis
 - (1) Normal echotexture/echogenicity/size/shape
 - (2) Epididymitis
 - (3) Spermatocele/cyst
 - (4) Adenomatoid tumor
 - iii) Other
 - (1) Hydrocele
 - (2) Pyocele
 - (3) Fournier gangrene
 - (4) Scrotal edema
 - (5) Hematocele
 - (6) Varicocele
 - (7) Hernia
 - (8) Nondescended testis
 - j) Pediatrics
 - i) Normal anatomy
 - (1) Abdomen
 - (2) Kidney
 - (3) Brain
 - (4) Neck

- ii) Brain
 - (1) Intracranial hemorrhage and complications
 - (a) Periventricular leukomalacia
 - (b) Hydrocephalus
 - (2) Shunt evaluation
 - (3) Congenital brain malformations
 - (a) Agenesis of corpus callosum
 - (b) Vein of Galen aneurysm
 - (c) Dandy-Walker malformation
 - (d) Aqueductal stenosis
- iii) Neonatal spine
 - (1) Tethered cord
 - (2) Intraspinal mass
- iv) Kidneys
 - (1) Hydronephrosis
 - (2) Stones
 - (3) Hydroureters
 - (4) Anomalies of position and fusion
 - (5) Renal scarring
 - (6) Masses
 - (7) Cystic disease
- v) Adrenal
 - (1) Hemorrhage
 - (2) Masses (neuroblastoma)
- vi) Liver
 - (1) Cirrhosis
 - (2) Choledochal cysts
 - (3) Masses
 - (4) Hepatitis/biliary atresia
- vii) Gallbladder
 - (1) Gallstones
 - (2) Biliary stones
 - (3) Hydrops
- viii) Pancreas: acute pancreatitis
- ix) Spleen
 - (1) Polysplenia
 - (2) Asplenia
- x) Hip
 - (1) Normal
 - (2) Congenital dislocation
 - (3) Effusion
- xi) Alimentary tract
 - (1) Intussusception
 - (2) Acute appendicitis

- (3) Hypertrophic pyloric stenosis
- xii) Scrotal
 - (1) Torsion
 - (2) Epididymitis
 - (3) Orchitis
 - (4) Masses
 - (5) Undescended testis
- xiii) Ovary
 - (1) Solid and cystic masses
 - (2) Ovarian torsion
- xiv) Uterus
 - (1) Normal appearance and size
 - (2) Imperforate hymen
 - (3) Uterine anomalies
- xv) Neck masses
- xvi) Deep vein thrombosis of upper and lower extremities
- xvii) Hepatic and renal organ transplants
- xviii) Liver and renal Doppler
- k) Musculoskeletal
 - i) Normal anatomy
 - (1) Tendon
 - (2) Muscle
 - (3) Ligament
 - (4) Cartilage
 - (5) Bone
 - (6) Nerve
 - ii) Tendon
 - (1) Tear (partial and full thickness)
 - (2) Tendinopathy/tendinosis
 - (3) Tenosynovitis
 - iii) Muscle
 - (1) Tear
 - (2) Hematoma
 - (3) Abscess
 - (4) Neoplasm
 - iv) Nerve
 - (1) Compression syndromes
 - (2) Neuroma
 - (3) Tumor
 - v) Bone
 - (1) Fracture
 - (2) Tumor
 - (3) Osteomyelitis
 - vi) Ligaments

- (1) Plantar fasciitis
- (2) Plantar fibroma
- (3) Pulley rupture
- vii) Soft tissues/joints
 - (1) Baker cyst
 - (2) Ganglion cyst
 - (3) Lipoma
 - (4) Foreign body
 - (5) Hematoma
 - (6) Cellulitis, abscess
 - (7) Necrotizing fasciitis (soft tissue gas)
 - (8) Joint effusion
 - (9) Synovitis
 - (10) Primary neoplasm
 - (11) Metastasis
 - (12) Lymphoma
- I) Breast
 - i) Sonomammographic anatomy
 - ii) Cyst versus solid mass
 - iii) Mastitis/abscess
 - iv) Characterization of cysts
 - v) Lymph node characterization
 - (1) Axillary
 - (2) Supraclavicular
 - (3) Intramammary
 - vi) Characterization of solid masses
 - (1) Benign versus malignant
 - (a) Cyst
 - (b) Fibroadenoma
 - (c) Hamartoma
 - (d) Abscess
 - (e) Hematoma
 - (f) Phyllodes tumor
 - (g) Ductal/lobular carcinoma
 - (h) Carcinoma in situ
 - (i) Metastasis
 - (j) Lymphoma
 - (k) Inflammatory carcinoma
 - vii) Architectural distortion
 - viii) Intraductal masses/abnormalities, galactocele
 - ix) Screening
 - x) Multifocal/centric malignancy
 - xi) Elastography
 - xii) Role of IV contrast

m) Interventional

- i) Pre-procedural evaluation
 - (1) Coagulation laboratory studies
 - (2) Anticoagulation medication
 - (3) Stratification of risk for percutaneous procedures
- ii) Informed consent
- iii) Sterile technique
- iv) Techniques for ultrasound-guided invasive procedures: understanding important landmarks and pitfalls of percutaneous procedures, including recognition of critical structures to be avoided
- v) Localization of fluid for paracentesis or thoracentesis to be performed by another service
- vi) Ultrasound-guided paracentesis
- vii) Ultrasound-guided thoracentesis
- viii) Aspiration of fluid collections, cysts
- ix) Biopsy of soft tissue masses
- x) Fine needle aspiration versus core biopsy in specific applications
 - (1) Focal liver mass
 - (2) Renal mass
 - (3) Thyroid/parathyroid mass
 - (4) Lymphadenopathy
- xi) Random core liver biopsy
- xii) Random core renal biopsy
- xiii) Catheter placement for abscess and fluid drainage (pleural, peritoneal, and other spaces)
- xiv) Postprocedural evaluation
 - (1) Radiographic studies
 - (2) Patient monitoring
 - (3) Management of complications
- xv) Pseudoaneurysm management: contraindications and technique of non-surgical treatment with ultrasound-guided compression repair versus thrombin injection
- xvi) Intraoperative ultrasound guidance

Urinary Imaging

1) Kidneys

- a) Malignant tumors
 - i) Primary
 - ii) Secondary
- b) Benign tumors
- c) Endocrine tumors
- d) Cystic disease
- e) Complicated cysts
- f) Granulomatous diseases
- g) Infection/inflammation
- h) Hemorrhage
- i) Infarction and ischemia
- j) Trauma/iatrogenic
- k) Congenital anomalies
- l) Medical renal disease
- m) Inherited diseases involving the kidneys (including transplantation)

2) Ureter

- a) Malignant tumors
- b) Benign tumors
- c) Infection/inflammation
- d) Hemorrhage
- e) Trauma/iatrogenic
- f) Congenital anomalies
- g) Stricture
- h) Filling defects

3) Bladder and Neobladder

- a) Malignant tumors
- b) Benign tumors
- c) Infection/inflammation
- d) Hemorrhage
- e) Trauma/iatrogenic
- f) Congenital anomalies

4) Prostate Gland and Seminal Vesicles

- a) Malignant tumors
- b) Benign tumors and hyperplasia
- c) Infection/inflammation
- d) Trauma/iatrogenic
- e) Congenital anomalies

5) Urethra and Penis

- a) Malignant tumors
- b) Benign tumors
- c) Infection/inflammation
- d) Trauma/iatrogenic
- e) Congenital anomalies
- f) Stricture

6) Retroperitoneum

- a) Malignant tumors
 - i) Primary
 - ii) Secondary
- b) Benign tumors
- c) Hemorrhage
- d) Trauma/iatrogenic
- e) Congenital anomalies
- f) Aortic aneurysm
- g) Retroperitoneal fibrosis
- h) Pelvic lipomatosis
- i) Venous anomalies
- j) Fournier gangrene

7) Vascular Diseases Affecting the Genitourinary Tract

- a) Aneurysms
- b) Stenoses
- c) Malformations
- d) Fistulae
- e) Occlusions
- f) Congenital anomalies

8) Intravascular Contrast Media

- a) Extravasation
- b) Physiology
- c) Adverse reactions (idiosyncratic and nonidiosyncratic)
- d) Prevention and treatment of adverse reactions

9) Urolithiasis (Including Kidney, Ureter, Bladder)**10) Techniques**

- a) Excretory urography
- b) Cystography
- c) Urethrography (including antegrade and retrograde)
- d) CT (including CT urography, CT angiography)
- e) MRI (including MR urography, MR angiography)

- f) Ultrasound (including Doppler and color flow)
- g) Hysterosalpingography

Vascular Imaging

- 1) Normal and Variant Anatomy as Depicted by Various Imaging Modalities (US, MRI, CT, and angiography)**
 - a) Arterial (excluding heart and CNS since that content will be covered in neurology and cardiac sections)
 - b) Venous (again excluding heart and CNS)
- 2) Vascular Anatomy/Pathology before and after Intervention. Examples include:**
 - a) Aortic aneurysms before and after stent graft placement
 - b) Arterial and venous stenosis/occlusions before and after endovascular procedures, such as angioplasty, stent placement, lysis, or thrombectomy
 - c) Anatomy and pathology seen before and after open vascular procedures. Procedures include bypass grafts for tissue perfusion and dialysis access.
- 3) Vascular Pathology as Depicted by Various Imaging Modalities. Categories include:**
 - a) Congenital anomalies
 - b) Inflammatory conditions such as vasculitis
 - c) Neoplasia
 - d) Embolic phenomena
 - e) Trauma – blunt and penetrating
 - f) Atherosclerosis
- 4) Physics Knowledge Needed to Safely Operate a C-arm Fluoroscopy Unit**
 - a) Radiation protection
 - b) Optimal use of radiation
 - c) Digital subtraction angiography (DSA), including its artifacts